WO2022217042A1 - Quinoline-4(1h)-ones à substitution naphtyle et composés apparentés et leur utilisation dans le traitement d'affections médicales - Google Patents
Quinoline-4(1h)-ones à substitution naphtyle et composés apparentés et leur utilisation dans le traitement d'affections médicales Download PDFInfo
- Publication number
- WO2022217042A1 WO2022217042A1 PCT/US2022/024006 US2022024006W WO2022217042A1 WO 2022217042 A1 WO2022217042 A1 WO 2022217042A1 US 2022024006 W US2022024006 W US 2022024006W WO 2022217042 A1 WO2022217042 A1 WO 2022217042A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- certain embodiments
- nitrogen
- substituted
- occurrences
- heterocyclyl
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 314
- PMZDQRJGMBOQBF-UHFFFAOYSA-N quinolin-4-ol Chemical class C1=CC=C2C(O)=CC=NC2=C1 PMZDQRJGMBOQBF-UHFFFAOYSA-N 0.000 title abstract description 6
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 166
- 201000011510 cancer Diseases 0.000 claims abstract description 134
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 91
- 102200006539 rs121913529 Human genes 0.000 claims abstract description 76
- 230000000694 effects Effects 0.000 claims abstract description 38
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 17
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 16
- 101710113436 GTPase KRas Proteins 0.000 claims abstract 5
- 229920006395 saturated elastomer Polymers 0.000 claims description 364
- 229910052757 nitrogen Inorganic materials 0.000 claims description 339
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 264
- 125000005842 heteroatom Chemical group 0.000 claims description 246
- 229910052760 oxygen Inorganic materials 0.000 claims description 242
- 239000001301 oxygen Chemical group 0.000 claims description 242
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 241
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 237
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 236
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 228
- 229910052717 sulfur Chemical group 0.000 claims description 228
- 239000011593 sulfur Chemical group 0.000 claims description 228
- 125000000623 heterocyclic group Chemical group 0.000 claims description 215
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims description 132
- 125000000217 alkyl group Chemical group 0.000 claims description 125
- 125000005843 halogen group Chemical group 0.000 claims description 95
- 125000002618 bicyclic heterocycle group Chemical group 0.000 claims description 79
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 74
- 238000000034 method Methods 0.000 claims description 63
- 229910052739 hydrogen Inorganic materials 0.000 claims description 58
- 239000001257 hydrogen Substances 0.000 claims description 58
- 125000003545 alkoxy group Chemical group 0.000 claims description 54
- 125000001188 haloalkyl group Chemical group 0.000 claims description 52
- 125000001072 heteroaryl group Chemical group 0.000 claims description 51
- 125000001931 aliphatic group Chemical group 0.000 claims description 50
- 150000003839 salts Chemical class 0.000 claims description 49
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 46
- 229910052799 carbon Inorganic materials 0.000 claims description 42
- 125000004438 haloalkoxy group Chemical group 0.000 claims description 32
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 32
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 30
- 125000006555 (C3-C5) cycloalkyl group Chemical group 0.000 claims description 27
- 125000001624 naphthyl group Chemical group 0.000 claims description 23
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 21
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 20
- 206010009944 Colon cancer Diseases 0.000 claims description 20
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 19
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 19
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 19
- 201000002528 pancreatic cancer Diseases 0.000 claims description 19
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 19
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 18
- 125000004429 atom Chemical group 0.000 claims description 15
- 230000001404 mediated effect Effects 0.000 claims description 15
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 13
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 13
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 12
- 239000003937 drug carrier Substances 0.000 claims description 11
- 206010006187 Breast cancer Diseases 0.000 claims description 9
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 9
- 206010060862 Prostate cancer Diseases 0.000 claims description 8
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 8
- 201000005202 lung cancer Diseases 0.000 claims description 8
- 208000020816 lung neoplasm Diseases 0.000 claims description 8
- 208000026310 Breast neoplasm Diseases 0.000 claims description 7
- 208000006990 cholangiocarcinoma Diseases 0.000 claims description 7
- 241000282414 Homo sapiens Species 0.000 claims description 6
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 5
- 125000004432 carbon atom Chemical group C* 0.000 claims description 5
- 201000007270 liver cancer Diseases 0.000 claims description 5
- 208000014018 liver neoplasm Diseases 0.000 claims description 5
- 201000000849 skin cancer Diseases 0.000 claims description 5
- 206010004593 Bile duct cancer Diseases 0.000 claims description 4
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 4
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 4
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 4
- 201000010881 cervical cancer Diseases 0.000 claims description 4
- 206010017758 gastric cancer Diseases 0.000 claims description 4
- 201000011549 stomach cancer Diseases 0.000 claims description 4
- 208000026900 bile duct neoplasm Diseases 0.000 claims description 3
- 201000011682 nervous system cancer Diseases 0.000 claims description 3
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims description 2
- 125000001183 hydrocarbyl group Chemical group 0.000 claims 6
- 150000002430 hydrocarbons Chemical group 0.000 description 137
- 239000002246 antineoplastic agent Substances 0.000 description 114
- -1 monocyclic hydrocarbon Chemical class 0.000 description 79
- 239000003112 inhibitor Substances 0.000 description 56
- 239000000203 mixture Substances 0.000 description 55
- 208000035475 disorder Diseases 0.000 description 52
- 239000003814 drug Substances 0.000 description 39
- 201000010099 disease Diseases 0.000 description 35
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 27
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 27
- 125000001424 substituent group Chemical group 0.000 description 26
- 230000035772 mutation Effects 0.000 description 25
- 125000003386 piperidinyl group Chemical group 0.000 description 25
- 125000002393 azetidinyl group Chemical group 0.000 description 24
- 150000001721 carbon Chemical group 0.000 description 24
- 125000001309 chloro group Chemical group Cl* 0.000 description 22
- 125000001153 fluoro group Chemical group F* 0.000 description 22
- 150000002431 hydrogen Chemical class 0.000 description 22
- 125000003118 aryl group Chemical group 0.000 description 20
- 238000003556 assay Methods 0.000 description 19
- 239000000126 substance Substances 0.000 description 19
- 229940124597 therapeutic agent Drugs 0.000 description 19
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 description 15
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 15
- 125000002619 bicyclic group Chemical group 0.000 description 15
- 239000003795 chemical substances by application Substances 0.000 description 15
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 15
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 15
- 208000029974 neurofibrosarcoma Diseases 0.000 description 15
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 14
- 239000012453 solvate Substances 0.000 description 14
- 125000002757 morpholinyl group Chemical group 0.000 description 13
- 125000004193 piperazinyl group Chemical group 0.000 description 13
- 230000001105 regulatory effect Effects 0.000 description 13
- 125000005960 1,4-diazepanyl group Chemical group 0.000 description 12
- 125000004575 3-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 12
- 125000004567 azetidin-3-yl group Chemical group N1CC(C1)* 0.000 description 12
- 125000003636 chemical group Chemical group 0.000 description 12
- 208000018463 endometrial serous adenocarcinoma Diseases 0.000 description 12
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 description 12
- 208000024891 symptom Diseases 0.000 description 12
- 206010033128 Ovarian cancer Diseases 0.000 description 11
- 208000005017 glioblastoma Diseases 0.000 description 11
- 239000000523 sample Substances 0.000 description 11
- 230000001225 therapeutic effect Effects 0.000 description 11
- 208000000172 Medulloblastoma Diseases 0.000 description 10
- 239000004480 active ingredient Substances 0.000 description 10
- 229910052736 halogen Inorganic materials 0.000 description 10
- 230000005764 inhibitory process Effects 0.000 description 10
- 125000004485 2-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])C1([H])* 0.000 description 9
- 206010018338 Glioma Diseases 0.000 description 9
- 239000002552 dosage form Substances 0.000 description 9
- 238000009472 formulation Methods 0.000 description 9
- 230000002062 proliferating effect Effects 0.000 description 9
- 230000001603 reducing effect Effects 0.000 description 9
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 206010052747 Adenocarcinoma pancreas Diseases 0.000 description 8
- 208000032612 Glial tumor Diseases 0.000 description 8
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 8
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 8
- 206010061535 Ovarian neoplasm Diseases 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- 150000002367 halogens Chemical class 0.000 description 8
- 201000002094 pancreatic adenocarcinoma Diseases 0.000 description 8
- 206010038038 rectal cancer Diseases 0.000 description 8
- 102200006538 rs121913530 Human genes 0.000 description 8
- 229910001868 water Inorganic materials 0.000 description 8
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 description 7
- 206010003571 Astrocytoma Diseases 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 208000007571 Ovarian Epithelial Carcinoma Diseases 0.000 description 7
- 208000015634 Rectal Neoplasms Diseases 0.000 description 7
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 description 7
- 125000002947 alkylene group Chemical group 0.000 description 7
- 230000008901 benefit Effects 0.000 description 7
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 7
- 125000002883 imidazolyl group Chemical group 0.000 description 7
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 7
- 201000001441 melanoma Diseases 0.000 description 7
- 201000008968 osteosarcoma Diseases 0.000 description 7
- 201000008129 pancreatic ductal adenocarcinoma Diseases 0.000 description 7
- 125000003226 pyrazolyl group Chemical group 0.000 description 7
- 125000004076 pyridyl group Chemical group 0.000 description 7
- 125000000714 pyrimidinyl group Chemical group 0.000 description 7
- 201000001275 rectum cancer Diseases 0.000 description 7
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 7
- 206010042863 synovial sarcoma Diseases 0.000 description 7
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 7
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 7
- 208000001446 Anaplastic Thyroid Carcinoma Diseases 0.000 description 6
- 206010002240 Anaplastic thyroid cancer Diseases 0.000 description 6
- 201000001342 Fallopian tube cancer Diseases 0.000 description 6
- 208000013452 Fallopian tube neoplasm Diseases 0.000 description 6
- 208000030070 Malignant epithelial tumor of ovary Diseases 0.000 description 6
- 206010029260 Neuroblastoma Diseases 0.000 description 6
- 208000003019 Neurofibromatosis 1 Diseases 0.000 description 6
- 208000024834 Neurofibromatosis type 1 Diseases 0.000 description 6
- 206010061328 Ovarian epithelial cancer Diseases 0.000 description 6
- 208000008900 Pancreatic Ductal Carcinoma Diseases 0.000 description 6
- 150000001413 amino acids Chemical class 0.000 description 6
- 239000002585 base Substances 0.000 description 6
- 210000000988 bone and bone Anatomy 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 208000029742 colonic neoplasm Diseases 0.000 description 6
- 208000011588 combined hepatocellular carcinoma and cholangiocarcinoma Diseases 0.000 description 6
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 6
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 6
- 125000002950 monocyclic group Chemical group 0.000 description 6
- 208000024641 papillary serous cystadenocarcinoma Diseases 0.000 description 6
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 6
- 102000016914 ras Proteins Human genes 0.000 description 6
- 108010014186 ras Proteins Proteins 0.000 description 6
- 102200006531 rs121913529 Human genes 0.000 description 6
- 210000004872 soft tissue Anatomy 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- 208000019179 thyroid gland undifferentiated (anaplastic) carcinoma Diseases 0.000 description 6
- 229960004066 trametinib Drugs 0.000 description 6
- LIRYPHYGHXZJBZ-UHFFFAOYSA-N trametinib Chemical compound CC(=O)NC1=CC=CC(N2C(N(C3CC3)C(=O)C3=C(NC=4C(=CC(I)=CC=4)F)N(C)C(=O)C(C)=C32)=O)=C1 LIRYPHYGHXZJBZ-UHFFFAOYSA-N 0.000 description 6
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 5
- 239000004215 Carbon black (E152) Substances 0.000 description 5
- 108010009540 DNA (Cytosine-5-)-Methyltransferase 1 Proteins 0.000 description 5
- 102100036279 DNA (cytosine-5)-methyltransferase 1 Human genes 0.000 description 5
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 5
- 101000950687 Homo sapiens Mitogen-activated protein kinase 7 Proteins 0.000 description 5
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 description 5
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 description 5
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 description 5
- 206010025323 Lymphomas Diseases 0.000 description 5
- 229940124647 MEK inhibitor Drugs 0.000 description 5
- 102100037805 Mitogen-activated protein kinase 7 Human genes 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 235000001014 amino acid Nutrition 0.000 description 5
- 239000005557 antagonist Substances 0.000 description 5
- 230000001413 cellular effect Effects 0.000 description 5
- 229960002271 cobimetinib Drugs 0.000 description 5
- RESIMIUSNACMNW-BXRWSSRYSA-N cobimetinib fumarate Chemical compound OC(=O)\C=C\C(O)=O.C1C(O)([C@H]2NCCCC2)CN1C(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F.C1C(O)([C@H]2NCCCC2)CN1C(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F RESIMIUSNACMNW-BXRWSSRYSA-N 0.000 description 5
- 238000002648 combination therapy Methods 0.000 description 5
- 125000004122 cyclic group Chemical group 0.000 description 5
- 125000000753 cycloalkyl group Chemical group 0.000 description 5
- 208000006359 hepatoblastoma Diseases 0.000 description 5
- 229930195733 hydrocarbon Natural products 0.000 description 5
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 208000000587 small cell lung carcinoma Diseases 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- DKZYXHCYPUVGAF-UHFFFAOYSA-N 1-[6-(3,5-dichloro-4-hydroxyphenyl)-4-[[4-[(dimethylamino)methyl]cyclohexyl]amino]-1,5-naphthyridin-3-yl]ethanone Chemical compound CN(C)CC1CCC(CC1)Nc1c(cnc2ccc(nc12)-c1cc(Cl)c(O)c(Cl)c1)C(C)=O DKZYXHCYPUVGAF-UHFFFAOYSA-N 0.000 description 4
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 208000003174 Brain Neoplasms Diseases 0.000 description 4
- 201000009030 Carcinoma Diseases 0.000 description 4
- 208000005243 Chondrosarcoma Diseases 0.000 description 4
- PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 description 4
- 208000009798 Craniopharyngioma Diseases 0.000 description 4
- 206010014967 Ependymoma Diseases 0.000 description 4
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 208000006265 Renal cell carcinoma Diseases 0.000 description 4
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- 208000024313 Testicular Neoplasms Diseases 0.000 description 4
- 206010057644 Testis cancer Diseases 0.000 description 4
- 208000020990 adrenal cortex carcinoma Diseases 0.000 description 4
- 208000007128 adrenocortical carcinoma Diseases 0.000 description 4
- 125000003342 alkenyl group Chemical group 0.000 description 4
- 239000003963 antioxidant agent Substances 0.000 description 4
- 235000006708 antioxidants Nutrition 0.000 description 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 4
- 229950003054 binimetinib Drugs 0.000 description 4
- ACWZRVQXLIRSDF-UHFFFAOYSA-N binimetinib Chemical group OCCONC(=O)C=1C=C2N(C)C=NC2=C(F)C=1NC1=CC=C(Br)C=C1F ACWZRVQXLIRSDF-UHFFFAOYSA-N 0.000 description 4
- 238000001574 biopsy Methods 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 239000002875 cyclin dependent kinase inhibitor Substances 0.000 description 4
- 229940043378 cyclin-dependent kinase inhibitor Drugs 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 235000019441 ethanol Nutrition 0.000 description 4
- 125000000524 functional group Chemical group 0.000 description 4
- 230000002496 gastric effect Effects 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 description 4
- 230000000670 limiting effect Effects 0.000 description 4
- 229940124302 mTOR inhibitor Drugs 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 description 4
- 238000007481 next generation sequencing Methods 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 239000002935 phosphatidylinositol 3 kinase inhibitor Substances 0.000 description 4
- 229940043441 phosphoinositide 3-kinase inhibitor Drugs 0.000 description 4
- 239000006187 pill Substances 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- 238000000159 protein binding assay Methods 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Substances C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- 125000006413 ring segment Chemical group 0.000 description 4
- 229950010746 selumetinib Drugs 0.000 description 4
- CYOHGALHFOKKQC-UHFFFAOYSA-N selumetinib Chemical compound OCCONC(=O)C=1C=C2N(C)C=NC2=C(F)C=1NC1=CC=C(Br)C=C1Cl CYOHGALHFOKKQC-UHFFFAOYSA-N 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 201000003120 testicular cancer Diseases 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 238000002877 time resolved fluorescence resonance energy transfer Methods 0.000 description 4
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 4
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 4
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 description 4
- 239000000080 wetting agent Substances 0.000 description 4
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 description 3
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 3
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 3
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 229940122531 Anaplastic lymphoma kinase inhibitor Drugs 0.000 description 3
- 229940124290 BCR-ABL tyrosine kinase inhibitor Drugs 0.000 description 3
- 229940125814 BTK kinase inhibitor Drugs 0.000 description 3
- 206010006143 Brain stem glioma Diseases 0.000 description 3
- 229940126074 CDK kinase inhibitor Drugs 0.000 description 3
- 102100034744 Cell division cycle 7-related protein kinase Human genes 0.000 description 3
- 108020004705 Codon Proteins 0.000 description 3
- 102100034770 Cyclin-dependent kinase inhibitor 3 Human genes 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 229940124087 DNA topoisomerase II inhibitor Drugs 0.000 description 3
- 229940126289 DNA-PK inhibitor Drugs 0.000 description 3
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 3
- 108010052167 Dihydroorotate Dehydrogenase Proteins 0.000 description 3
- 102100032823 Dihydroorotate dehydrogenase (quinone), mitochondrial Human genes 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 208000006168 Ewing Sarcoma Diseases 0.000 description 3
- 208000022072 Gallbladder Neoplasms Diseases 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 3
- 208000017604 Hodgkin disease Diseases 0.000 description 3
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 3
- 101000945740 Homo sapiens Cell division cycle 7-related protein kinase Proteins 0.000 description 3
- 101000945639 Homo sapiens Cyclin-dependent kinase inhibitor 3 Proteins 0.000 description 3
- 101000744394 Homo sapiens Oxidized purine nucleoside triphosphate hydrolase Proteins 0.000 description 3
- 101000595923 Homo sapiens Placenta growth factor Proteins 0.000 description 3
- 101000777293 Homo sapiens Serine/threonine-protein kinase Chk1 Proteins 0.000 description 3
- 101000621390 Homo sapiens Wee1-like protein kinase Proteins 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 229940122245 Janus kinase inhibitor Drugs 0.000 description 3
- 229940123830 K-Ras inhibitor Drugs 0.000 description 3
- 208000008839 Kidney Neoplasms Diseases 0.000 description 3
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 3
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 3
- 240000007472 Leucaena leucocephala Species 0.000 description 3
- 229940124787 MELK inhibitor Drugs 0.000 description 3
- 201000010133 Oligodendroglioma Diseases 0.000 description 3
- 108700020796 Oncogene Proteins 0.000 description 3
- 102100039792 Oxidized purine nucleoside triphosphate hydrolase Human genes 0.000 description 3
- 239000012661 PARP inhibitor Substances 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 3
- 208000007641 Pinealoma Diseases 0.000 description 3
- 102100035194 Placenta growth factor Human genes 0.000 description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 description 3
- 229940121906 Poly ADP ribose polymerase inhibitor Drugs 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 229940079156 Proteasome inhibitor Drugs 0.000 description 3
- 201000000582 Retinoblastoma Diseases 0.000 description 3
- 206010039491 Sarcoma Diseases 0.000 description 3
- 102100031081 Serine/threonine-protein kinase Chk1 Human genes 0.000 description 3
- 206010041067 Small cell lung cancer Diseases 0.000 description 3
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
- 239000000317 Topoisomerase II Inhibitor Substances 0.000 description 3
- 229940124674 VEGF-R inhibitor Drugs 0.000 description 3
- 208000014070 Vestibular schwannoma Diseases 0.000 description 3
- 102100023037 Wee1-like protein kinase Human genes 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 208000004064 acoustic neuroma Diseases 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 208000009956 adenocarcinoma Diseases 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 239000000556 agonist Substances 0.000 description 3
- 235000010443 alginic acid Nutrition 0.000 description 3
- 229920000615 alginic acid Polymers 0.000 description 3
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 3
- 125000004450 alkenylene group Chemical group 0.000 description 3
- 229940024606 amino acid Drugs 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000000611 antibody drug conjugate Substances 0.000 description 3
- 229940049595 antibody-drug conjugate Drugs 0.000 description 3
- 230000033590 base-excision repair Effects 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 229940022399 cancer vaccine Drugs 0.000 description 3
- 125000004452 carbocyclyl group Chemical group 0.000 description 3
- 239000012876 carrier material Substances 0.000 description 3
- 239000003086 colorant Substances 0.000 description 3
- 201000010989 colorectal carcinoma Diseases 0.000 description 3
- 238000013270 controlled release Methods 0.000 description 3
- 230000002939 deleterious effect Effects 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 201000010175 gallbladder cancer Diseases 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 208000014829 head and neck neoplasm Diseases 0.000 description 3
- 125000005549 heteroarylene group Chemical group 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 239000003701 inert diluent Substances 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 201000005249 lung adenocarcinoma Diseases 0.000 description 3
- 201000005243 lung squamous cell carcinoma Diseases 0.000 description 3
- 206010027191 meningioma Diseases 0.000 description 3
- RDSACQWTXKSHJT-NSHDSACASA-N n-[3,4-difluoro-2-(2-fluoro-4-iodoanilino)-6-methoxyphenyl]-1-[(2s)-2,3-dihydroxypropyl]cyclopropane-1-sulfonamide Chemical compound C1CC1(C[C@H](O)CO)S(=O)(=O)NC=1C(OC)=CC(F)=C(F)C=1NC1=CC=C(I)C=C1F RDSACQWTXKSHJT-NSHDSACASA-N 0.000 description 3
- 208000007538 neurilemmoma Diseases 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 125000004043 oxo group Chemical group O=* 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 235000021317 phosphate Nutrition 0.000 description 3
- 229910052698 phosphorus Inorganic materials 0.000 description 3
- 239000011574 phosphorus Substances 0.000 description 3
- 208000024724 pineal body neoplasm Diseases 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 208000029340 primitive neuroectodermal tumor Diseases 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000003207 proteasome inhibitor Substances 0.000 description 3
- 125000006239 protecting group Chemical group 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- 229950008933 refametinib Drugs 0.000 description 3
- 206010039667 schwannoma Diseases 0.000 description 3
- 238000009097 single-agent therapy Methods 0.000 description 3
- 230000008410 smoothened signaling pathway Effects 0.000 description 3
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- XAUDJQYHKZQPEU-KVQBGUIXSA-N 5-aza-2'-deoxycytidine Chemical compound O=C1N=C(N)N=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 XAUDJQYHKZQPEU-KVQBGUIXSA-N 0.000 description 2
- 206010000830 Acute leukaemia Diseases 0.000 description 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 2
- 206010001197 Adenocarcinoma of the cervix Diseases 0.000 description 2
- 208000034246 Adenocarcinoma of the cervix uteri Diseases 0.000 description 2
- 208000009888 Adrenocortical Adenoma Diseases 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- 206010061424 Anal cancer Diseases 0.000 description 2
- 208000007860 Anus Neoplasms Diseases 0.000 description 2
- 206010065869 Astrocytoma, low grade Diseases 0.000 description 2
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 2
- 206010005949 Bone cancer Diseases 0.000 description 2
- 208000018084 Bone neoplasm Diseases 0.000 description 2
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 2
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 2
- 102100027207 CD27 antigen Human genes 0.000 description 2
- 101150013553 CD40 gene Proteins 0.000 description 2
- 108010021064 CTLA-4 Antigen Proteins 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 241000282465 Canis Species 0.000 description 2
- 201000009047 Chordoma Diseases 0.000 description 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 2
- RGSFGYAAUTVSQA-UHFFFAOYSA-N Cyclopentane Chemical compound C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 2
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 241000283073 Equus caballus Species 0.000 description 2
- 241000282324 Felis Species 0.000 description 2
- 201000008808 Fibrosarcoma Diseases 0.000 description 2
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 2
- 201000010915 Glioblastoma multiforme Diseases 0.000 description 2
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 2
- 102100039619 Granulocyte colony-stimulating factor Human genes 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 description 2
- 101000584612 Homo sapiens GTPase KRas Proteins 0.000 description 2
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 description 2
- 101000679903 Homo sapiens Tumor necrosis factor receptor superfamily member 25 Proteins 0.000 description 2
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 102000013462 Interleukin-12 Human genes 0.000 description 2
- 108010065805 Interleukin-12 Proteins 0.000 description 2
- 102000003812 Interleukin-15 Human genes 0.000 description 2
- 108090000172 Interleukin-15 Proteins 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- 102000000588 Interleukin-2 Human genes 0.000 description 2
- 108010038501 Interleukin-6 Receptors Proteins 0.000 description 2
- 102100037792 Interleukin-6 receptor subunit alpha Human genes 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 2
- 108010061593 Member 14 Tumor Necrosis Factor Receptors Proteins 0.000 description 2
- 206010027406 Mesothelioma Diseases 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- GMPKIPWJBDOURN-UHFFFAOYSA-N Methoxyamine Chemical compound CON GMPKIPWJBDOURN-UHFFFAOYSA-N 0.000 description 2
- 208000034578 Multiple myelomas Diseases 0.000 description 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 2
- 229910002651 NO3 Inorganic materials 0.000 description 2
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 2
- 238000000636 Northern blotting Methods 0.000 description 2
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 2
- 206010073338 Optic glioma Diseases 0.000 description 2
- 208000007913 Pituitary Neoplasms Diseases 0.000 description 2
- 108010064218 Poly (ADP-Ribose) Polymerase-1 Proteins 0.000 description 2
- 102100023712 Poly [ADP-ribose] polymerase 1 Human genes 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- 102100040678 Programmed cell death protein 1 Human genes 0.000 description 2
- 101710089372 Programmed cell death protein 1 Proteins 0.000 description 2
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 2
- 108090000315 Protein Kinase C Proteins 0.000 description 2
- 102000003923 Protein Kinase C Human genes 0.000 description 2
- 238000011529 RT qPCR Methods 0.000 description 2
- 206010038389 Renal cancer Diseases 0.000 description 2
- 208000004337 Salivary Gland Neoplasms Diseases 0.000 description 2
- 206010061934 Salivary gland cancer Diseases 0.000 description 2
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 238000002105 Southern blotting Methods 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 2
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- 102100028785 Tumor necrosis factor receptor superfamily member 14 Human genes 0.000 description 2
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 description 2
- 102100022203 Tumor necrosis factor receptor superfamily member 25 Human genes 0.000 description 2
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 2
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 description 2
- 208000002495 Uterine Neoplasms Diseases 0.000 description 2
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 208000015234 adrenal cortex adenoma Diseases 0.000 description 2
- 201000003354 adrenal cortical adenoma Diseases 0.000 description 2
- 125000000304 alkynyl group Chemical group 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 230000003042 antagnostic effect Effects 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 201000011165 anus cancer Diseases 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 239000012472 biological sample Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 201000000053 blastoma Diseases 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 201000008274 breast adenocarcinoma Diseases 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 2
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 2
- 125000002837 carbocyclic group Chemical group 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 201000006662 cervical adenocarcinoma Diseases 0.000 description 2
- 208000024207 chronic leukemia Diseases 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- BGTOWKSIORTVQH-UHFFFAOYSA-N cyclopentanone Chemical compound O=C1CCCC1 BGTOWKSIORTVQH-UHFFFAOYSA-N 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- 238000006073 displacement reaction Methods 0.000 description 2
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 2
- 229940043264 dodecyl sulfate Drugs 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 239000008298 dragée Substances 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 201000008184 embryoma Diseases 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 238000000799 fluorescence microscopy Methods 0.000 description 2
- MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 2
- 238000001640 fractional crystallisation Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 201000006585 gastric adenocarcinoma Diseases 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 229940093915 gynecological organic acid Drugs 0.000 description 2
- 201000002222 hemangioblastoma Diseases 0.000 description 2
- 125000004475 heteroaralkyl group Chemical group 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 102000049555 human KRAS Human genes 0.000 description 2
- 125000005113 hydroxyalkoxy group Chemical group 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 238000003364 immunohistochemistry Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 102000006495 integrins Human genes 0.000 description 2
- 108010044426 integrins Proteins 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 201000000573 juvenile pilocytic astrocytoma Diseases 0.000 description 2
- 201000010982 kidney cancer Diseases 0.000 description 2
- 229940043355 kinase inhibitor Drugs 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 239000008297 liquid dosage form Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 201000009020 malignant peripheral nerve sheath tumor Diseases 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 239000002853 nucleic acid probe Substances 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- 230000000174 oncolytic effect Effects 0.000 description 2
- 208000008511 optic nerve glioma Diseases 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- 239000002304 perfume Substances 0.000 description 2
- 230000000737 periodic effect Effects 0.000 description 2
- 239000008177 pharmaceutical agent Substances 0.000 description 2
- 125000004934 phenanthridinyl group Chemical group C1(=CC=CC2=NC=C3C=CC=CC3=C12)* 0.000 description 2
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 2
- 201000004123 pineal gland cancer Diseases 0.000 description 2
- 125000003367 polycyclic group Chemical group 0.000 description 2
- 238000003752 polymerase chain reaction Methods 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 201000005825 prostate adenocarcinoma Diseases 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 125000005551 pyridylene group Chemical group 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 230000007781 signaling event Effects 0.000 description 2
- 229910052710 silicon Inorganic materials 0.000 description 2
- 239000010703 silicon Substances 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 239000007909 solid dosage form Substances 0.000 description 2
- 239000008247 solid mixture Substances 0.000 description 2
- 229960003787 sorafenib Drugs 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- HNINFCBLGHCFOJ-UHFFFAOYSA-N tert-butyl 3,8-diazabicyclo[3.2.1]octane-8-carboxylate Chemical compound C1NCC2CCC1N2C(=O)OC(C)(C)C HNINFCBLGHCFOJ-UHFFFAOYSA-N 0.000 description 2
- NEMXVXVJGXZDRR-UHFFFAOYSA-N tert-butyl n-(azetidin-3-yl)carbamate Chemical compound CC(C)(C)OC(=O)NC1CNC1 NEMXVXVJGXZDRR-UHFFFAOYSA-N 0.000 description 2
- 125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 238000000844 transformation Methods 0.000 description 2
- 229960000575 trastuzumab Drugs 0.000 description 2
- 206010046766 uterine cancer Diseases 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- LSPHULWDVZXLIL-UHFFFAOYSA-N (+/-)-Camphoric acid Chemical compound CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
- QIJRTFXNRTXDIP-UHFFFAOYSA-N (1-carboxy-2-sulfanylethyl)azanium;chloride;hydrate Chemical compound O.Cl.SCC(N)C(O)=O QIJRTFXNRTXDIP-UHFFFAOYSA-N 0.000 description 1
- DENYZIUJOTUUNY-MRXNPFEDSA-N (2R)-14-fluoro-2-methyl-6,9,10,19-tetrazapentacyclo[14.2.1.02,6.08,18.012,17]nonadeca-1(18),8,12(17),13,15-pentaen-11-one Chemical compound FC=1C=C2C=3C=4C(CN5[C@@](C4NC3C1)(CCC5)C)=NNC2=O DENYZIUJOTUUNY-MRXNPFEDSA-N 0.000 description 1
- PAORVUMOXXAMPL-SECBINFHSA-N (2s)-3,3,3-trifluoro-2-methoxy-2-phenylpropanoyl chloride Chemical compound CO[C@](C(Cl)=O)(C(F)(F)F)C1=CC=CC=C1 PAORVUMOXXAMPL-SECBINFHSA-N 0.000 description 1
- LOGFVTREOLYCPF-KXNHARMFSA-N (2s,3r)-2-[[(2r)-1-[(2s)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoic acid Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-KXNHARMFSA-N 0.000 description 1
- FPVKHBSQESCIEP-UHFFFAOYSA-N (8S)-3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol Natural products C1C(O)C(CO)OC1N1C(NC=NCC2O)=C2N=C1 FPVKHBSQESCIEP-UHFFFAOYSA-N 0.000 description 1
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 description 1
- 125000004400 (C1-C12) alkyl group Chemical group 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N (R)-alpha-Tocopherol Natural products OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
- LKJPYSCBVHEWIU-KRWDZBQOSA-N (R)-bicalutamide Chemical compound C([C@@](O)(C)C(=O)NC=1C=C(C(C#N)=CC=1)C(F)(F)F)S(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-KRWDZBQOSA-N 0.000 description 1
- LAMIXXKAWNLXOC-INIZCTEOSA-N (S)-HDAC-42 Chemical compound O=C([C@@H](C(C)C)C=1C=CC=CC=1)NC1=CC=C(C(=O)NO)C=C1 LAMIXXKAWNLXOC-INIZCTEOSA-N 0.000 description 1
- AUGCSOFQTDKPSO-RGVLZGJSSA-N (e)-n-[3-(dimethylamino)propyl]-n'-hydroxy-2-(naphthalen-1-yloxymethyl)oct-2-enediamide Chemical compound C1=CC=C2C(OC/C(C(=O)NCCCN(C)C)=C\CCCCC(=O)NO)=CC=CC2=C1 AUGCSOFQTDKPSO-RGVLZGJSSA-N 0.000 description 1
- MOWXJLUYGFNTAL-DEOSSOPVSA-N (s)-[2-chloro-4-fluoro-5-(7-morpholin-4-ylquinazolin-4-yl)phenyl]-(6-methoxypyridazin-3-yl)methanol Chemical compound N1=NC(OC)=CC=C1[C@@H](O)C1=CC(C=2C3=CC=C(C=C3N=CN=2)N2CCOCC2)=C(F)C=C1Cl MOWXJLUYGFNTAL-DEOSSOPVSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- BKWJAKQVGHWELA-UHFFFAOYSA-N 1-[6-(2-hydroxypropan-2-yl)-2-pyridinyl]-6-[4-(4-methyl-1-piperazinyl)anilino]-2-prop-2-enyl-3-pyrazolo[3,4-d]pyrimidinone Chemical compound C1CN(C)CCN1C(C=C1)=CC=C1NC1=NC=C2C(=O)N(CC=C)N(C=3N=C(C=CC=3)C(C)(C)O)C2=N1 BKWJAKQVGHWELA-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- BOMZMNZEXMAQQW-UHFFFAOYSA-N 2,5,11-trimethyl-6h-pyrido[4,3-b]carbazol-2-ium-9-ol;acetate Chemical compound CC([O-])=O.C[N+]1=CC=C2C(C)=C(NC=3C4=CC(O)=CC=3)C4=C(C)C2=C1 BOMZMNZEXMAQQW-UHFFFAOYSA-N 0.000 description 1
- VLIUIBXPEDFJRF-UHFFFAOYSA-N 2-(n-(2-chlorophenyl)anilino)-n-[7-(hydroxyamino)-7-oxoheptyl]pyrimidine-5-carboxamide Chemical compound N1=CC(C(=O)NCCCCCCC(=O)NO)=CN=C1N(C=1C(=CC=CC=1)Cl)C1=CC=CC=C1 VLIUIBXPEDFJRF-UHFFFAOYSA-N 0.000 description 1
- PEMUGDMSUDYLHU-ZEQRLZLVSA-N 2-[(2S)-4-[7-(8-chloronaphthalen-1-yl)-2-[[(2S)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]-1-(2-fluoroprop-2-enoyl)piperazin-2-yl]acetonitrile Chemical compound ClC=1C=CC=C2C=CC=C(C=12)N1CC=2N=C(N=C(C=2CC1)N1C[C@@H](N(CC1)C(C(=C)F)=O)CC#N)OC[C@H]1N(CCC1)C PEMUGDMSUDYLHU-ZEQRLZLVSA-N 0.000 description 1
- RTQWWZBSTRGEAV-PKHIMPSTSA-N 2-[[(2s)-2-[bis(carboxymethyl)amino]-3-[4-(methylcarbamoylamino)phenyl]propyl]-[2-[bis(carboxymethyl)amino]propyl]amino]acetic acid Chemical compound CNC(=O)NC1=CC=C(C[C@@H](CN(CC(C)N(CC(O)=O)CC(O)=O)CC(O)=O)N(CC(O)=O)CC(O)=O)C=C1 RTQWWZBSTRGEAV-PKHIMPSTSA-N 0.000 description 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
- JNODDICFTDYODH-UHFFFAOYSA-N 2-hydroxytetrahydrofuran Chemical compound OC1CCCO1 JNODDICFTDYODH-UHFFFAOYSA-N 0.000 description 1
- 125000004918 2-methyl-2-pentyl group Chemical group CC(C)(CCC)* 0.000 description 1
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 1
- 229940080296 2-naphthalenesulfonate Drugs 0.000 description 1
- HPJALMWOZYIZGE-UHFFFAOYSA-N 2-oxa-6-azaspiro[3.3]heptane Chemical compound C1NCC11COC1 HPJALMWOZYIZGE-UHFFFAOYSA-N 0.000 description 1
- NDMPLJNOPCLANR-UHFFFAOYSA-N 3,4-dihydroxy-15-(4-hydroxy-18-methoxycarbonyl-5,18-seco-ibogamin-18-yl)-16-methoxy-1-methyl-6,7-didehydro-aspidospermidine-3-carboxylic acid methyl ester Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 NDMPLJNOPCLANR-UHFFFAOYSA-N 0.000 description 1
- MZSAMHOCTRNOIZ-UHFFFAOYSA-N 3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy-N-phenylaniline Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC=1C=C(NC2=CC=CC=C2)C=CC=1 MZSAMHOCTRNOIZ-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- ZRPLANDPDWYOMZ-UHFFFAOYSA-N 3-cyclopentylpropionic acid Chemical compound OC(=O)CCC1CCCC1 ZRPLANDPDWYOMZ-UHFFFAOYSA-N 0.000 description 1
- 125000004919 3-methyl-2-pentyl group Chemical group CC(C(C)*)CC 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-M 3-phenylpropionate Chemical compound [O-]C(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-M 0.000 description 1
- 102100037263 3-phosphoinositide-dependent protein kinase 1 Human genes 0.000 description 1
- CLPFFLWZZBQMAO-UHFFFAOYSA-N 4-(5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-5-yl)benzonitrile Chemical compound C1=CC(C#N)=CC=C1C1N2C=NC=C2CCC1 CLPFFLWZZBQMAO-UHFFFAOYSA-N 0.000 description 1
- ZHSKUOZOLHMKEA-UHFFFAOYSA-N 4-[5-[bis(2-chloroethyl)amino]-1-methylbenzimidazol-2-yl]butanoic acid;hydron;chloride Chemical compound Cl.ClCCN(CCCl)C1=CC=C2N(C)C(CCCC(O)=O)=NC2=C1 ZHSKUOZOLHMKEA-UHFFFAOYSA-N 0.000 description 1
- 125000004920 4-methyl-2-pentyl group Chemical group CC(CC(C)*)C 0.000 description 1
- 102100022464 5'-nucleotidase Human genes 0.000 description 1
- SRBJWIBAMIKCMV-GFCCVEGCSA-N 5-[(8-chloroisoquinolin-3-yl)amino]-3-[(2r)-1-(dimethylamino)propan-2-yl]oxypyrazine-2-carbonitrile Chemical compound N1=C(C#N)C(O[C@@H](CN(C)C)C)=NC(NC=2N=CC3=C(Cl)C=CC=C3C=2)=C1 SRBJWIBAMIKCMV-GFCCVEGCSA-N 0.000 description 1
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 description 1
- GMIZZEXBPRLVIV-SECBINFHSA-N 6-bromo-3-(1-methylpyrazol-4-yl)-5-[(3r)-piperidin-3-yl]pyrazolo[1,5-a]pyrimidin-7-amine Chemical compound C1=NN(C)C=C1C1=C2N=C([C@H]3CNCCC3)C(Br)=C(N)N2N=C1 GMIZZEXBPRLVIV-SECBINFHSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- PBCZSGKMGDDXIJ-HQCWYSJUSA-N 7-hydroxystaurosporine Chemical compound N([C@H](O)C1=C2C3=CC=CC=C3N3C2=C24)C(=O)C1=C2C1=CC=CC=C1N4[C@H]1C[C@@H](NC)[C@@H](OC)[C@]3(C)O1 PBCZSGKMGDDXIJ-HQCWYSJUSA-N 0.000 description 1
- PBCZSGKMGDDXIJ-UHFFFAOYSA-N 7beta-hydroxystaurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3C(O)NC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(C)O1 PBCZSGKMGDDXIJ-UHFFFAOYSA-N 0.000 description 1
- JLFSBHQQXIAQEC-UHFFFAOYSA-N 9x5a2qia7c Chemical compound C1=CC(C(=O)NN2)=C3C2=NC(CN2CC4=CC=CC=C4C2)=NC3=C1 JLFSBHQQXIAQEC-UHFFFAOYSA-N 0.000 description 1
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 description 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
- 206010000871 Acute monocytic leukaemia Diseases 0.000 description 1
- 206010000890 Acute myelomonocytic leukaemia Diseases 0.000 description 1
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 description 1
- 208000006468 Adrenal Cortex Neoplasms Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 201000003076 Angiosarcoma Diseases 0.000 description 1
- 235000003276 Apios tuberosa Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 235000010777 Arachis hypogaea Nutrition 0.000 description 1
- 235000010744 Arachis villosulicarpa Nutrition 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 1
- 206010004146 Basal cell carcinoma Diseases 0.000 description 1
- 206010060999 Benign neoplasm Diseases 0.000 description 1
- 102100031505 Beta-1,4 N-acetylgalactosaminyltransferase 1 Human genes 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- 108700012439 CA9 Proteins 0.000 description 1
- 102100024217 CAMPATH-1 antigen Human genes 0.000 description 1
- 108010065524 CD52 Antigen Proteins 0.000 description 1
- 108010062802 CD66 antigens Proteins 0.000 description 1
- JBEWLUHPJXPMET-UHFFFAOYSA-N COCOC1=NC2=CC=CC=C2C(Br)=C1 Chemical compound COCOC1=NC2=CC=CC=C2C(Br)=C1 JBEWLUHPJXPMET-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 102100025570 Cancer/testis antigen 1 Human genes 0.000 description 1
- 102100024423 Carbonic anhydrase 9 Human genes 0.000 description 1
- SHHKQEUPHAENFK-UHFFFAOYSA-N Carboquone Chemical compound O=C1C(C)=C(N2CC2)C(=O)C(C(COC(N)=O)OC)=C1N1CC1 SHHKQEUPHAENFK-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 102100024533 Carcinoembryonic antigen-related cell adhesion molecule 1 Human genes 0.000 description 1
- 208000017897 Carcinoma of esophagus Diseases 0.000 description 1
- AOCCBINRVIKJHY-UHFFFAOYSA-N Carmofur Chemical compound CCCCCCNC(=O)N1C=C(F)C(=O)NC1=O AOCCBINRVIKJHY-UHFFFAOYSA-N 0.000 description 1
- 208000006332 Choriocarcinoma Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 206010052360 Colorectal adenocarcinoma Diseases 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- 108010069514 Cyclic Peptides Proteins 0.000 description 1
- 102000001189 Cyclic Peptides Human genes 0.000 description 1
- 108090000266 Cyclin-dependent kinases Proteins 0.000 description 1
- 102000003903 Cyclin-dependent kinases Human genes 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- ZBNZXTGUTAYRHI-UHFFFAOYSA-N Dasatinib Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl ZBNZXTGUTAYRHI-UHFFFAOYSA-N 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 101150016325 EPHA3 gene Proteins 0.000 description 1
- 101150068804 ETR2 gene Proteins 0.000 description 1
- 201000009051 Embryonal Carcinoma Diseases 0.000 description 1
- SAMRUMKYXPVKPA-VFKOLLTISA-N Enocitabine Chemical compound O=C1N=C(NC(=O)CCCCCCCCCCCCCCCCCCCCC)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 SAMRUMKYXPVKPA-VFKOLLTISA-N 0.000 description 1
- 102100030324 Ephrin type-A receptor 3 Human genes 0.000 description 1
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 description 1
- 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 description 1
- OBMLHUPNRURLOK-XGRAFVIBSA-N Epitiostanol Chemical compound C1[C@@H]2S[C@@H]2C[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 OBMLHUPNRURLOK-XGRAFVIBSA-N 0.000 description 1
- 208000031637 Erythroblastic Acute Leukemia Diseases 0.000 description 1
- 208000036566 Erythroleukaemia Diseases 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 description 1
- 108010007457 Extracellular Signal-Regulated MAP Kinases Proteins 0.000 description 1
- 229940124783 FAK inhibitor Drugs 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 102100037813 Focal adhesion kinase 1 Human genes 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 102000013446 GTP Phosphohydrolases Human genes 0.000 description 1
- 108091006109 GTPases Proteins 0.000 description 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 description 1
- 102000013382 Gelatinases Human genes 0.000 description 1
- 108010026132 Gelatinases Proteins 0.000 description 1
- 241000206672 Gelidium Species 0.000 description 1
- 101710088083 Glomulin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 102000016285 Guanine Nucleotide Exchange Factors Human genes 0.000 description 1
- 108010067218 Guanine Nucleotide Exchange Factors Proteins 0.000 description 1
- 208000001258 Hemangiosarcoma Diseases 0.000 description 1
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 description 1
- 239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
- 101000600756 Homo sapiens 3-phosphoinositide-dependent protein kinase 1 Proteins 0.000 description 1
- 101000678236 Homo sapiens 5'-nucleotidase Proteins 0.000 description 1
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 description 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 1
- 101000729811 Homo sapiens Beta-1,4 N-acetylgalactosaminyltransferase 1 Proteins 0.000 description 1
- 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 description 1
- 101000914324 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 5 Proteins 0.000 description 1
- 101000914321 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 7 Proteins 0.000 description 1
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 description 1
- 101001068133 Homo sapiens Hepatitis A virus cellular receptor 2 Proteins 0.000 description 1
- 101001034652 Homo sapiens Insulin-like growth factor 1 receptor Proteins 0.000 description 1
- 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 description 1
- 101000868279 Homo sapiens Leukocyte surface antigen CD47 Proteins 0.000 description 1
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 description 1
- 101000844245 Homo sapiens Non-receptor tyrosine-protein kinase TYK2 Proteins 0.000 description 1
- 101000617725 Homo sapiens Pregnancy-specific beta-1-glycoprotein 2 Proteins 0.000 description 1
- 101001117317 Homo sapiens Programmed cell death 1 ligand 1 Proteins 0.000 description 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
- 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 1
- 101000610605 Homo sapiens Tumor necrosis factor receptor superfamily member 10A Proteins 0.000 description 1
- 101000610604 Homo sapiens Tumor necrosis factor receptor superfamily member 10B Proteins 0.000 description 1
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 description 1
- 101000864342 Homo sapiens Tyrosine-protein kinase BTK Proteins 0.000 description 1
- 101000604583 Homo sapiens Tyrosine-protein kinase SYK Proteins 0.000 description 1
- 101000666896 Homo sapiens V-type immunoglobulin domain-containing suppressor of T-cell activation Proteins 0.000 description 1
- 101000851007 Homo sapiens Vascular endothelial growth factor receptor 2 Proteins 0.000 description 1
- 101001117146 Homo sapiens [Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 1, mitochondrial Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000037982 Immune checkpoint proteins Human genes 0.000 description 1
- 108091008036 Immune checkpoint proteins Proteins 0.000 description 1
- 102100039688 Insulin-like growth factor 1 receptor Human genes 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 102000003996 Interferon-beta Human genes 0.000 description 1
- 108090000467 Interferon-beta Proteins 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 102000003777 Interleukin-1 beta Human genes 0.000 description 1
- 108090000193 Interleukin-1 beta Proteins 0.000 description 1
- 206010061252 Intraocular melanoma Diseases 0.000 description 1
- 241000764238 Isis Species 0.000 description 1
- SHGAZHPCJJPHSC-NUEINMDLSA-N Isotretinoin Chemical compound OC(=O)C=C(C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NUEINMDLSA-N 0.000 description 1
- 102000042838 JAK family Human genes 0.000 description 1
- 108091082332 JAK family Proteins 0.000 description 1
- 102000002698 KIR Receptors Human genes 0.000 description 1
- 108010043610 KIR Receptors Proteins 0.000 description 1
- 101150069255 KLRC1 gene Proteins 0.000 description 1
- 229940124785 KRAS inhibitor Drugs 0.000 description 1
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 1
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 239000005517 L01XE01 - Imatinib Substances 0.000 description 1
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 1
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 1
- 239000005511 L01XE05 - Sorafenib Substances 0.000 description 1
- 239000002067 L01XE06 - Dasatinib Substances 0.000 description 1
- 239000005536 L01XE08 - Nilotinib Substances 0.000 description 1
- 239000003798 L01XE11 - Pazopanib Substances 0.000 description 1
- 239000002118 L01XE12 - Vandetanib Substances 0.000 description 1
- 239000002145 L01XE14 - Bosutinib Substances 0.000 description 1
- 239000002146 L01XE16 - Crizotinib Substances 0.000 description 1
- 239000002144 L01XE18 - Ruxolitinib Substances 0.000 description 1
- 239000002138 L01XE21 - Regorafenib Substances 0.000 description 1
- 239000002137 L01XE24 - Ponatinib Substances 0.000 description 1
- 239000002176 L01XE26 - Cabozantinib Substances 0.000 description 1
- 239000002177 L01XE27 - Ibrutinib Substances 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 208000018142 Leiomyosarcoma Diseases 0.000 description 1
- 102100032913 Leukocyte surface antigen CD47 Human genes 0.000 description 1
- HLFSDGLLUJUHTE-SNVBAGLBSA-N Levamisole Chemical compound C1([C@H]2CN3CCSC3=N2)=CC=CC=C1 HLFSDGLLUJUHTE-SNVBAGLBSA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 108091054455 MAP kinase family Proteins 0.000 description 1
- 102000043136 MAP kinase family Human genes 0.000 description 1
- 229940126560 MAPK inhibitor Drugs 0.000 description 1
- 101100404845 Macaca mulatta NKG2A gene Proteins 0.000 description 1
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100028123 Macrophage colony-stimulating factor 1 Human genes 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 1
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 1
- 208000007054 Medullary Carcinoma Diseases 0.000 description 1
- IVDYZAAPOLNZKG-KWHRADDSSA-N Mepitiostane Chemical compound O([C@@H]1[C@]2(CC[C@@H]3[C@@]4(C)C[C@H]5S[C@H]5C[C@@H]4CC[C@H]3[C@@H]2CC1)C)C1(OC)CCCC1 IVDYZAAPOLNZKG-KWHRADDSSA-N 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical class OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- VFKZTMPDYBFSTM-KVTDHHQDSA-N Mitobronitol Chemical compound BrC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CBr VFKZTMPDYBFSTM-KVTDHHQDSA-N 0.000 description 1
- 229930192392 Mitomycin Natural products 0.000 description 1
- 208000035489 Monocytic Acute Leukemia Diseases 0.000 description 1
- 108010063954 Mucins Proteins 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 description 1
- 208000033835 Myelomonocytic Acute Leukemia Diseases 0.000 description 1
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical group C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 1
- FBKMWOJEPMPVTQ-UHFFFAOYSA-N N'-(3-bromo-4-fluorophenyl)-N-hydroxy-4-[2-(sulfamoylamino)ethylamino]-1,2,5-oxadiazole-3-carboximidamide Chemical compound NS(=O)(=O)NCCNC1=NON=C1C(=NO)NC1=CC=C(F)C(Br)=C1 FBKMWOJEPMPVTQ-UHFFFAOYSA-N 0.000 description 1
- HRNLUBSXIHFDHP-UHFFFAOYSA-N N-(2-aminophenyl)-4-[[[4-(3-pyridinyl)-2-pyrimidinyl]amino]methyl]benzamide Chemical compound NC1=CC=CC=C1NC(=O)C(C=C1)=CC=C1CNC1=NC=CC(C=2C=NC=CC=2)=N1 HRNLUBSXIHFDHP-UHFFFAOYSA-N 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- QGZYDVAGYRLSKP-UHFFFAOYSA-N N-[7-(hydroxyamino)-7-oxoheptyl]-2-(N-phenylanilino)-5-pyrimidinecarboxamide Chemical compound N1=CC(C(=O)NCCCCCCC(=O)NO)=CN=C1N(C=1C=CC=CC=1)C1=CC=CC=C1 QGZYDVAGYRLSKP-UHFFFAOYSA-N 0.000 description 1
- 102100022682 NKG2-A/NKG2-B type II integral membrane protein Human genes 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 102100032028 Non-receptor tyrosine-protein kinase TYK2 Human genes 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- 102000038030 PI3Ks Human genes 0.000 description 1
- 108091007960 PI3Ks Proteins 0.000 description 1
- 102000016387 Pancreatic elastase Human genes 0.000 description 1
- 108010067372 Pancreatic elastase Proteins 0.000 description 1
- 208000000821 Parathyroid Neoplasms Diseases 0.000 description 1
- 208000034038 Pathologic Neovascularization Diseases 0.000 description 1
- 208000002471 Penile Neoplasms Diseases 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 201000007286 Pilocytic astrocytoma Diseases 0.000 description 1
- 201000005746 Pituitary adenoma Diseases 0.000 description 1
- 206010061538 Pituitary tumour benign Diseases 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 102000012338 Poly(ADP-ribose) Polymerases Human genes 0.000 description 1
- 108010061844 Poly(ADP-ribose) Polymerases Proteins 0.000 description 1
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- HFVNWDWLWUCIHC-GUPDPFMOSA-N Prednimustine Chemical compound O=C([C@@]1(O)CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)[C@@H](O)C[C@@]21C)COC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 HFVNWDWLWUCIHC-GUPDPFMOSA-N 0.000 description 1
- 102100022019 Pregnancy-specific beta-1-glycoprotein 2 Human genes 0.000 description 1
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 description 1
- 102100023832 Prolyl endopeptidase FAP Human genes 0.000 description 1
- 208000033826 Promyelocytic Acute Leukemia Diseases 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 102100033810 RAC-alpha serine/threonine-protein kinase Human genes 0.000 description 1
- 102100033479 RAF proto-oncogene serine/threonine-protein kinase Human genes 0.000 description 1
- 108010025832 RANK Ligand Proteins 0.000 description 1
- 102000014128 RANK Ligand Human genes 0.000 description 1
- 101001039269 Rattus norvegicus Glycine N-methyltransferase Proteins 0.000 description 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 1
- 102100029986 Receptor tyrosine-protein kinase erbB-3 Human genes 0.000 description 1
- 101710100969 Receptor tyrosine-protein kinase erbB-3 Proteins 0.000 description 1
- 206010038934 Retinopathy proliferative Diseases 0.000 description 1
- BKRGVLQUQGGVSM-KBXCAEBGSA-N Revanil Chemical compound C1=CC(C=2[C@H](N(C)C[C@H](C=2)NC(=O)N(CC)CC)C2)=C3C2=CNC3=C1 BKRGVLQUQGGVSM-KBXCAEBGSA-N 0.000 description 1
- 208000008938 Rhabdoid tumor Diseases 0.000 description 1
- 206010073334 Rhabdoid tumour Diseases 0.000 description 1
- 235000004443 Ricinus communis Nutrition 0.000 description 1
- OTKJDMGTUTTYMP-ROUUACIJSA-N Safingol ( L-threo-sphinganine) Chemical compound CCCCCCCCCCCCCCC[C@H](O)[C@@H](N)CO OTKJDMGTUTTYMP-ROUUACIJSA-N 0.000 description 1
- 201000010208 Seminoma Diseases 0.000 description 1
- 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 1
- OCOKWVBYZHBHLU-UHFFFAOYSA-N Sobuzoxane Chemical compound C1C(=O)N(COC(=O)OCC(C)C)C(=O)CN1CCN1CC(=O)N(COC(=O)OCC(C)C)C(=O)C1 OCOKWVBYZHBHLU-UHFFFAOYSA-N 0.000 description 1
- 208000021712 Soft tissue sarcoma Diseases 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 208000001662 Subependymal Glioma Diseases 0.000 description 1
- 102000042834 TEC family Human genes 0.000 description 1
- 108091082333 TEC family Proteins 0.000 description 1
- CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 description 1
- 102100038126 Tenascin Human genes 0.000 description 1
- 108010008125 Tenascin Proteins 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 1
- 108010078233 Thymalfasin Proteins 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 239000004012 Tofacitinib Substances 0.000 description 1
- IVTVGDXNLFLDRM-HNNXBMFYSA-N Tomudex Chemical compound C=1C=C2NC(C)=NC(=O)C2=CC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)S1 IVTVGDXNLFLDRM-HNNXBMFYSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 102100036922 Tumor necrosis factor ligand superfamily member 13B Human genes 0.000 description 1
- 101710181056 Tumor necrosis factor ligand superfamily member 13B Proteins 0.000 description 1
- 102100040113 Tumor necrosis factor receptor superfamily member 10A Human genes 0.000 description 1
- 102100040112 Tumor necrosis factor receptor superfamily member 10B Human genes 0.000 description 1
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 description 1
- 102100029823 Tyrosine-protein kinase BTK Human genes 0.000 description 1
- 102100038183 Tyrosine-protein kinase SYK Human genes 0.000 description 1
- 208000023915 Ureteral Neoplasms Diseases 0.000 description 1
- 206010046458 Urethral neoplasms Diseases 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000008385 Urogenital Neoplasms Diseases 0.000 description 1
- 201000005969 Uveal melanoma Diseases 0.000 description 1
- 102100038282 V-type immunoglobulin domain-containing suppressor of T-cell activation Human genes 0.000 description 1
- 108091008605 VEGF receptors Proteins 0.000 description 1
- 201000003761 Vaginal carcinoma Diseases 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- ZVNYJIZDIRKMBF-UHFFFAOYSA-N Vesnarinone Chemical compound C1=C(OC)C(OC)=CC=C1C(=O)N1CCN(C=2C=C3CCC(=O)NC3=CC=2)CC1 ZVNYJIZDIRKMBF-UHFFFAOYSA-N 0.000 description 1
- 208000008383 Wilms tumor Diseases 0.000 description 1
- 108010072912 YM753 compound Proteins 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- GUWXKKAWLCENJA-WGWHJZDNSA-N [(2r,3s,5r)-5-(2-amino-6-oxo-3h-purin-9-yl)-3-hydroxyoxolan-2-yl]methyl [(2r,3s,5r)-5-(4-amino-2-oxo-1,3,5-triazin-1-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Chemical compound O=C1N=C(N)N=CN1[C@@H]1O[C@H](CO)[C@@H](OP(O)(=O)OC[C@@H]2[C@H](C[C@@H](O2)N2C3=C(C(N=C(N)N3)=O)N=C2)O)C1 GUWXKKAWLCENJA-WGWHJZDNSA-N 0.000 description 1
- JOSCNYCOYXTLTN-GFCCVEGCSA-N [3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxyphenyl]-[(3R)-3-(hydroxymethyl)pyrrolidin-1-yl]methanone Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC=1C=C(C=CC=1)C(=O)N1C[C@@H](CC1)CO JOSCNYCOYXTLTN-GFCCVEGCSA-N 0.000 description 1
- JWSIZPAOIFLWKM-UHFFFAOYSA-N [3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxyphenyl]-[3-(dimethylamino)-4-hydroxypyrrolidin-1-yl]methanone Chemical compound CN(C)C1CN(CC1O)C(=O)c1cccc(Oc2cc(CN)cc(n2)C(F)(F)F)c1 JWSIZPAOIFLWKM-UHFFFAOYSA-N 0.000 description 1
- IEDXPSOJFSVCKU-HOKPPMCLSA-N [4-[[(2S)-5-(carbamoylamino)-2-[[(2S)-2-[6-(2,5-dioxopyrrolidin-1-yl)hexanoylamino]-3-methylbutanoyl]amino]pentanoyl]amino]phenyl]methyl N-[(2S)-1-[[(2S)-1-[[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]-N-methylcarbamate Chemical compound CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C)[C@@H](O)c1ccccc1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C(=O)OCc1ccc(NC(=O)[C@H](CCCNC(N)=O)NC(=O)[C@@H](NC(=O)CCCCCN2C(=O)CCC2=O)C(C)C)cc1)C(C)C IEDXPSOJFSVCKU-HOKPPMCLSA-N 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000003655 absorption accelerator Substances 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 150000008043 acidic salts Chemical class 0.000 description 1
- 208000017733 acquired polycythemia vera Diseases 0.000 description 1
- 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000021841 acute erythroid leukemia Diseases 0.000 description 1
- 208000011912 acute myelomonocytic leukemia M4 Diseases 0.000 description 1
- 229940124988 adagrasib Drugs 0.000 description 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
- 229950009557 adavosertib Drugs 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 229950009084 adecatumumab Drugs 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
- 208000024447 adrenal gland neoplasm Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229960001686 afatinib Drugs 0.000 description 1
- ULXXDDBFHOBEHA-CWDCEQMOSA-N afatinib Chemical compound N1=CN=C2C=C(O[C@@H]3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC1=CC=C(F)C(Cl)=C1 ULXXDDBFHOBEHA-CWDCEQMOSA-N 0.000 description 1
- 108010081667 aflibercept Proteins 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 108700025316 aldesleukin Proteins 0.000 description 1
- 229960005310 aldesleukin Drugs 0.000 description 1
- 229960000548 alemtuzumab Drugs 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 150000001447 alkali salts Chemical class 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 125000004419 alkynylene group Chemical group 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 230000003281 allosteric effect Effects 0.000 description 1
- 229940087168 alpha tocopherol Drugs 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- ROBVIMPUHSLWNV-UHFFFAOYSA-N aminoglutethimide Chemical compound C=1C=C(N)C=CC=1C1(CC)CCC(=O)NC1=O ROBVIMPUHSLWNV-UHFFFAOYSA-N 0.000 description 1
- 229960003437 aminoglutethimide Drugs 0.000 description 1
- XCPGHVQEEXUHNC-UHFFFAOYSA-N amsacrine Chemical compound COC1=CC(NS(C)(=O)=O)=CC=C1NC1=C(C=CC=C2)C2=NC2=CC=CC=C12 XCPGHVQEEXUHNC-UHFFFAOYSA-N 0.000 description 1
- 229960001220 amsacrine Drugs 0.000 description 1
- 206010002224 anaplastic astrocytoma Diseases 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- 125000005160 aryl oxy alkyl group Chemical group 0.000 description 1
- 125000005228 aryl sulfonate group Chemical group 0.000 description 1
- 125000000732 arylene group Chemical group 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010385 ascorbyl palmitate Nutrition 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 238000011914 asymmetric synthesis Methods 0.000 description 1
- 229960003005 axitinib Drugs 0.000 description 1
- RITAVMQDGBJQJZ-FMIVXFBMSA-N axitinib Chemical compound CNC(=O)C1=CC=CC=C1SC1=CC=C(C(\C=C\C=2N=CC=CC=2)=NN2)C2=C1 RITAVMQDGBJQJZ-FMIVXFBMSA-N 0.000 description 1
- 229960002756 azacitidine Drugs 0.000 description 1
- KLNFSAOEKUDMFA-UHFFFAOYSA-N azanide;2-hydroxyacetic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OCC(O)=O KLNFSAOEKUDMFA-UHFFFAOYSA-N 0.000 description 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
- 229960003270 belimumab Drugs 0.000 description 1
- 229960003094 belinostat Drugs 0.000 description 1
- NCNRHFGMJRPRSK-MDZDMXLPSA-N belinostat Chemical compound ONC(=O)\C=C\C1=CC=CC(S(=O)(=O)NC=2C=CC=CC=2)=C1 NCNRHFGMJRPRSK-MDZDMXLPSA-N 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 235000012216 bentonite Nutrition 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 229940050390 benzoate Drugs 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- 125000000649 benzylidene group Chemical group [H]C(=[*])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-N beta-phenylpropanoic acid Natural products OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 1
- 229960000397 bevacizumab Drugs 0.000 description 1
- 150000005347 biaryls Chemical class 0.000 description 1
- 229960000997 bicalutamide Drugs 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 201000007180 bile duct carcinoma Diseases 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 201000001531 bladder carcinoma Diseases 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- IUEWAGVJRJORLA-HZPDHXFCSA-N bmn-673 Chemical compound CN1N=CN=C1[C@H]1C(NNC(=O)C2=CC(F)=C3)=C2C3=N[C@@H]1C1=CC=C(F)C=C1 IUEWAGVJRJORLA-HZPDHXFCSA-N 0.000 description 1
- 229910052796 boron Inorganic materials 0.000 description 1
- 229960001467 bortezomib Drugs 0.000 description 1
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 description 1
- 229960003736 bosutinib Drugs 0.000 description 1
- UBPYILGKFZZVDX-UHFFFAOYSA-N bosutinib Chemical compound C1=C(Cl)C(OC)=CC(NC=2C3=CC(OC)=C(OCCCN4CCN(C)CC4)C=C3N=CC=2C#N)=C1Cl UBPYILGKFZZVDX-UHFFFAOYSA-N 0.000 description 1
- 229960000455 brentuximab vedotin Drugs 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 208000003362 bronchogenic carcinoma Diseases 0.000 description 1
- 229960005539 bryostatin 1 Drugs 0.000 description 1
- MJQUEDHRCUIRLF-TVIXENOKSA-N bryostatin 1 Chemical compound C([C@@H]1CC(/[C@@H]([C@@](C(C)(C)/C=C/2)(O)O1)OC(=O)/C=C/C=C/CCC)=C\C(=O)OC)[C@H]([C@@H](C)O)OC(=O)C[C@H](O)C[C@@H](O1)C[C@H](OC(C)=O)C(C)(C)[C@]1(O)C[C@@H]1C\C(=C\C(=O)OC)C[C@H]\2O1 MJQUEDHRCUIRLF-TVIXENOKSA-N 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
- 229960001292 cabozantinib Drugs 0.000 description 1
- ONIQOQHATWINJY-UHFFFAOYSA-N cabozantinib Chemical compound C=12C=C(OC)C(OC)=CC2=NC=CC=1OC(C=C1)=CC=C1NC(=O)C1(C(=O)NC=2C=CC(F)=CC=2)CC1 ONIQOQHATWINJY-UHFFFAOYSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- FATUQANACHZLRT-KMRXSBRUSA-L calcium glucoheptonate Chemical compound [Ca+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O FATUQANACHZLRT-KMRXSBRUSA-L 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 229960001838 canakinumab Drugs 0.000 description 1
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 229960002115 carboquone Drugs 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- BLMPQMFVWMYDKT-NZTKNTHTSA-N carfilzomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)[C@]1(C)OC1)NC(=O)CN1CCOCC1)CC1=CC=CC=C1 BLMPQMFVWMYDKT-NZTKNTHTSA-N 0.000 description 1
- 229960002438 carfilzomib Drugs 0.000 description 1
- 108010021331 carfilzomib Proteins 0.000 description 1
- 229960003261 carmofur Drugs 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- OHUHVTCQTUDPIJ-JYCIKRDWSA-N ceralasertib Chemical compound C[C@@H]1COCCN1C1=CC(C2(CC2)[S@](C)(=N)=O)=NC(C=2C=3C=CNC=3N=CC=2)=N1 OHUHVTCQTUDPIJ-JYCIKRDWSA-N 0.000 description 1
- 229960001602 ceritinib Drugs 0.000 description 1
- VERWOWGGCGHDQE-UHFFFAOYSA-N ceritinib Chemical compound CC=1C=C(NC=2N=C(NC=3C(=CC=CC=3)S(=O)(=O)C(C)C)C(Cl)=CN=2)C(OC(C)C)=CC=1C1CCNCC1 VERWOWGGCGHDQE-UHFFFAOYSA-N 0.000 description 1
- 208000019065 cervical carcinoma Diseases 0.000 description 1
- 229960003230 cetrorelix Drugs 0.000 description 1
- SBNPWPIBESPSIF-MHWMIDJBSA-N cetrorelix Chemical compound C([C@@H](C(=O)N[C@H](CCCNC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 SBNPWPIBESPSIF-MHWMIDJBSA-N 0.000 description 1
- 108700008462 cetrorelix Proteins 0.000 description 1
- 229960005395 cetuximab Drugs 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 229910052729 chemical element Inorganic materials 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 125000003016 chromanyl group Chemical group O1C(CCC2=CC=CC=C12)* 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- 229950006647 cixutumumab Drugs 0.000 description 1
- 229960002436 cladribine Drugs 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000006552 constitutive activation Effects 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000013256 coordination polymer Substances 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 229960005061 crizotinib Drugs 0.000 description 1
- KTEIFNKAUNYNJU-GFCCVEGCSA-N crizotinib Chemical compound O([C@H](C)C=1C(=C(F)C=CC=1Cl)Cl)C(C(=NC=1)N)=CC=1C(=C1)C=NN1C1CCNCC1 KTEIFNKAUNYNJU-GFCCVEGCSA-N 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 208000030381 cutaneous melanoma Diseases 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 150000001924 cycloalkanes Chemical class 0.000 description 1
- 125000000392 cycloalkenyl group Chemical group 0.000 description 1
- 125000002993 cycloalkylene group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 208000002445 cystadenocarcinoma Diseases 0.000 description 1
- 229960001305 cysteine hydrochloride Drugs 0.000 description 1
- 229960000684 cytarabine Drugs 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 229960002465 dabrafenib Drugs 0.000 description 1
- BFSMGDJOXZAERB-UHFFFAOYSA-N dabrafenib Chemical compound S1C(C(C)(C)C)=NC(C=2C(=C(NS(=O)(=O)C=3C(=CC=CC=3F)F)C=CC=2)F)=C1C1=CC=NC(N)=N1 BFSMGDJOXZAERB-UHFFFAOYSA-N 0.000 description 1
- 229960002204 daratumumab Drugs 0.000 description 1
- 229960002448 dasatinib Drugs 0.000 description 1
- 125000004856 decahydroquinolinyl group Chemical group N1(CCCC2CCCCC12)* 0.000 description 1
- 229960003603 decitabine Drugs 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 229960002923 denileukin diftitox Drugs 0.000 description 1
- 108010017271 denileukin diftitox Proteins 0.000 description 1
- 229960001251 denosumab Drugs 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 125000002576 diazepinyl group Chemical group N1N=C(C=CC=C1)* 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- OTKJDMGTUTTYMP-UHFFFAOYSA-N dihydrosphingosine Natural products CCCCCCCCCCCCCCCC(O)C(N)CO OTKJDMGTUTTYMP-UHFFFAOYSA-N 0.000 description 1
- 229960004497 dinutuximab Drugs 0.000 description 1
- 125000000532 dioxanyl group Chemical group 0.000 description 1
- 125000005879 dioxolanyl group Chemical group 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 1
- 230000007783 downstream signaling Effects 0.000 description 1
- ZWAOHEXOSAUJHY-ZIYNGMLESA-N doxifluridine Chemical compound O[C@@H]1[C@H](O)[C@@H](C)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ZWAOHEXOSAUJHY-ZIYNGMLESA-N 0.000 description 1
- 229950005454 doxifluridine Drugs 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 230000037437 driver mutation Effects 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000002183 duodenal effect Effects 0.000 description 1
- 229940121647 egfr inhibitor Drugs 0.000 description 1
- 229950000549 elliptinium acetate Drugs 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 210000000750 endocrine system Anatomy 0.000 description 1
- 201000003914 endometrial carcinoma Diseases 0.000 description 1
- 229950011487 enocitabine Drugs 0.000 description 1
- KTEIFNKAUNYNJU-LBPRGKRZSA-N ent-crizotinib Chemical compound O([C@@H](C)C=1C(=C(F)C=CC=1Cl)Cl)C(C(=NC=1)N)=CC=1C(=C1)C=NN1C1CCNCC1 KTEIFNKAUNYNJU-LBPRGKRZSA-N 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 1
- 208000037828 epithelial carcinoma Diseases 0.000 description 1
- 229950002973 epitiostanol Drugs 0.000 description 1
- 229960001433 erlotinib Drugs 0.000 description 1
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 1
- 229950009569 etaracizumab Drugs 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- GOZRRIWDZQPGMN-UHFFFAOYSA-N ethyl 2-[5-(7h-purin-6-ylsulfanyl)pentanoylamino]acetate Chemical compound CCOC(=O)CNC(=O)CCCCSC1=NC=NC2=C1NC=N2 GOZRRIWDZQPGMN-UHFFFAOYSA-N 0.000 description 1
- 235000019439 ethyl acetate Nutrition 0.000 description 1
- 229940093499 ethyl acetate Drugs 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 229960002199 etretinate Drugs 0.000 description 1
- HQMNCQVAMBCHCO-DJRRULDNSA-N etretinate Chemical compound CCOC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)C=C(OC)C(C)=C1C HQMNCQVAMBCHCO-DJRRULDNSA-N 0.000 description 1
- 229960005167 everolimus Drugs 0.000 description 1
- 229950011548 fadrozole Drugs 0.000 description 1
- 201000001343 fallopian tube carcinoma Diseases 0.000 description 1
- 229950009929 farletuzumab Drugs 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- IJJVMEJXYNJXOJ-UHFFFAOYSA-N fluquinconazole Chemical compound C=1C=C(Cl)C=C(Cl)C=1N1C(=O)C2=CC(F)=CC=C2N=C1N1C=NC=N1 IJJVMEJXYNJXOJ-UHFFFAOYSA-N 0.000 description 1
- 229960002074 flutamide Drugs 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- OSVMTWJCGUFAOD-KZQROQTASA-N formestane Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1O OSVMTWJCGUFAOD-KZQROQTASA-N 0.000 description 1
- 229960004421 formestane Drugs 0.000 description 1
- YAKWPXVTIGTRJH-UHFFFAOYSA-N fotemustine Chemical compound CCOP(=O)(OCC)C(C)NC(=O)N(CCCl)N=O YAKWPXVTIGTRJH-UHFFFAOYSA-N 0.000 description 1
- 229960004783 fotemustine Drugs 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 150000002270 gangliosides Chemical class 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229960002584 gefitinib Drugs 0.000 description 1
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
- 229960005277 gemcitabine Drugs 0.000 description 1
- 229960003297 gemtuzumab ozogamicin Drugs 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- 229950001546 guadecitabine Drugs 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 208000025750 heavy chain disease Diseases 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- DMEGYFMYUHOHGS-UHFFFAOYSA-N heptamethylene Natural products C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229940022353 herceptin Drugs 0.000 description 1
- 125000004415 heterocyclylalkyl group Chemical group 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229940121372 histone deacetylase inhibitor Drugs 0.000 description 1
- 239000003276 histone deacetylase inhibitor Substances 0.000 description 1
- 102000055277 human IL2 Human genes 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 229960001001 ibritumomab tiuxetan Drugs 0.000 description 1
- 229960001507 ibrutinib Drugs 0.000 description 1
- XYFPWWZEPKGCCK-GOSISDBHSA-N ibrutinib Chemical compound C1=2C(N)=NC=NC=2N([C@H]2CN(CCC2)C(=O)C=C)N=C1C(C=C1)=CC=C1OC1=CC=CC=C1 XYFPWWZEPKGCCK-GOSISDBHSA-N 0.000 description 1
- 229960003445 idelalisib Drugs 0.000 description 1
- YKLIKGKUANLGSB-HNNXBMFYSA-N idelalisib Chemical compound C1([C@@H](NC=2[C]3N=CN=C3N=CN=2)CC)=NC2=CC=CC(F)=C2C(=O)N1C1=CC=CC=C1 YKLIKGKUANLGSB-HNNXBMFYSA-N 0.000 description 1
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 1
- 229960001101 ifosfamide Drugs 0.000 description 1
- 229960002411 imatinib Drugs 0.000 description 1
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 1
- 229940126533 immune checkpoint blocker Drugs 0.000 description 1
- 229950008097 improsulfan Drugs 0.000 description 1
- DBIGHPPNXATHOF-UHFFFAOYSA-N improsulfan Chemical compound CS(=O)(=O)OCCCNCCCOS(C)(=O)=O DBIGHPPNXATHOF-UHFFFAOYSA-N 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 229940050282 inebilizumab-cdon Drugs 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 229960001388 interferon-beta Drugs 0.000 description 1
- 229940100601 interleukin-6 Drugs 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 229960005386 ipilimumab Drugs 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 150000002537 isoquinolines Chemical class 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 229960005280 isotretinoin Drugs 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- FPCCSQOGAWCVBH-UHFFFAOYSA-N ketanserin Chemical compound C1=CC(F)=CC=C1C(=O)C1CCN(CCN2C(C3=CC=CC=C3NC2=O)=O)CC1 FPCCSQOGAWCVBH-UHFFFAOYSA-N 0.000 description 1
- 229960005417 ketanserin Drugs 0.000 description 1
- 229950000518 labetuzumab Drugs 0.000 description 1
- 229940001447 lactate Drugs 0.000 description 1
- 229940099584 lactobionate Drugs 0.000 description 1
- JYTUSYBCFIZPBE-AMTLMPIISA-N lactobionic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-N 0.000 description 1
- 229940070765 laurate Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 229960003784 lenvatinib Drugs 0.000 description 1
- WOSKHXYHFSIKNG-UHFFFAOYSA-N lenvatinib Chemical compound C=12C=C(C(N)=O)C(OC)=CC2=NC=CC=1OC(C=C1Cl)=CC=C1NC(=O)NC1CC1 WOSKHXYHFSIKNG-UHFFFAOYSA-N 0.000 description 1
- HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 description 1
- 229960003881 letrozole Drugs 0.000 description 1
- 229960001614 levamisole Drugs 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 206010024627 liposarcoma Diseases 0.000 description 1
- 229950011263 lirilumab Drugs 0.000 description 1
- 229960003587 lisuride Drugs 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 208000022080 low-grade astrocytoma Diseases 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 201000005296 lung carcinoma Diseases 0.000 description 1
- 208000037829 lymphangioendotheliosarcoma Diseases 0.000 description 1
- 208000012804 lymphangiosarcoma Diseases 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 208000026037 malignant tumor of neck Diseases 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229950001869 mapatumumab Drugs 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 208000023356 medullary thyroid gland carcinoma Diseases 0.000 description 1
- 229950009246 mepitiostane Drugs 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- BMGQWWVMWDBQGC-IIFHNQTCSA-N midostaurin Chemical compound CN([C@H]1[C@H]([C@]2(C)O[C@@H](N3C4=CC=CC=C4C4=C5C(=O)NCC5=C5C6=CC=CC=C6N2C5=C43)C1)OC)C(=O)C1=CC=CC=C1 BMGQWWVMWDBQGC-IIFHNQTCSA-N 0.000 description 1
- 229950010895 midostaurin Drugs 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 229960005485 mitobronitol Drugs 0.000 description 1
- VFKZTMPDYBFSTM-GUCUJZIJSA-N mitolactol Chemical compound BrC[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)CBr VFKZTMPDYBFSTM-GUCUJZIJSA-N 0.000 description 1
- 229950010913 mitolactol Drugs 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 201000004058 mixed glioma Diseases 0.000 description 1
- 229950007812 mocetinostat Drugs 0.000 description 1
- 239000007932 molded tablet Substances 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 208000001611 myxosarcoma Diseases 0.000 description 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 1
- QRGHOAATPOLDPF-VQFNDLOPSA-N nanatinostat Chemical compound N1=CC(C(=O)NO)=CN=C1N1C[C@@H]([C@@H]2NCC=3N=C4C=CC(F)=CC4=CC=3)[C@@H]2C1 QRGHOAATPOLDPF-VQFNDLOPSA-N 0.000 description 1
- WQWUQDVFRYMMCY-UHFFFAOYSA-N naphthalen-1-yl trifluoromethanesulfonate Chemical class C1=CC=C2C(OS(=O)(=O)C(F)(F)F)=CC=CC2=C1 WQWUQDVFRYMMCY-UHFFFAOYSA-N 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-M naphthalene-2-sulfonate Chemical compound C1=CC=CC2=CC(S(=O)(=O)[O-])=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-M 0.000 description 1
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
- 229950007221 nedaplatin Drugs 0.000 description 1
- QZGIWPZCWHMVQL-UIYAJPBUSA-N neocarzinostatin chromophore Chemical compound O1[C@H](C)[C@H](O)[C@H](O)[C@@H](NC)[C@H]1O[C@@H]1C/2=C/C#C[C@H]3O[C@@]3([C@@H]3OC(=O)OC3)C#CC\2=C[C@H]1OC(=O)C1=C(O)C=CC2=C(C)C=C(OC)C=C12 QZGIWPZCWHMVQL-UIYAJPBUSA-N 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 210000005170 neoplastic cell Anatomy 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229960001346 nilotinib Drugs 0.000 description 1
- HHZIURLSWUIHRB-UHFFFAOYSA-N nilotinib Chemical compound C1=NC(C)=CN1C1=CC(NC(=O)C=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)=CC(C(F)(F)F)=C1 HHZIURLSWUIHRB-UHFFFAOYSA-N 0.000 description 1
- 229950010203 nimotuzumab Drugs 0.000 description 1
- VFEDRRNHLBGPNN-UHFFFAOYSA-N nimustine Chemical compound CC1=NC=C(CNC(=O)N(CCCl)N=O)C(N)=N1 VFEDRRNHLBGPNN-UHFFFAOYSA-N 0.000 description 1
- 229960001420 nimustine Drugs 0.000 description 1
- PCHKPVIQAHNQLW-CQSZACIVSA-N niraparib Chemical compound N1=C2C(C(=O)N)=CC=CC2=CN1C(C=C1)=CC=C1[C@@H]1CCCNC1 PCHKPVIQAHNQLW-CQSZACIVSA-N 0.000 description 1
- 229950011068 niraparib Drugs 0.000 description 1
- YMVWGSQGCWCDGW-UHFFFAOYSA-N nitracrine Chemical compound C1=CC([N+]([O-])=O)=C2C(NCCCN(C)C)=C(C=CC=C3)C3=NC2=C1 YMVWGSQGCWCDGW-UHFFFAOYSA-N 0.000 description 1
- 229950008607 nitracrine Drugs 0.000 description 1
- 150000002829 nitrogen Chemical class 0.000 description 1
- 125000006574 non-aromatic ring group Chemical group 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 229960003347 obinutuzumab Drugs 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 201000002575 ocular melanoma Diseases 0.000 description 1
- 229960002450 ofatumumab Drugs 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229960000572 olaparib Drugs 0.000 description 1
- FAQDUNYVKQKNLD-UHFFFAOYSA-N olaparib Chemical compound FC1=CC=C(CC2=C3[CH]C=CC=C3C(=O)N=N2)C=C1C(=O)N(CC1)CCN1C(=O)C1CC1 FAQDUNYVKQKNLD-UHFFFAOYSA-N 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 231100000590 oncogenic Toxicity 0.000 description 1
- 230000002246 oncogenic effect Effects 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 244000309459 oncolytic virus Species 0.000 description 1
- 229950007283 oregovomab Drugs 0.000 description 1
- 229960003278 osimertinib Drugs 0.000 description 1
- DUYJMQONPNNFPI-UHFFFAOYSA-N osimertinib Chemical compound COC1=CC(N(C)CCN(C)C)=C(NC(=O)C=C)C=C1NC1=NC=CC(C=2C3=CC=CC=C3N(C)C=2)=N1 DUYJMQONPNNFPI-UHFFFAOYSA-N 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 125000000160 oxazolidinyl group Chemical group 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- ICMWWNHDUZJFDW-DHODBPELSA-N oxymetholone Chemical compound C([C@@H]1CC2)C(=O)\C(=C/O)C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@](C)(O)[C@@]2(C)CC1 ICMWWNHDUZJFDW-DHODBPELSA-N 0.000 description 1
- 229960005244 oxymetholone Drugs 0.000 description 1
- ICMWWNHDUZJFDW-UHFFFAOYSA-N oxymetholone Natural products C1CC2CC(=O)C(=CO)CC2(C)C2C1C1CCC(C)(O)C1(C)CC2 ICMWWNHDUZJFDW-UHFFFAOYSA-N 0.000 description 1
- 229960004390 palbociclib Drugs 0.000 description 1
- AHJRHEGDXFFMBM-UHFFFAOYSA-N palbociclib Chemical compound N1=C2N(C3CCCC3)C(=O)C(C(=O)C)=C(C)C2=CN=C1NC(N=C1)=CC=C1N1CCNCC1 AHJRHEGDXFFMBM-UHFFFAOYSA-N 0.000 description 1
- 229960001972 panitumumab Drugs 0.000 description 1
- 229960005184 panobinostat Drugs 0.000 description 1
- FWZRWHZDXBDTFK-ZHACJKMWSA-N panobinostat Chemical compound CC1=NC2=CC=C[CH]C2=C1CCNCC1=CC=C(\C=C\C(=O)NO)C=C1 FWZRWHZDXBDTFK-ZHACJKMWSA-N 0.000 description 1
- 208000004019 papillary adenocarcinoma Diseases 0.000 description 1
- 201000010198 papillary carcinoma Diseases 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 210000002990 parathyroid gland Anatomy 0.000 description 1
- 235000010603 pastilles Nutrition 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- 229960000639 pazopanib Drugs 0.000 description 1
- CUIHSIWYWATEQL-UHFFFAOYSA-N pazopanib Chemical compound C1=CC2=C(C)N(C)N=C2C=C1N(C)C(N=1)=CC=NC=1NC1=CC=C(C)C(S(N)(=O)=O)=C1 CUIHSIWYWATEQL-UHFFFAOYSA-N 0.000 description 1
- 229960002621 pembrolizumab Drugs 0.000 description 1
- 229960005570 pemtumomab Drugs 0.000 description 1
- 125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 description 1
- FPVKHBSQESCIEP-JQCXWYLXSA-N pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 description 1
- 229960002340 pentostatin Drugs 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- SZFPYBIJACMNJV-UHFFFAOYSA-N perifosine Chemical compound CCCCCCCCCCCCCCCCCCOP([O-])(=O)OC1CC[N+](C)(C)CC1 SZFPYBIJACMNJV-UHFFFAOYSA-N 0.000 description 1
- 229950010632 perifosine Drugs 0.000 description 1
- JRKICGRDRMAZLK-UHFFFAOYSA-L peroxydisulfate Chemical compound [O-]S(=O)(=O)OOS([O-])(=O)=O JRKICGRDRMAZLK-UHFFFAOYSA-L 0.000 description 1
- 229960002087 pertuzumab Drugs 0.000 description 1
- 125000001791 phenazinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3N=C12)* 0.000 description 1
- 125000001484 phenothiazinyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3NC12)* 0.000 description 1
- 125000001644 phenoxazinyl group Chemical group C1(=CC=CC=2OC3=CC=CC=C3NC12)* 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- VLCMRTMCMQJSKM-UHFFFAOYSA-N phenyl-[4-phenyl-8-(trifluoromethyl)quinolin-3-yl]methanone Chemical class C=1C=CC=CC=1C(=O)C1=CN=C2C(C(F)(F)F)=CC=CC2=C1C1=CC=CC=C1 VLCMRTMCMQJSKM-UHFFFAOYSA-N 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- 125000005545 phthalimidyl group Chemical group 0.000 description 1
- 208000021310 pituitary gland adenoma Diseases 0.000 description 1
- 229950010765 pivalate Drugs 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
- 229960000502 poloxamer Drugs 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 description 1
- 208000037244 polycythemia vera Diseases 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 229960001131 ponatinib Drugs 0.000 description 1
- PHXJVRSECIGDHY-UHFFFAOYSA-N ponatinib Chemical compound C1CN(C)CCN1CC(C(=C1)C(F)(F)F)=CC=C1NC(=O)C1=CC=C(C)C(C#CC=2N3N=CC=CC3=NC=2)=C1 PHXJVRSECIGDHY-UHFFFAOYSA-N 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- JHDKZFFAIZKUCU-ZRDIBKRKSA-N pracinostat Chemical compound ONC(=O)/C=C/C1=CC=C2N(CCN(CC)CC)C(CCCC)=NC2=C1 JHDKZFFAIZKUCU-ZRDIBKRKSA-N 0.000 description 1
- 229950003618 pracinostat Drugs 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 229960004694 prednimustine Drugs 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 208000016800 primary central nervous system lymphoma Diseases 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 229960003857 proglumide Drugs 0.000 description 1
- KCXFHTAICRTXLI-UHFFFAOYSA-N propane-1-sulfonic acid Chemical compound CCCS(O)(=O)=O KCXFHTAICRTXLI-UHFFFAOYSA-N 0.000 description 1
- 239000000473 propyl gallate Substances 0.000 description 1
- 235000010388 propyl gallate Nutrition 0.000 description 1
- 229940075579 propyl gallate Drugs 0.000 description 1
- 229960004063 propylene glycol Drugs 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000001422 pyrrolinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- 125000001453 quaternary ammonium group Chemical group 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 125000004621 quinuclidinyl group Chemical group N12C(CC(CC1)CC2)* 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 229960004432 raltitrexed Drugs 0.000 description 1
- 229960002633 ramucirumab Drugs 0.000 description 1
- BMKDZUISNHGIBY-UHFFFAOYSA-N razoxane Chemical compound C1C(=O)NC(=O)CN1C(C)CN1CC(=O)NC(=O)C1 BMKDZUISNHGIBY-UHFFFAOYSA-N 0.000 description 1
- 229960000460 razoxane Drugs 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 208000020615 rectal carcinoma Diseases 0.000 description 1
- 229960004836 regorafenib Drugs 0.000 description 1
- FNHKPVJBJVTLMP-UHFFFAOYSA-N regorafenib Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=C(F)C(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 FNHKPVJBJVTLMP-UHFFFAOYSA-N 0.000 description 1
- 239000003488 releasing hormone Substances 0.000 description 1
- 201000007444 renal pelvis carcinoma Diseases 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000003340 retarding agent Substances 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229950006743 ricolinostat Drugs 0.000 description 1
- 229960004641 rituximab Drugs 0.000 description 1
- OHRURASPPZQGQM-GCCNXGTGSA-N romidepsin Chemical compound O1C(=O)[C@H](C(C)C)NC(=O)C(=C/C)/NC(=O)[C@H]2CSSCC\C=C\[C@@H]1CC(=O)N[C@H](C(C)C)C(=O)N2 OHRURASPPZQGQM-GCCNXGTGSA-N 0.000 description 1
- 229960003452 romidepsin Drugs 0.000 description 1
- 108010091666 romidepsin Proteins 0.000 description 1
- OHRURASPPZQGQM-UHFFFAOYSA-N romidepsin Natural products O1C(=O)C(C(C)C)NC(=O)C(=CC)NC(=O)C2CSSCCC=CC1CC(=O)NC(C(C)C)C(=O)N2 OHRURASPPZQGQM-UHFFFAOYSA-N 0.000 description 1
- HFNKQEVNSGCOJV-OAHLLOKOSA-N ruxolitinib Chemical compound C1([C@@H](CC#N)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CCCC1 HFNKQEVNSGCOJV-OAHLLOKOSA-N 0.000 description 1
- 229960000215 ruxolitinib Drugs 0.000 description 1
- 229950008902 safingol Drugs 0.000 description 1
- 201000008407 sebaceous adenocarcinoma Diseases 0.000 description 1
- 229950008834 seribantumab Drugs 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 229950008684 sibrotuzumab Drugs 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 229960003323 siltuximab Drugs 0.000 description 1
- 229960000714 sipuleucel-t Drugs 0.000 description 1
- 201000003708 skin melanoma Diseases 0.000 description 1
- 102000030938 small GTPase Human genes 0.000 description 1
- 108060007624 small GTPase Proteins 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
- 229950010372 sobuzoxane Drugs 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- WBHQBSYUUJJSRZ-UHFFFAOYSA-M sodium bisulfate Chemical compound [Na+].OS([O-])(=O)=O WBHQBSYUUJJSRZ-UHFFFAOYSA-M 0.000 description 1
- 229910000342 sodium bisulfate Inorganic materials 0.000 description 1
- 229940100996 sodium bisulfate Drugs 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 229940001584 sodium metabisulfite Drugs 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 229940001482 sodium sulfite Drugs 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- 229960005325 sonidegib Drugs 0.000 description 1
- VZZJRYRQSPEMTK-CALCHBBNSA-N sonidegib Chemical compound C1[C@@H](C)O[C@@H](C)CN1C(N=C1)=CC=C1NC(=O)C1=CC=CC(C=2C=CC(OC(F)(F)F)=CC=2)=C1C VZZJRYRQSPEMTK-CALCHBBNSA-N 0.000 description 1
- NXQKSXLFSAEQCZ-SFHVURJKSA-N sotorasib Chemical compound FC1=CC2=C(N(C(N=C2N2[C@H](CN(CC2)C(C=C)=O)C)=O)C=2C(=NC=CC=2C)C(C)C)N=C1C1=C(C=CC=C1O)F NXQKSXLFSAEQCZ-SFHVURJKSA-N 0.000 description 1
- 229940073531 sotorasib Drugs 0.000 description 1
- 241000894007 species Species 0.000 description 1
- XFLBOEMFLGLWFF-HDXRNPEWSA-N spiruchostatin Chemical compound C1SSCC\C=C\[C@H]2OC(=O)C[C@H](O)[C@@H](C(C)C)NC(=O)[C@@H]1NC(=O)[C@@H](C)NC(=O)C2 XFLBOEMFLGLWFF-HDXRNPEWSA-N 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- HKSZLNNOFSGOKW-FYTWVXJKSA-N staurosporine Chemical class C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1[C@H]1C[C@@H](NC)[C@@H](OC)[C@]4(C)O1 HKSZLNNOFSGOKW-FYTWVXJKSA-N 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000003206 sterilizing agent Substances 0.000 description 1
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
- 229960001052 streptozocin Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 208000030819 subependymoma Diseases 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 150000003871 sulfonates Chemical class 0.000 description 1
- 150000003457 sulfones Chemical class 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 201000010965 sweat gland carcinoma Diseases 0.000 description 1
- 239000011885 synergistic combination Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 101150047061 tag-72 gene Proteins 0.000 description 1
- 229950004550 talazoparib Drugs 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229950008461 talimogene laherparepvec Drugs 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 229960001674 tegafur Drugs 0.000 description 1
- WFWLQNSHRPWKFK-ZCFIWIBFSA-N tegafur Chemical compound O=C1NC(=O)C(F)=CN1[C@@H]1OCCC1 WFWLQNSHRPWKFK-ZCFIWIBFSA-N 0.000 description 1
- 229960000235 temsirolimus Drugs 0.000 description 1
- QFJCIRLUMZQUOT-UHFFFAOYSA-N temsirolimus Natural products C1CC(O)C(OC)CC1CC(C)C1OC(=O)C2CCCCN2C(=O)C(=O)C(O)(O2)C(C)CCC2CC(OC)C(C)=CC=CC=CC(C)CC(C)C(=O)C(OC)C(O)C(C)=CC(C)C(=O)C1 QFJCIRLUMZQUOT-UHFFFAOYSA-N 0.000 description 1
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 1
- 229960001278 teniposide Drugs 0.000 description 1
- WDPWEXWMQDRXAL-UHFFFAOYSA-N tert-butyl 1,4-diazepane-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCCNCC1 WDPWEXWMQDRXAL-UHFFFAOYSA-N 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000005308 thiazepinyl group Chemical group S1N=C(C=CC=C1)* 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- NZVYCXVTEHPMHE-ZSUJOUNUSA-N thymalfasin Chemical compound CC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O NZVYCXVTEHPMHE-ZSUJOUNUSA-N 0.000 description 1
- 229960004231 thymalfasin Drugs 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 229960003989 tocilizumab Drugs 0.000 description 1
- AOBORMOPSGHCAX-DGHZZKTQSA-N tocofersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-DGHZZKTQSA-N 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- 229960001350 tofacitinib Drugs 0.000 description 1
- UJLAWZDWDVHWOW-YPMHNXCESA-N tofacitinib Chemical compound C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)C1=NC=NC2=C1C=CN2 UJLAWZDWDVHWOW-YPMHNXCESA-N 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 229960005267 tositumomab Drugs 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- OQUFJVRYDFIQBW-UHFFFAOYSA-N trametinib dimethyl sulfoxide Chemical group CS(C)=O.CC(=O)NC1=CC=CC(N2C(N(C3CC3)C(=O)C3=C(NC=4C(=CC(I)=CC=4)F)N(C)C(=O)C(C)=C32)=O)=C1 OQUFJVRYDFIQBW-UHFFFAOYSA-N 0.000 description 1
- 229960001308 trametinib dimethyl sulfoxide Drugs 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- ZDPHROOEEOARMN-UHFFFAOYSA-N undecanoic acid Chemical compound CCCCCCCCCCC(O)=O ZDPHROOEEOARMN-UHFFFAOYSA-N 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 210000000626 ureter Anatomy 0.000 description 1
- 208000010570 urinary bladder carcinoma Diseases 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical class CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
- 229960000241 vandetanib Drugs 0.000 description 1
- UHTHHESEBZOYNR-UHFFFAOYSA-N vandetanib Chemical compound COC1=CC(C(/N=CN2)=N/C=3C(=CC(Br)=CC=3)F)=C2C=C1OCC1CCN(C)CC1 UHTHHESEBZOYNR-UHFFFAOYSA-N 0.000 description 1
- 201000011531 vascular cancer Diseases 0.000 description 1
- 229950011257 veliparib Drugs 0.000 description 1
- JNAHVYVRKWKWKQ-CYBMUJFWSA-N veliparib Chemical compound N=1C2=CC=CC(C(N)=O)=C2NC=1[C@@]1(C)CCCN1 JNAHVYVRKWKWKQ-CYBMUJFWSA-N 0.000 description 1
- 229960003862 vemurafenib Drugs 0.000 description 1
- GPXBXXGIAQBQNI-UHFFFAOYSA-N vemurafenib Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=CC(=CN=C3NC=2)C=2C=CC(Cl)=CC=2)=C1F GPXBXXGIAQBQNI-UHFFFAOYSA-N 0.000 description 1
- 229950005577 vesnarinone Drugs 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- UGGWPQSBPIFKDZ-KOTLKJBCSA-N vindesine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(N)=O)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 UGGWPQSBPIFKDZ-KOTLKJBCSA-N 0.000 description 1
- 229960004355 vindesine Drugs 0.000 description 1
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 description 1
- 229960002066 vinorelbine Drugs 0.000 description 1
- 229960004449 vismodegib Drugs 0.000 description 1
- BPQMGSKTAYIVFO-UHFFFAOYSA-N vismodegib Chemical compound ClC1=CC(S(=O)(=O)C)=CC=C1C(=O)NC1=CC=C(Cl)C(C=2N=CC=CC=2)=C1 BPQMGSKTAYIVFO-UHFFFAOYSA-N 0.000 description 1
- 229950001212 volociximab Drugs 0.000 description 1
- XZAFZXJXZHRNAQ-STQMWFEESA-N vosaroxin Chemical compound C1[C@H](OC)[C@@H](NC)CN1C1=CC=C2C(=O)C(C(O)=O)=CN(C=3SC=CN=3)C2=N1 XZAFZXJXZHRNAQ-STQMWFEESA-N 0.000 description 1
- 229950007907 vosaroxin Drugs 0.000 description 1
- 208000013013 vulvar carcinoma Diseases 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1
- 229950009268 zinostatin Drugs 0.000 description 1
- 229960002760 ziv-aflibercept Drugs 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Definitions
- the invention provides naphthyl-substituted quinolin-4(1H)-oncs and related compounds, pharmaceutical compositions, their use for inhibiting K-Ras G12D activity, and their use in the treatment of medical disorders, such as cancer.
- K-Ras Viral Oncogene Homolog
- K-Ras G12D and G12C activating mutations of K-Ras
- K-Ras G12D inhibitor compounds for treating cancer has been described in, for example, international patent application WO 2021/041671, the contents of which are herein incorporated by reference in its entirety.
- the invention provides naphthyl-substituted quinolin-4( 1H)-oncs and related compounds, pharmaceutical compositions, their use for inhibiting K-Ras G12D activity, and their use in the treatment of medical disorders, such as cancer.
- one aspect of the invention provides a collection of naphthyl-substituted 3,4-dihydroisoquinolin- 1 (2H)-oncs and related compounds, such as a compound represented by Formula I: or a pharmaceutically acceptable salt thereof, where the variables are as defined in the detailed description. Further description of additional collections of naphthyl-substituted quinolin-4( 1H)- ones and related compounds are described in the detailed description.
- the compounds may be part of a pharmaceutical composition comprising a pharmaceutically acceptable carrier.
- Another aspect of the invention provides a collection of naphthyl-substituted quinolin- 4(1 H)-oncs and related compounds, such as a compound represented by Formula II: or a pharmaceutically acceptable salt thereof, where the variables are as defined in the detailed description. Further description of additional collections of naphthyl-substituted quinolin-4( 1H)- ones and related compounds are described in the detailed description.
- the compounds may be part of a pharmaceutical composition comprising a pharmaceutically acceptable carrier.
- Another aspect of the invention provides a collection of naphthyl-substituted AH- pyrazino[l,2-a]pyrazin-4-ones and related compounds, such as a compound represented by Formula III: or a pharmaceutically acceptable salt thereof, where the variables are as defined in the detailed description. Further description of additional collections of naphthyl-substituted AH- pyrazino[l,2-a]pyrazin-4-ones and related compounds are described in the detailed description.
- the compounds may be part of a pharmaceutical composition comprising a pharmaceutically acceptable carrier.
- Another aspect of the invention provides a method of treating a disorder mediated by K- Ras G12D in a subject.
- the method comprises administering a therapeutically effective amount of a compound described herein, such as a compound of Formula I, II, or III, to a subject in need thereof to treat the disorder, as further described in the detailed description.
- Another aspect of the invention provides a method of inhibiting K-Ras G12D activity.
- the method comprises contacting K-Ras G12D with an effective amount of a compound described herein, such as a compound of Formula I, II, or III, to inhibit K-Ras G12D activity, as further described in the detailed description.
- the invention provides naphthyl-substituted quinolin-4( 1H)-oncs and related compounds, pharmaceutical compositions, their use for inhibiting K-Ras G12D activity, and their use in the treatment of medical disorders, such as cancer.
- the practice of the present invention employs, unless otherwise indicated, conventional techniques of organic chemistry, pharmacology, molecular biology (including recombinant techniques), cell biology, biochemistry, and immunology. Such techniques are explained in the literature, such as in “Comprehensive Organic Synthesis” (B.M. Trost & I. Fleming, eds., 1991-1992); “Handbook of experimental immunology” (D.M. Weir & C.C.
- aliphatic or “aliphatic group”, as used herein, means a straight-chain (i.e., unbranched) or branched, substituted or unsubstituted hydrocarbon chain that is completely saturated or that contains one or more units of unsaturation, or a monocyclic hydrocarbon or bicyclic hydrocarbon that is completely saturated or that contains one or more units of unsaturation, but which is not aromatic (also referred to herein as “cycloaliphatic”), that has a single point of attachment to the rest of the molecule.
- aliphatic groups contain 1-6 aliphatic carbon atoms. In some embodiments, aliphatic groups contain 1-5 aliphatic carbon atoms.
- aliphatic groups contain 1-4 aliphatic carbon atoms. In still other embodiments, aliphatic groups contain 1-3 aliphatic carbon atoms, and in yet other embodiments, aliphatic groups contain 1-2 aliphatic carbon atoms.
- “cycloaliphatic” refers to a monocyclic C3-C6 hydrocarbon that is completely saturated or that contains one or more units of unsaturation, but which is not aromatic, that has a single point of attachment to the rest of the molecule.
- Suitable aliphatic groups include, but are not limited to, linear or branched, substituted or unsubstituted alkyl, alkenyl, alkynyl groups and hybrids thereof such as (cycloalkyl)alkyl, (cycloalkenyl)alkyl or (cycloalkyl)alkenyl.
- bicyclic ring or “bicyclic ring system” refers to any bicyclic ring system, i.e. carbocyclic or heterocyclic, saturated or having one or more units of unsaturation, having one or more atoms in common between the two rings of the ring system.
- the term includes any permissible ring fusion, such as ortho -fused or spirocyclic.
- heterocyclic is a subset of “bicyclic” that requires that one or more heteroatoms are present in one or both rings of the bicycle.
- Such heteroatoms may be present at ring junctions and are optionally substituted, and may be selected from nitrogen (including N- oxides), oxygen, sulfur (including oxidized forms such as sulfones and sulfonates), phosphorus (including oxidized forms such as phosphates), boron, etc.
- a bicyclic group has 7-12 ring members and 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
- bridged bicyclic refers to any bicyclic ring system, i.e. carbocyclic or heterocyclic, saturated or partially unsaturated, having at least one bridge.
- a “bridge” is an unbranched chain of atoms or an atom or a valence bond connecting two bridgeheads, where a “bridgehead” is any skeletal atom of the ring system which is bonded to three or more skeletal atoms (excluding hydrogen).
- a bridged bicyclic group has 7-12 ring members and 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
- Such bridged bicyclic groups are well known in the art and include those groups set forth below where each group is attached to the rest of the molecule at any substitutable carbon or nitrogen atom.
- a bridged bicyclic group is optionally substituted with one or more substituents as set forth for aliphatic groups. Additionally or alternatively, any substitutable nitrogen of a bridged bicyclic group is optionally substituted.
- Exemplary bicyclic rings include:
- Exemplary bridged bicyclics include:
- lower alkyl refers to a C 1-4 straight or branched alkyl group.
- exemplary lower alkyl groups are methyl, ethyl, propyl, isopropyl, butyl, isobutyl, and tert-butyl.
- lower haloalkyl refers to a CIM straight or branched alkyl group that is substituted with one or more halogen atoms.
- heteroatom means one or more of oxygen, sulfur, nitrogen, phosphorus, or silicon (including, any oxidized form of nitrogen, sulfur, phosphorus, or silicon; the quatemized form of any basic nitrogen or; a substitutable nitrogen of a heterocyclic ring, for example N (as in 3 , 4 - d i h y d ro - 2 H- p y rrp l y l ) , NH (as in pyrrolidinyl) or NR + (as in N-substituted pyrrolidinyl)).
- unsaturated as used herein, means that a moiety has one or more units of unsaturation.
- bivalent C1-8 saturated or unsaturated, straight or branched, hydrocarbon chain
- bivalent alkylene, alkenylene, and alkynylene chains that are straight or branched as defined herein.
- alkylene refers to a bivalent alkyl group.
- An “alkylene chain” is a polymethylene group, i.e., -(CH2) n- , wherein n is a positive integer, preferably from 1 to 6, from 1 to 4, from 1 to 3, from 1 to 2, or from 2 to 3.
- a substituted alkylene chain is a polymethylene group in which one or more methylene hydrogen atoms are replaced with a substituent. Suitable substituents include those described below for a substituted aliphatic group.
- -(Co alkylene)- refers to a bond. Accordingly, the term “-(Co-3 alkylene)-” encompasses a bond (i.e., Co) and a -(C1-3 alkylene)- group.
- alkenylene refers to a bivalent alkenyl group.
- a substituted alkenylene chain is a polymethylene group containing at least one double bond in which one or more hydrogen atoms are replaced with a substituent. Suitable substituents include those described below for a substituted aliphatic group.
- halogen means F, Cl, Br, or I.
- aryl used alone or as part of a larger moiety as in “aralkyl,” “aralkoxy,” or “aryloxyalkyl,” refers to monocyclic or bicyclic ring systems having a total of five to fourteen ring members, wherein at least one ring in the system is aromatic and wherein each ring in the system contains 3 to 7 ring members.
- aryl may be used interchangeably with the term “aryl ring.”
- aryl refers to an aromatic ring system which includes, but not limited to, phenyl, biphenyl, naphthyl, anthracyl and the like, which may bear one or more substituents.
- aryl is a group in which an aromatic ring is fused to one or more non-aromatic rings, such as indanyl, phthalimidyl, naphthimidyl, phenanthridinyl, or tetrahydronaphthyl, and the like.
- phenylene refers to a multivalent phenyl group having the appropriate number of open valences to account for groups attached to it. For example, “phenylene” is a bivalent phenyl group when it has two groups attached trivalent phenyl group when it has three groups attached to it (e.g., ).
- arylene refers to a bivalent aryl group.
- heteroaryl and “heteroar-,” used alone or as part of a larger moiety, e.g., “heteroaralkyl,” or “heteroaralkoxy,” refer to groups having 5 to 10 ring atoms, preferably 5, 6, or 9 ring atoms; having 6, 10, or 14 p electrons shared in a cyclic array; and having, in addition to carbon atoms, from one to five heteroatoms.
- heteroatom refers to nitrogen, oxygen, or sulfur, and includes any oxidized form of nitrogen or sulfur, and any quaternized form of a basic nitrogen.
- Heteroaryl groups include, without limitation, thienyl, furanyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, oxazolyl, isoxazolyl, oxadiazolyl, thiazolyl, isothiazolyl, thiadiazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, indolizinyl, purinyl, naphthyridinyl, and pteridinyl.
- heteroaryl and “heteroar-”, as used herein, also include groups in which a hetero aromatic ring is fused to one or more aryl, cycloaliphatic, or heterocyclyl rings, where unless otherwise specified, the radical or point of attachment is on the heteroaromatic ring or on one of the rings to which the hetero aromatic ring is fused.
- Nonlimiting examples include indolyl, isoindolyl, benzothienyl, benzofuranyl, dibenzofuranyl, indazolyl, benzimidazolyl, benzthiazolyl, quinolyl, isoquinolyl, cinnolinyl, phthalazinyl, quinazolinyl, quinoxalinyl, 4/7-quinolizinyl, carbazolyl, acridinyl, phenazinyl, phenothiazinyl, phenoxazinyl, tetrahydroquinolinyl, and tetrahydroisoquinolinyl.
- a heteroaryl group may be mono- or bicyclic.
- heteroaryl may be used interchangeably with the terms “heteroaryl ring,” “heteroaryl group,” or “heteroaromatic,” any of which terms include rings that are optionally substituted.
- heteroarylkyl refers to an alkyl group substituted by a heteroaryl, wherein the alkyl and heteroaryl portions independently are optionally substituted.
- heteroarylene refers to a multivalent heteroaryl group having the appropriate number of open valences to account for groups attached to it.
- heteroarylene is a bivalent heteroaryl group when it has two groups attached to it; “heteroarylene” is a trivalent heteroaryl group when it has three groups attached to it.
- pyridinylene refers to a multivalent pyridine radical having the appropriate number of open valences to account for groups attached to it.
- pyridinylene is a bivalent pyridine radical when it has two
- heterocycle As used herein, the terms “heterocycle,” “heterocyclyl,” “heterocyclic radical,” and “heterocyclic ring” are used interchangeably and refer to a stable 5- to 7-membered monocyclic or 7-10-membered bicyclic heterocyclic moiety that is either saturated or partially unsaturated, and having, in addition to carbon atoms, one or more, preferably one to four, heteroatoms, as defined above.
- nitrogen includes a substituted nitrogen.
- the nitrogen in a saturated or partially unsaturated ring having 0-3 heteroatoms selected from oxygen, sulfur or nitrogen, the nitrogen may be N (as in 3,4- di h y dro-2H-py rro l y l ) , NH (as in pyrrolidinyl), or + NR (as in A-substitutcd pyrrolidinyl).
- a heterocyclic ring can be attached to its pendant group at any heteroatom or carbon atom that results in a stable structure and any of the ring atoms can be optionally substituted.
- saturated or partially unsaturated heterocyclic radicals include, without limitation, tetrahydrofuranyl, tetrahydrothiophenyl pyrrolidinyl, piperidinyl, pyrrolinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, decahydroquinolinyl, oxazolidinyl, piperazinyl, dioxanyl, dioxolanyl, diazepinyl, oxazepinyl, thiazepinyl, morpholinyl, 2-oxa-6- azaspiro[3.3]heptane, and quinuclidinyl.
- heterocycle used interchangeably herein, and also include groups in which a heterocyclyl ring is fused to one or more aryl, heteroaryl, or cycloaliphatic rings, such as indolinyl, 3H-indolyl, chromanyl, phenanthridinyl, or tetrahydroquinolinyl.
- a heterocyclyl group may be mono- or bicyclic.
- heterocyclylalkyl refers to an alkyl group substituted by a heterocyclyl, wherein the alkyl and heterocyclyl portions independently are optionally substituted.
- oxo-heterocyclyl refers to a heterocyclyl substituted by an oxo group.
- heterocyclylene refers to a multivalent heterocyclyl group having the appropriate number of open valences to account for groups attached to it. For example, “heterocyclylene” is a bivalent heterocyclyl group when it has two groups attached to it; “heterocyclylene” is a trivalent heterocyclyl group when it has three groups attached to it.
- partially unsaturated refers to a ring moiety that includes at least one double or triple bond.
- partially unsaturated is intended to encompass rings having multiple sites of unsaturation, but is not intended to include aryl or heteroaryl moieties, as herein defined.
- compounds of the invention may contain “optionally substituted” moieties.
- substituted whether preceded by the term “optionally” or not, means that one or more hydrogens of the designated moiety are replaced with a suitable substituent.
- an “optionally substituted” group may have a suitable substituent at each substitutable position of the group, and when more than one position in any given structure may be substituted with more than one substituent selected from a specified group, the substituent may be either the same or different at every position.
- Combinations of substituents envisioned by this invention are preferably those that result in the formation of stable or chemically feasible compounds.
- stable refers to compounds that are not substantially altered when subjected to conditions to allow for their production, detection, and, in certain embodiments, their recovery, purification, and use for one or more of the purposes disclosed herein.
- S(O) 2 N C(NR° 2 ) 2 ; -(CH 2 ) 0-4 S(O)R°; -N(R°)S(O) 2 NRo 2 ; -N(R°)S(O) 2 R°; -N(OR°)R°; - C(NH)NR° 2 ; -P(0) 2 R°; -P(0)R° 2 ; -0P(0)R° 2 ; -0P(0)(0R°) 2 ; SiR° 3 ; -(C1-4 straight or branched alkylene)0-N(R°) 2 ; or — (C i 4 straight or branched alkylene)C(0)0-N(R°) 2 .
- R * is C1-6 aliphatic
- R * is optionally substituted with halogen, - R*, -(haloR*), -OH, -OR*, -0(haloR*), -CN, -C(0)OH, -C(0)OR*, -NH 2 , -NHR*, -NR* 2 , or -N0 2
- each R* is independently selected from Ci 4 aliphatic, -CH 2 Ph, -0(CH 2 )o iPh, or a 5-6-membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, and wherein each R* is unsubstituted or where preceded by halo is substituted only with one or more halogens.
- An optional substituent on a substitutable nitrogen is independently -R ⁇ , -NR ⁇ 2 , - C(0)R ⁇ , -C(0)0R ⁇ , -C(0)C(0)R ⁇ , -C(0)CH 2 C(0)R ⁇ , -S(0) 2 R ⁇ , -S(0) 2 NR ⁇ 2 , -C(S)NR ⁇ 2 , - C(NH)NR ⁇ 2 , or -N(R ⁇ )S(0) 2 R ⁇ ; wherein each R ⁇ is independently hydrogen, C1-6 aliphatic, unsubstituted -OPh, or an unsubstituted 5-6-membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or, two independent occurrences of R ⁇ , taken together with their intervening atom(s) form an unsubstituted 3-12-membered saturated, partially unsaturated,
- the term "pharmaceutically acceptable salt” refers to those salts which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response and the like, and are commensurate with a reasonable benefit/risk ratio.
- Pharmaceutically acceptable salts are well known in the art. For example, S. M. Berge et al., describe pharmaceutically acceptable salts in detail in J. Pharmaceutical Sciences, 1977, 66, 1-19, incorporated herein by reference.
- Pharmaceutically acceptable salts of the compounds of this invention include those derived from suitable inorganic and organic acids and bases.
- Examples of pharmaceutically acceptable, nontoxic acid addition salts are salts of an amino group formed with inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid and perchloric acid or with organic acids such as acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid or malonic acid or by using other methods used in the art such as ion exchange.
- inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid and perchloric acid
- organic acids such as acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid or malonic acid or by using other methods used in the art such as ion exchange.
- salts include adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, formate, fumarate, glucoheptonate, glycerophosphate, gluconate, hemisulfate, heptanoate, hexanoate, hydroiodide, 2-hydroxy-ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pectinate,
- Salts derived from appropriate bases include alkali metal, alkaline earth metal, ammonium and N + (Ci 4alkyl)4 salts.
- Representative alkali or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium, and the like.
- Further pharmaceutically acceptable salts include, when appropriate, nontoxic ammonium, quaternary ammonium, and amine cations formed using counterions such as halide, hydroxide, carboxylate, sulfate, phosphate, nitrate, loweralkyl sulfonate and aryl sulfonate.
- structures depicted herein are also meant to include all isomeric (e.g ., enantiomeric, diastereomeric, and geometric (or conformational)) forms of the structure; for example, the R and S configurations for each asymmetric center, Z and E double bond isomers, and Z and E conformational isomers. Therefore, single stereochemical isomers as well as enantiomeric, diastereomeric, and geometric (or conformational) mixtures of the present compounds are within the scope of the invention. Unless otherwise stated, all tautomeric forms of the compounds of the invention are within the scope of the invention.
- structures depicted herein are also meant to include compounds that differ only in the presence of one or more isotopically enriched atoms.
- compounds having the present structures including the replacement of hydrogen by deuterium or tritium, or the replacement of a carbon by a 13 C- or 14 C-enriched carbon are within the scope of this invention.
- Such compounds are useful, for example, as analytical tools, as probes in biological assays, or as therapeutic agents in accordance with the present invention.
- Diastereomeric mixtures can be separated into their individual diastereomers on the basis of their physical chemical differences by methods known to those skilled in the art, such as, for example, by chromatography and/or fractional crystallization.
- Enantiomers can be separated by converting the enantiomeric mixture into a diastereomeric mixture by reaction with an appropriate optically active compound (e.g ., chiral auxiliary such as a chiral alcohol or Mosher’s acid chloride), separating the diastereomers and converting (e.g., hydrolyzing) the individual diastereomers to the corresponding pure enantiomers.
- an appropriate optically active compound e.g ., chiral auxiliary such as a chiral alcohol or Mosher’s acid chloride
- a particular enantiomer of a compound of the present invention may be prepared by asymmetric synthesis.
- diastereomeric salts are formed with an appropriate optically- active acid or base, followed by resolution of the diastereomers thus formed by fractional crystallization or chromatographic means known in the art, and subsequent recovery of the pure enantiomers.
- Individual stereoisomers of the compounds of the invention may, for example, be substantially free of other isomers, or may be admixed, for example, as racemates or with all other, or other selected, stereoisomers.
- Chiral center(s) in a compound of the present invention can have the S or R configuration as defined by the IUPAC 1974 Recommendations.
- a compound described herein may exist as an atropisomer (e.g., substituted biaryls)
- all forms of such atropisomer are considered part of this invention.
- Chemical names, common names, and chemical structures may be used interchangeably to describe the same structure. If a chemical compound is referred to using both a chemical structure and a chemical name, and an ambiguity exists between the structure and the name, the structure predominates. It should also be noted that any carbon as well as heteroatom with unsatisfied valences in the text, schemes, examples and tables herein is assumed to have the sufficient number of hydrogen atom(s) to satisfy the valences.
- alkyl refers to a saturated straight or branched hydrocarbon, such as a straight or branched group of 1-12, 1-10, or 1-6 carbon atoms, referred to herein as C1-C12 alkyl, C1-C10 alkyl, and C1-C6 alkyl, respectively.
- Exemplary alkyl groups include, but are not limited to, methyl, ethyl, propyl, isopropyl, 2-methyl- 1 -propyl, 2-methyl-2-propyl, 2-methyl- 1 -butyl, 3- methyl-1 -butyl, 2-methyl-3-butyl, 2,2-dimethyl- 1 -propyl, 2-methyl- 1 -pentyl, 3 -methyl- 1 -pentyl, 4-methyl- 1 -pentyl, 2-methyl-2-pentyl, 3-methyl-2-pentyl, 4-methyl-2-pentyl, 2,2-dimethyl- 1- butyl, 3, 3 -dimethyl- 1 -butyl, 2-ethyl- 1 -butyl, butyl, isobutyl, t-butyl, pentyl, isopentyl, neopentyl, hexyl, heptyl, octyl, etc.
- cycloalkyl refers to a monovalent saturated cyclic, bicyclic, or bridged cyclic (e.g ., adamantyl) hydrocarbon group of 3-12, 3-8, 4-8, or 4-6 carbons, referred to herein, e.g., as “C3-C6 cycloalkyl,” derived from a cycloalkane.
- exemplary cycloalkyl groups include cyclohexyl, cyclopentyl, cyclobutyl, and cyclopropyl.
- cycloalkylene refers to a bivalent cycloalkyl group.
- haloalkyl refers to an alkyl group that is substituted with at least one halogen.
- exemplary haloalkyl groups include -CH2F, -CHF2, -CF3, -CH2CF3, -CF2CF3, and the like.
- haloalkylene refers to a bivalent haloalkyl group.
- hydroxy alkyl refers to an alkyl group that is substituted with at least one hydroxyl.
- exemplary hydroxyalkyl groups include -CH2CH2OH, -C(H)(OH)CH3, -CH 2 C(H)(OH)CH 2 CH 2 OH, and the like.
- alkenyl and alkynyl are art-recognized and refer to unsaturated aliphatic groups analogous in length and possible substitution to the alkyls described above, but that contain at least one double or triple bond respectively.
- Carbocyclylene refers to a multivalent carbocyclyl group having the appropriate number of open valences to account for groups attached to it.
- “carbocyclylene” is a bivalent carbocyclyl group when it has two groups attached to it; “carbocyclylene” is a trivalent carbocyclyl group when it has three groups attached to it.
- alkoxyl or “alkoxy” are art-recognized and refer to an alkyl group, as defined above, having an oxygen radical attached thereto.
- Representative alkoxyl groups include methoxy, ethoxy, propyloxy, ieri-butoxy and the like.
- haloalkoxyl refers to an alkoxyl group that is substituted with at least one halogen.
- Exemplary haloalkoxyl groups include -OCH2F, -OCHF2, -OCF3, -OCH2CF3, -OCF2CF3, and the like.
- hydroxyalkoxyl refers to an alkoxyl group that is substituted with at least one hydroxyl.
- hydroxyalkoxyl groups include -OCH2CH2OH, -0CH 2 C(H)(0H)CH 2 CH 2 0H, and the like.
- alkoxylene refers to a bivalent alkoxyl group.
- a cyclopentane susbsituted with an oxo group is cyclopentanone.
- the chemical structure encompasses and .
- a chemical structure containing a polycyclic fused ring when depicted with one or more substituent(s) having a bond that crosses multiple rings, the one or more substituent(s) may be independently attached to any of the rings crossed by the bond.
- the chemical structure encompasses, for example,
- One or more compounds of the invention may exist in unsolvated as well as solvated forms with pharmaceutically acceptable solvents such as water, ethanol, and the like, and it is intended that the invention embrace both solvated and unsolvated forms.
- “Solvate” means a physical association of a compound of this invention with one or more solvent molecules. This physical association involves varying degrees of ionic and covalent bonding, including hydrogen bonding. In certain instances the solvate will be capable of isolation, for example when one or more solvent molecules are incorporated in the crystal lattice of the crystalline solid. “Solvate” encompasses both solution-phase and isolatable solvates. Non-limiting examples of suitable solvates include ethanolates, methanolates, and the like. “Hydrate” is a solvate wherein the solvent molecule is H2O.
- the terms “subject” and “patient” are used interchangeably and refer to organisms to be treated by the methods of the present invention.
- Such organisms preferably include, but are not limited to, mammals (e.g ., murines, simians, equines, bovines, porcines, canines, felines, and the like), and, most preferably, includes humans.
- an inhibitor has an IC50 and/or binding constant of less than about 100 mM, less than about 50 mM, less than about 1 mM, less than about 500 nM, less than about 100 nM, less than about 10 nM, or less than about 1 nM.
- K-Ras refers to a mammalian K-Ras protein.
- the assignment of amino acid codon and residue positions for human K-Ras is based on the amino acid sequence identified by UniProtKB/Swiss-Prot P01116.
- K-Ras G12D refers to a mutant form of a mammalian K-Ras protein that contains an amino acid substitution of an aspartic acid, instead of a glycine, at amino acid position 12.
- the assignment of amino acid codon and residue positions for human K-Ras is based on the amino acid sequence identified by UniProtKB/Swiss-Prot P01116:
- V ariantp Gly 12 Asp .
- K-Ras inhibitor or “K-Ras antagonist” are defined as a compound that binds to and/or inhibits K-Ras with measurable affinity. In some embodiments, inhibition in the presence of the inhibitor is observed in a dose-dependent manner.
- the measured signal (e.g., signaling activity or biological activity) is at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 100% lower than the signal measured with a negative control under comparable conditions.
- inhibitor or “K-Ras G12D inhibitor” or “K-Ras G12D antagonist” are defined as a compound that binds to and/or inhibits K-Ras G12D with measurable affinity. In some embodiments, inhibition in the presence of the inhibitor is observed in a dose-dependent manner.
- the measured signal (e.g ., signaling activity or biological activity) is at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 100% lower than the signal measured with a negative control under comparable conditions.
- measurable affinity and “measurably inhibit,” as used herein, means a measurable change or inhibition in K-Ras activity, such as K-Ras G12D activity, between a sample comprising a compound of the present invention, or composition thereof, and K-Ras, such as K-Ras G12D, and an equivalent sample comprising K-Ras, such as K-Ras G12D, in the absence of said compound, or composition thereof.
- an effective amount refers to the amount of a compound sufficient to effect beneficial or desired results (e.g., a therapeutic, ameliorative, inhibitory, or preventative result).
- An effective amount can be administered in one or more administrations, applications, or dosages and is not intended to be limited to a particular formulation or administration route.
- treating includes any effect, e.g., lessening, reducing, modulating, ameliorating or eliminating, that results in the improvement of the condition, disease, disorder, and the like, or ameliorating a symptom thereof.
- treatment can be administered after one or more symptoms have developed.
- treatment can be administered in the absence of symptoms.
- treatment can be administered to a susceptible individual prior to the onset of symptoms (e.g., in light of a history of symptoms and/or in light of genetic or other susceptibility factors). Treatment can also be continued after symptoms have resolved, for example, to prevent or delay their recurrence.
- K-Ras-associated disease or disorder means any disease or other deleterious condition in which K-Ras, or a variant or mutant thereof, is known to play a role.
- a non-limiting example of a K-Ras-associated disease or disorder is a K-Ras-associated cancer.
- K-Ras G12D disorder mediated by K-Ras G12D
- disease mediated by K-Ras G12D or “disease mediated by K-Ras G12D” or "K-Ras G12D-associated disease or disorder,” as used herein, refer to diseases or disorders associated with, or mediated by, or having a K-Ras G12D mutation.
- a non-limiting example of a K-Ras G12D-associated disease or disorder is a K-Ras G12D-associated cancer.
- composition refers to the combination of an active agent with a carrier, inert or active, making the composition especially suitable for diagnostic or therapeutic use in vivo or ex vivo.
- the term “pharmaceutically acceptable carrier” refers to any of the standard pharmaceutical carriers, such as a phosphate buffered saline solution, water, emulsions ( e.g ., such as an oil/water or water/oil emulsions), and various types of wetting agents.
- the compositions also can include stabilizers and preservatives.
- stabilizers and adjuvants see e.g., Martin, Remington’s Pharmaceutical Sciences, 15th Ed., Mack Publ. Co., Easton, PA [1975].
- salts of the compounds of the present invention are contemplated as being pharmaceutically acceptable.
- salts of acids and bases that are non- pharmaceutically acceptable may also find use, for example, in the preparation or purification of a pharmaceutically acceptable compound.
- a compound of the invention contains both a basic moiety (such as, but not limited to, a pyridine or imidazole) and an acidic moiety (such as, but not limited to, a carboxylic acid) zwitterions (“inner salts”) may be formed.
- acidic and basic salts used within the scope of the invention are pharmaceutically acceptable (i.e., non-toxic, physiologically acceptable) salts.
- Such salts of the compounds of the invention may be formed, for example, by reacting a compound of the invention with an amount of acid or base, such as an equivalent amount, in a medium such as one in which the salt precipitates or in an aqueous medium followed by lyophilization.
- compositions are described as having, including, or comprising specific components, or where processes and methods are described as having, including, or comprising specific steps, it is contemplated that, additionally, there are compositions of the present invention that consist essentially of, or consist of, the recited components, and that there are processes and methods according to the present invention that consist essentially of, or consist of, the recited processing steps.
- compositions specifying a percentage are by weight unless otherwise specified.
- the invention provides naphthyl-substituted quinolin-4( 1H)-oncs and related compounds.
- the compounds may be used in the pharmaceutical compositions and therapeutic methods described herein. Exemplary compounds are described in the following sections, along with exemplary procedures for making the compounds.
- One aspect of the invention provides a compound represented by Formula I: or a pharmaceutically acceptable salt thereof; wherein:
- R 1 is naphthyl; an 8-10 membered saturated or partially unsaturated bicyclic heterocyclyl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; an 8-10 membered bicyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 5-6 membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or phenyl; each of which is substituted with m occurrences of R 5 ;
- R 2 is an 8-10 membered saturated or partially unsaturated bicyclic heterocyclyl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 3-7 membered saturated or partially unsaturated monocyclic heterocyclyl having 1 or 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 5-6 membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; phenyl; or Ci- 6 aliphatic; each of which is substituted with n occurrences of R 6 ;
- R 3 is hydrogen; or one occurrence of R 3 is hydrogen, and the other occurrence of R 3 is taken together with R 4 to form a double bond between the atoms to which R 3 and R 4 are attached; or both occurrences of R 3 are taken together to form an oxo substituent;
- R 4 is taken together with one occurrence of R 3 to form a double bond between the atoms to which R 3 and R 4 are attached;
- R 5 represents independently for each occurrence C2-6 alkynyl, C2-6 alkenyl, Ci- 6 alkyl, hydroxyl, Ci- 6 alkoxyl, halo, or cyano;
- R 6 and R 7 each represent independently for each occurrence halo, hydroxyl, Ci- 6 alkoxyl, Ci- 6 haloalkoxyl, Ci- 6 alkyl, Ci- 6 haloalkyl, Ci- 6 hydroxyalkyl, or -N(R 9 )2;
- R 8 and R 9 each represent independently for each occurrence hydrogen, C M alkyl, or C3-5 cycloalkyl; or two occurrences of R 9 attached to the same nitrogen atom are taken together with the nitrogen atom to which they are attached to form a 4-7 membered saturated ring having one nitrogen atom;
- a 1 is a 4-7 membered saturated monocyclic heterocyclyl having 1 or 2 nitrogen atoms; a 6-11 membered saturated spirocyclic heterocyclyl having 1 or 2 nitrogen atoms; a 6-11 membered saturated ortho- fused heterocyclyl having 1 or 2 nitrogen atoms; or a 5-6 membered monocyclic heteroaryl having one nitrogen atom and 0, 1, or 2 additional heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted with p occurrences
- X 1 is C(H) 2 , C(R 4 )(H), or N(R 4 );
- X 2 is N or C(CN);
- X 3 is N or C(H);
- X 4 is C(O) or C(H) 2 ;
- L is a covalent bond or a C 1-4 bivalent saturated or unsaturated, straight or branched hydrocarbon chain wherein one or two methylene units of the chain are optionally and independently replaced by -0-, -N(R 9 )-, or -C(O)-;
- Y 1 , Y 2 , and Y 3 represent independently a C1-3 bivalent saturated or unsaturated, straight hydrocarbon chain wherein one or two methylene units of the chain are optionally and independently replaced by -0-, -C(H)(R 7 )-, or -C(R 7 ) 2 -; and m, n, and p are each independently 0, 1, 2, or 3.
- the definition of a variable is a single chemical group selected from those chemical groups set forth above
- the definition of a variable is a collection of two or more of the chemical groups selected from those set forth above
- the compound is defined by a combination of variables in which the variables are defined by (i) or (ii).
- the compound is a compound of Formula I.
- R 1 is naphthyl; an 8-10 membered saturated or partially unsaturated bicyclic heterocyclyl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; an 8-10 membered bicyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 5-6 membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or phenyl; each of which is substituted with m occurrences of R 5 .
- R 1 is naphthyl, an 8-10 membered saturated or partially unsaturated bicyclic heterocyclyl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or an 8-10 membered bicyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted with m occurrences of R 5 .
- R 1 is phenyl or a 5-6 membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted with m occurrences of R 5 .
- R 1 is naphthyl or phenyl; each of which is substituted with m occurrences of R 5 .
- R 1 is an 8-10 membered saturated or partially unsaturated bicyclic heterocyclyl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; an 8-10 membered bicyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or a 5-6 membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted with m occurrences of R 5 .
- R 1 is naphthyl or an 8-10 membered bicyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted with m occurrences of R 5 .
- R 1 is an 8-10 membered saturated or partially unsaturated bicyclic heterocyclyl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or an 8-10 membered bicyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted with m occurrences of R 5 .
- R 1 is naphthyl substituted with m occurrences of R 5 . In certain embodiments, R 1 is 1-naphthyl substituted with m occurrences of R 5 . In certain embodiments,
- R 1 is an 8-10 membered saturated or partially unsaturated bicyclic heterocyclyl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said heterocyclyl is substituted with m occurrences of R 5 .
- R 1 is an 8-10 membered saturated or partially unsaturated bicyclic heterocyclyl having 1 or 2 heteroatoms independently selected from nitrogen and oxygen; wherein said heterocyclyl is substituted with m occurrences of R 5 .
- R 1 is In certain embodiments, R 1 is
- R 1 is an 8-10 membered bicyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said heteroaryl is substituted with m occurrences of R 5 .
- R 1 is an 8-10 membered bicyclic heteroaryl having 1 or 2 heteroatoms independently selected from nitrogen and oxygen, and sulfur; wherein said heteroaryl is substituted with m occurrences of R 5 .
- R 1 is quinolinyl, isoquinolinyl, or indazolyl; each of which is substituted with m occurrences of R 5 .
- R 1 is quinolinyl substituted with m occurrences of R 5 .
- R 1 is quinoline-4-yl substituted with m occurrences of R 5 .
- R 1 is isoquinolinyl substituted with m occurrences of R 5 .
- R 1 is isoquinolin-l-yl substituted with m occurrences of R 5 .
- R 1 is indazolyl substituted with m occurrences of R 5 .
- R 1 is phenyl substituted with m occurrences of R 5 . In certain embodiments, R 1 is In certain embodiments, R 1 is [0089] In certain embodiments, R 1 is a 5-6 membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said heteroaryl is substituted with m occurrences of R 5 . In certain embodiments, R 1 is a 6-membered monocyclic heteroaryl having 1, 2, or 3 nitrogen atoms; wherein said heteroaryl is substituted with m occurrences of R 5 . In certain embodiments, R 1 is a 5-membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said heteroaryl is substituted with m occurrences of R 5 .
- R 1 is selected from the groups depicted in the compounds in Table 1, below. In certain embodiments, R 1 is selected from the groups depicted in the compounds in Table 1 or 1-A, below.
- R 2 is an 8-10 membered saturated or partially unsaturated bicyclic heterocyclyl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 3-7 membered saturated or partially unsaturated monocyclic heterocyclyl having 1 or 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 5-6 membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; phenyl; or Ci- 6 aliphatic; each of which is substituted with n occurrences of R 6 .
- R 2 is an 8-10 membered saturated or partially unsaturated bicyclic heterocyclyl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 3-7 membered saturated or partially unsaturated monocyclic heterocyclyl having 1 or 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or a 5-6 membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted with n occurrences of R 6 .
- R 2 is phenyl or Ci- 6 aliphatic; each of which is substituted with n occurrences of R 6 .
- R 2 is an 8-10 membered saturated or partially unsaturated bicyclic heterocyclyl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or a 3-7 membered saturated or partially unsaturated monocyclic heterocyclyl having 1 or 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted with n occurrences of R 6 .
- R 2 is a 3-7 membered saturated or partially unsaturated monocyclic heterocyclyl having 1 or 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or a 5-6 membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted with n occurrences of R 6 .
- R 2 is a 3-7 membered saturated or partially unsaturated monocyclic heterocyclyl having 1 or 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 5-6 membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; phenyl; or Ci- 6 aliphatic; each of which is substituted with n occurrences of R 6 .
- R 2 is a 3-7 membered saturated or partially unsaturated monocyclic heterocyclyl having 1 or 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or Ci- 6 aliphatic; each of which is substituted with n occurrences of R 6 .
- R 2 is a 5-6 membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or phenyl; each of which is substituted with n occurrences of R 6 .
- R 2 is an 8-10 membered saturated or partially unsaturated bicyclic heterocyclyl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said heterocyclyl is substituted with n occurrences of R 6 .
- R 2 is an 8-10 membered saturated bicyclic heterocyclyl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said heterocyclyl is substituted with n occurrences of R 6 .
- R 2 is an 8-10 membered partially unsaturated bicyclic heterocyclyl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said heterocyclyl is substituted with n occurrences of R 6 .
- R 2 is an 8-10 membered saturated or partially unsaturated bicyclic heterocyclyl having 1 or 2 heteroatoms independently selected from nitrogen and oxygen; wherein said heterocyclyl is substituted with n occurrences of R 6 .
- R 2 is an 8-10 membered saturated or partially unsaturated bicyclic heterocyclyl having 1 nitrogen atom; wherein said heterocyclyl is substituted with n occurrences of R 6 .
- R 2 is an 8-10 membered saturated bicyclic heterocyclyl having 1 nitrogen atom; wherein said heterocyclyl is substituted with n occurrences of R 6 .
- R 2 is an 8-10 membered saturated bicyclic heterocyclyl having 1 nitrogen atom; wherein said heterocyclyl is substituted with n occurrences of R 6 .
- R 2 is substituted with n occurrences of R 6 .
- R 2 is an 8-10 membered saturated or partially unsaturated bicyclic heterocyclyl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In certain embodiments, R 2 is an 8-10 membered saturated bicyclic heterocyclyl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In certain embodiments, R 2 is an 8-10 membered partially unsaturated bicyclic heterocyclyl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur.
- R 2 is an 8-10 membered saturated or partially unsaturated bicyclic heterocyclyl having 1 or 2 heteroatoms independently selected from nitrogen and oxygen. In certain embodiments, R 2 is an 8-10 membered saturated or partially unsaturated bicyclic heterocyclyl having 1 nitrogen atom. In certain embodiments, R 2 is an 8-10 membered saturated bicyclic heterocyclyl having 1 nitrogen atom. In certain embodiments, R 2 is
- R 2 is a 3-7 membered saturated or partially unsaturated monocyclic heterocyclyl having 1 or 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said heterocyclyl is substituted with n occurrences of R 6 .
- R 2 is a 4-6 membered saturated or partially unsaturated monocyclic heterocyclyl having 1 or 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said heterocyclyl is substituted with n occurrences of R 6 .
- R 2 is a 5-6 membered saturated or partially unsaturated monocyclic heterocyclyl having 1 or 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said heterocyclyl is substituted with n occurrences of R 6 .
- R 2 is a 5-membered saturated or partially unsaturated monocyclic heterocyclyl having 1 or 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said heterocyclyl is substituted with n occurrences of R 6 .
- R 2 is a 6-membered saturated or partially unsaturated monocyclic heterocyclyl having 1 or 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said heterocyclyl is substituted with n occurrences of R 6 .
- R 2 is a 3-7 membered saturated monocyclic heterocyclyl having 1 or 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said heterocyclyl is substituted with n occurrences of R 6 .
- R 2 is a 5-6 membered saturated monocyclic heterocyclyl having 1 or 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said heterocyclyl is substituted with n occurrences of R 6 .
- R 2 is a 3-7 membered partially unsaturated monocyclic heterocyclyl having 1 or 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said heterocyclyl is substituted with n occurrences of R 6 .
- R 2 is a 5-6 membered partially unsaturated monocyclic heterocyclyl having 1 or 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said heterocyclyl is substituted with n occurrences of R 6 .
- R 2 is a 3-7 membered saturated or partially unsaturated monocyclic heterocyclyl having 1 or 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said heterocyclyl is substituted with n occurrences of R 6 .
- R 2 is a 5-6 membered saturated or partially unsaturated monocyclic heterocyclyl having 1 or 2 heteroatoms independently selected from nitrogen and oxygen; wherein said heterocyclyl is substituted with n occurrences of R 6 .
- R 2 is a 5-6 membered saturated monocyclic heterocyclyl having 1 or 2 heteroatoms independently selected from nitrogen and oxygen; wherein said heterocyclyl is substituted with n occurrences of R 6 .
- R 2 is azetidinyl, pyrrolidinyl, piperidinyl, or morpholinyl; each of which is substituted with n occurrences of R 6 .
- R 2 is azetidinyl substituted with n occurrences of R 6 .
- R 2 is pyrrolidinyl substituted with n occurrences of R 6 .
- R 2 is pyrrolidin-2-yl substituted with n occurrences of R 6 .
- R 2 is pyrrolidin-2-yl substituted with a single occurrence of R 6 at the 1-position.
- R 2 is piperidinyl substituted with n occurrences of R 6 .
- R 2 is morpholinyl substituted with n occurrences of R 6 .
- R 2 is azetidinyl, pyrrolidinyl, piperidinyl, or morpholinyl. In certain embodiments, R 2 is azetidinyl. In certain embodiments, R 2 is pyrrolidinyl. In certain embodiments, R 2 is pyrrolidin-2-yl. In certain embodiments, R 2 is l-methyl-pyrrolidin-2-yl. In certain embodiments, R 2 is piperidinyl. In certain embodiments, R 2 is morpholinyl.
- R 2 is a 5-6 membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said heteroaryl is substituted with n occurrences of R 6 .
- R 2 is phenyl substituted with n occurrences of R 6 . In certain embodiments, R 2 is phenyl.
- R 2 is Ci- 6 aliphatic substituted with n occurrences of R 6 . In certain embodiments, R 2 is C3-6 cycloaliphatic substituted with n occurrences of R 6 . In certain embodiments, R 2 is a Ci- 6 aliphatic chain substituted with n occurrences of R 6 . In certain embodiments, R 2 is C3-6 cycloalkyl substituted with n occurrences of R 6 . In certain embodiments, R 2 is Ci- 6 alkyl substituted with n occurrences of R 6 .
- R 2 is Ci- 6 aliphatic. In certain embodiments, R 2 is C3-6 cycloaliphatic. In certain embodiments, R 2 is a Ci- 6 aliphatic chain. In certain embodiments, R 2 is C3-6 cycloalkyl. In certain embodiments, R 2 is Ci- 6 alkyl.
- R 2 is selected from the groups depicted in the compounds in Table 1, below. In certain embodiments, R 2 is selected from the groups depicted in the compounds in Table 1 or 1-A, below.
- R 3 is hydrogen; or one occurrence of R 3 is hydrogen, and the other occurrence of R 3 is taken together with R 4 to form a double bond between the atoms to which R 3 and R 4 are attached; or both occurrences of R 3 are taken together to form an oxo substituent.
- R 3 is hydrogen.
- one occurrence of R 3 is hydrogen, and the other occurrence of R 3 is taken together with R 4 to form a double bond between the atoms to which R 3 and R 4 are attached.
- both occurrences of R 3 are taken together to form an oxo substituent.
- R 3 is selected from the groups depicted in the compounds in Table 1, below.
- R 4 is taken together with one occurrence of R 3 to form a double bond between the atoms to which R 3 and R 4 are attached.
- R 4 is selected from the groups depicted in the compounds in Table 1, below.
- R 5 represents independently for each occurrence C2-6 alkynyl, C2-6 alkenyl, Ci- 6 alkyl, hydroxyl, Ci- 6 alkoxyl, halo, or cyano.
- R 5 represents independently for each occurrence C2-6 alkynyl, C2-6 alkenyl, Ci- 6 alkyl, or hydroxyl. In certain embodiments, R 5 represents independently for each occurrence ethynyl, ethenyl, C1-3 alkyl, or hydroxyl. In certain embodiments, R 5 represents independently for each occurrence C2-6 alkynyl or hydroxyl. In certain embodiments, R 5 represents independently for each occurrence ethynyl or hydroxyl. In certain embodiments, one occurrence of R 5 is ethynyl. In certain embodiments, one occurrence of R 5 is hydroxyl.
- R 5 represents independently for each occurrence C2-6 alkynyl, C2-6 alkenyl, or Ci- 6 alkyl. In certain embodiments, R 5 represents independently for each occurrence ethynyl, ethenyl, or C1-3 alkyl. In certain embodiments, R 5 represents independently for each occurrence hydroxyl or Ci- 6 alkoxyl. In certain embodiments, R 5 represents independently for each occurrence halo or cyano.
- R 5 represents independently for each occurrence C2-6 alkynyl. In certain embodiments, R 5 is ethynyl. In certain embodiments, R 5 represents independently for each occurrence C2-6 alkenyl. In certain embodiments, R 5 is ethenyl. In certain embodiments, R 5 represents independently for each occurrence Ci- 6 alkyl. In certain embodiments, R 5 represents independently for each occurrence C1-3 alkyl. In certain embodiments, R 5 is methyl. In certain embodiments, R 5 is hydroxyl. In certain embodiments, R 5 represents independently for each occurrence Ci- 6 alkoxyl. In certain embodiments, R 5 represents independently for each occurrence halo.
- R 5 represents independently for each occurrence fluoro or chloro. In certain embodiments, R 5 is fluoro. In certain embodiments, R 5 is chloro. In certain embodiments, R 5 is cyano. In certain embodiments, R 5 is selected from the groups depicted in the compounds in Table 1, below. In certain embodiments, R 5 is selected from the groups depicted in the compounds in Table 1 or 1-A, below.
- R 6 represents independently for each occurrence halo, hydroxyl, Ci- 6 alkoxyl, Ci- 6 haloalkoxyl, Ci- 6 alkyl, Ci- 6 haloalkyl, Ci- 6 hydroxyalkyl, or -N(R 9 )2.
- R 6 represents independently for each occurrence halo, hydroxyl, Ci- 6 alkoxyl, Ci- 6 alkyl, or Ci- 6 haloalkyl. In certain embodiments, R 6 represents independently for each occurrence halo, Ci- 6 alkyl, or Ci- 6 haloalkyl. In certain embodiments, R 6 represents independently for each occurrence halo or Ci- 6 alkyl. In certain embodiments, R 6 represents independently for each occurrence halo, hydroxyl, or Ci- 6 alkyl.
- R 6 represents independently for each occurrence halo, hydroxyl, Ci- 6 alkoxyl, Ci- 6 haloalkoxyl, or -N(R 9 )2. In certain embodiments, R 6 represents independently for each occurrence halo, hydroxyl, or -N(R 9 )2. In certain embodiments, R 6 represents independently for each occurrence halo, Ci- 6 alkoxyl, or Ci- 6 haloalkoxyl. In certain embodiments, R 6 represents independently for each occurrence halo, Ci- 6 alkyl, Ci- 6 haloalkyl, or Ci- 6 hydroxyalkyl.
- R 6 represents independently for each occurrence Ci- 6 alkyl, Ci- 6 haloalkyl, or Ci- 6 hydroxyalkyl. In certain embodiments, R 6 represents independently for each occurrence Ci- 6 alkyl or Ci- 6 haloalkyl.
- R 6 represents independently for each occurrence halo. In certain embodiments, R 6 represents independently for each occurrence fluoro or chloro. In certain embodiments, R 6 is fluoro. In certain embodiments, R 6 is chloro. In certain embodiments, R 6 is hydroxyl. In certain embodiments, R 6 represents independently for each occurrence Ci- 6 alkoxyl. In certain embodiments, R 6 is methoxy. In certain embodiments, R 6 represents independently for each occurrence Ci- 6 haloalkoxyl. In certain embodiments, R 6 is trifluoromethoxy. In certain embodiments, R 6 represents independently for each occurrence Ci- 6 alkyl. In certain embodiments, R 6 represents independently for each occurrence C1-3 alkyl.
- R 6 is methyl. In certain embodiments, R 6 represents independently for each occurrence Ci- 6 haloalkyl. In certain embodiments, R 6 is trifluoromethyl. In certain embodiments, R 6 represents independently for each occurrence Ci- 6 hydroxyalkyl. In certain embodiments, R 6 represents independently for each occurrence -N(R 9 )2. In certain embodiments, R 6 is -NH2. In certain embodiments, R 6 is selected from the groups depicted in the compounds in Table 1, below. In certain embodiments, R 6 is selected from the groups depicted in the compounds in Table 1 or 1-A, below.
- R 7 represents independently for each occurrence halo, hydroxyl, Ci- 6 alkoxyl, Ci- 6 haloalkoxyl, Ci- 6 alkyl, Ci- 6 haloalkyl, Ci- 6 hydroxyalkyl, or -N(R 9 )2.
- R 7 represents independently for each occurrence halo, hydroxyl, Ci- 6 alkoxyl, Ci- 6 alkyl, or Ci- 6 haloalkyl. In certain embodiments, R 7 represents independently for each occurrence halo, Ci- 6 alkyl, or Ci- 6 haloalkyl. In certain embodiments, R 7 represents independently for each occurrence halo or Ci- 6 alkyl. In certain embodiments, R 7 represents independently for each occurrence halo, hydroxyl, or Ci- 6 alkyl.
- R 7 represents independently for each occurrence halo, hydroxyl, Ci- 6 alkoxyl, Ci- 6 haloalkoxyl, or -N(R 9 )2. In certain embodiments, R 7 represents independently for each occurrence halo, hydroxyl, or -N(R 9 )2. In certain embodiments, R 7 represents independently for each occurrence halo, Ci- 6 alkoxyl, or Ci- 6 haloalkoxyl. In certain embodiments, R 7 represents independently for each occurrence halo, Ci- 6 alkyl, Ci- 6 haloalkyl, or Ci- 6 hydroxyalkyl.
- R 7 represents independently for each occurrence Ci- 6 alkyl, Ci- 6 haloalkyl, or Ci- 6 hydroxyalkyl. In certain embodiments, R 7 represents independently for each occurrence Ci- 6 alkyl or Ci- 6 haloalkyl.
- R 7 represents independently for each occurrence halo. In certain embodiments, R 7 represents independently for each occurrence fluoro or chloro. In certain embodiments, R 7 is fluoro. In certain embodiments, R 7 is chloro. In certain embodiments, R 7 is hydroxyl. In certain embodiments, R 7 represents independently for each occurrence Ci- 6 alkoxyl. In certain embodiments, R 7 is methoxy. In certain embodiments, R 7 represents independently for each occurrence Ci- 6 haloalkoxyl. In certain embodiments, R 7 is trifluoromethoxy. In certain embodiments, R 7 represents independently for each occurrence C1-6 alkyl. In certain embodiments, R 7 represents independently for each occurrence C1-3 alkyl.
- R 7 is methyl. In certain embodiments, R 7 represents independently for each occurrence Ci- 6 haloalkyl. In certain embodiments, R 7 is trifluoromethyl. In certain embodiments, R 7 represents independently for each occurrence Ci- 6 hydroxyalkyl. In certain embodiments, R 7 represents independently for each occurrence -N(R 9 )2. In certain embodiments, R 7 is -NH2. In certain embodiments, R 7 is selected from the groups depicted in the compounds in Table 1, below.
- R 8 is hydrogen, C1-4 alkyl, or C3-5 cycloalkyl. In certain embodiments, R 8 is hydrogen or C 1-4 alkyl. In certain embodiments, R 8 is hydrogen or methyl.
- R 8 is CIM alkyl or C3-5 cycloalkyl.
- R 8 is hydrogen. In certain embodiments, R 8 is CIM alkyl. In certain embodiments, R 8 is methyl. In certain embodiments, R 8 is C3-5 cycloalkyl. In certain embodiments, R 8 is cyclopropyl. In certain embodiments, R 8 is selected from the groups depicted in the compounds in Table 1, below.
- R 9 represents independently for each occurrence hydrogen, Ci-4 alkyl, or C3-5 cycloalkyl; or two occurrences of R 9 attached to the same nitrogen atom are taken together with the nitrogen atom to which they are attached to form a 4-7 membered saturated ring having one nitrogen atom.
- R 9 represents independently for each occurrence hydrogen, C1-4 alkyl, or C3-5 cycloalkyl. In certain embodiments, R 9 represents independently for each occurrence hydrogen or C1-4 alkyl. In certain embodiments, R 9 represents independently for each occurrence hydrogen or methyl. In certain embodiments, R 9 represents independently for each occurrence C1-4 alkyl or C3-5 cycloalkyl.
- two occurrences of R 9 attached to the same nitrogen atom are taken together with the nitrogen atom to which they are attached to form a 4-7 membered saturated ring having one nitrogen atom.
- R 9 is hydrogen. In certain embodiments, R 9 represents independently for each occurrence C M alkyl. In certain embodiments, R 9 is methyl. In certain embodiments, R 9 represents independently for each occurrence C3-5 cycloalkyl. In certain embodiments, R 9 is cyclopropyl. In certain embodiments, R 9 is selected from the groups depicted in the compounds in Table 1, below.
- a 1 is a 4-7 membered saturated monocyclic heterocyclyl having 1 or 2 nitrogen atoms; a 6-11 membered saturated spirocyclic heterocyclyl having 1 or 2 nitrogen atoms; a 6-11 membered saturated ortho- fused heterocyclyl having 1 or 2 nitrogen atoms; or a 5-6 membered monocyclic heteroaryl having one nitrogen atom and 0, 1, or 2 additional heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted with p occurrences of R 7 ; or A 1 is , [0130] In certain embodiments, A 1 is In certain embodiments, A 1 is In certain embodiments, A 1 is In certain embodiments, A 1 is In certain embodiments, A 1 is
- a 1 is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
- a 1 is a 4-7 membered saturated monocyclic heterocyclyl having 1 or 2 nitrogen atoms; a 6-11 membered saturated spirocyclic heterocyclyl having 1 or 2 nitrogen atoms; a 6-11 membered saturated ortho- fused heterocyclyl having 1 or 2 nitrogen atoms; or a 5- 6 membered monocyclic heteroaryl having one nitrogen atom and 0, 1, or 2 additional heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted with p occurrences of R 7 .
- a 1 is a 4-7 membered saturated monocyclic heterocyclyl having 1 or 2 nitrogen atoms; a 6-11 membered saturated spirocyclic heterocyclyl having 1 or 2 nitrogen atoms; or a 6-11 membered saturated ortho- fused heterocyclyl having 1 or 2 nitrogen atoms; each of which is substituted with p occurrences of R 7 ; or A 1 is
- a 1 is a 4-7 membered saturated monocyclic heterocyclyl having 1 or 2 nitrogen atoms; a 6-11 membered saturated spirocyclic heterocyclyl having 1 or 2 nitrogen atoms; or a 6-11 membered saturated ortho- fused heterocyclyl having 1 or 2 nitrogen atoms; each of which is substituted with p occurrences of R 7 .
- a 1 is a 6-11 membered saturated spirocyclic heterocyclyl having 1 or 2 nitrogen atoms; or a 6-11 membered saturated ortho- fused heterocyclyl having 1 or 2 nitrogen atoms; each of which is substituted with p occurrences of R 7 ; or A 1 is or
- a 1 is a 6-11 membered saturated spirocyclic heterocyclyl having 1 or 2 nitrogen atoms; or a 6-11 membered saturated ortho- fused heterocyclyl having 1 or 2 nitrogen atoms; each of which is substituted with p occurrences of R 7 .
- a 1 is a 4-7 membered saturated monocyclic heterocyclyl having 1 or 2 nitrogen atoms; or a 5-6 membered monocyclic heteroaryl having one nitrogen atom and 0, 1, or 2 additional heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted with p occurrences of R 7 .
- a 1 is a 4-7 membered saturated monocyclic heterocyclyl having 1 or 2 nitrogen atoms; a 6-11 membered saturated spirocyclic heterocyclyl having 1 or 2 nitrogen atoms; a 6-11 membered saturated ortho- fused heterocyclyl having 1 or 2 nitrogen atoms; or a 5- 6 membered monocyclic heteroaryl having one nitrogen atom and 0, 1, or 2 additional heteroatoms independently selected from nitrogen, oxygen, and sulfur.
- a 1 is a 4-7 membered saturated monocyclic heterocyclyl having 1 or 2 nitrogen atoms; a 6-11 membered saturated spirocyclic heterocyclyl having 1 or 2 nitrogen atoms; or a 6-11 membered saturated ortho- fused heterocyclyl having 1 or 2 nitrogen atoms; or
- a 1 is a 4-7 membered saturated monocyclic heterocyclyl having 1 or 2 nitrogen atoms; a 6-11 membered saturated spirocyclic heterocyclyl having 1 or 2 nitrogen atoms; or a 6-11 membered saturated ortho- fused heterocyclyl having 1 or 2 nitrogen atoms.
- a 1 is a 6-11 membered saturated spirocyclic heterocyclyl having 1 or 2 nitrogen atoms; or a 6-11 membered saturated ortho- fused heterocyclyl having 1 or 2
- a 1 is a 6-11 membered saturated spirocyclic heterocyclyl having 1 or 2 nitrogen atoms; or a 6-11 membered saturated ortho- fused heterocyclyl having 1 or 2 nitrogen atoms.
- a 1 is a 4-7 membered saturated monocyclic heterocyclyl having 1 or 2 nitrogen atoms; or a 5-6 membered monocyclic heteroaryl having one nitrogen atom and 0, 1, or 2 additional heteroatoms independently selected from nitrogen, oxygen, and sulfur.
- a 1 is a 4-7 membered saturated monocyclic heterocyclyl having 1 or 2 nitrogen atoms; wherein said heterocyclyl is substituted with p occurrences of R 7 .
- a 1 is a 5-6 membered saturated monocyclic heterocyclyl having 1 or 2 nitrogen atoms; wherein said heterocyclyl is substituted with p occurrences of R 7 .
- a 1 is a 4-7 membered saturated monocyclic heterocyclyl having 1 or 2 nitrogen atoms.
- a 1 is a 5-6 membered saturated monocyclic heterocyclyl having 1 or 2 nitrogen atoms.
- a 1 is 1,4-diazepanyl, piperidinyl, piperazinyl, pyrrolidinyl, or azetidinyl; each of which is substituted with p occurrences of R 7 .
- a 1 is 1,4-diazepanyl substituted with p occurrences of R 7 .
- a 1 is piperidinyl substituted with p occurrences of R 7 .
- a 1 is piperazinyl substituted with p occurrences of R 7 .
- a 1 is pyrrolidinyl substituted with p occurrences of R 7 .
- a 1 is azetidinyl substituted with p occurrences of R 7 .
- a 1 is 1,4-diazepanyl, piperidinyl, piperazinyl, pyrrolidinyl, or azetidinyl. In certain embodiments, A 1 is 1,4-diazepanyl. In certain embodiments, A 1 is piperidinyl. In certain embodiments, A 1 is piperazinyl. In certain embodiments, A 1 is pyrrolidinyl. In certain embodiments, A 1 is azetidinyl.
- a 1 is 1,4-diazepan-l-yl, piperidin-4-yl, piperazin-l-yl, pyrrolidin-3-yl, or azetidin-3-yl; each of which is substituted with p occurrences of R 7 .
- a 1 is 1,4-diazepan-l-yl substituted with p occurrences of R 7 .
- a 1 is piperidin-4-yl substituted with p occurrences of R 7 .
- a 1 is piperazin-l-yl substituted with p occurrences of R 7 .
- a 1 is pyrrolidin-3-yl substituted with p occurrences of R 7 .
- a 1 is azetidin-3-yl substituted with p occurrences of R 7 .
- a 1 is 1,4-diazepan-l-yl, piperidin-4-yl, piperazin-l-yl, pyrrolidin-3-yl, or azetidin-3-yl. In certain embodiments, A 1 is 1,4-diazepan-l-yl. In certain embodiments, A 1 is piperidin-4-yl. In certain embodiments, A 1 is piperazin-l-yl. In certain embodiments, A 1 is pyrrolidin-3-yl. In certain embodiments, A 1 is azetidin-3-yl.
- a 1 is a 6-11 membered saturated spirocyclic heterocyclyl having 1 or 2 nitrogen atoms; wherein said heterocyclyl is substituted with p occurrences of R 7 .
- a 1 is a 7-10 membered saturated spirocyclic heterocyclyl having 1 or 2 nitrogen atoms; wherein said heterocyclyl is substituted with p occurrences of R 7 .
- a 1 is a 6-11 membered saturated spirocyclic heterocyclyl having 2 nitrogen atoms; wherein said heterocyclyl is substituted with p occurrences of R 7 .
- a 1 is a 6-11 membered saturated spirocyclic heterocyclyl having 1 or 2 nitrogen atoms. In certain embodiments, A 1 is a 7-10 membered saturated spirocyclic heterocyclyl having 1 or 2 nitrogen atoms. In certain embodiments, A 1 is a 6-11 membered saturated spirocyclic heterocyclyl having 2 nitrogen atoms. In certain embodiments, A 1 is or In certain embodiments, A 1 is In certain embodiments, A 1 i is
- a 1 is a 6-11 membered saturated ortho- fused heterocyclyl having 1 or 2 nitrogen atoms; wherein said heterocyclyl is substituted with p occurrences of R 7 .
- a 1 is a 7-10 membered saturated ori/zo-fused heterocyclyl having 1 or 2 nitrogen atoms; wherein said heterocyclyl is substituted with p occurrences of R 7 .
- a 1 is a 6-11 membered saturated ori/zo-fused heterocyclyl having 1 or 2 nitrogen atoms.
- a 1 is a 7-10 membered saturated ori zo-fused heterocyclyl having 1 or 2 nitrogen atoms.
- a 1 is a 5-6 membered monocyclic heteroaryl having one nitrogen atom and 0, 1, or 2 additional heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said heteroaryl is substituted with p occurrences of R 7 .
- a 1 is a 6-membered monocyclic heteroaryl having 1, 2, or 3 nitrogen atoms; wherein said heteroaryl is substituted with p occurrences of R 7 .
- a 1 is pyridinyl or pyrimidinyl; each of which is substituted with p occurrences of R 7 .
- a 1 is pyridinyl substituted with p occurrences of R 7 .
- a 1 is pyridin-4-yl substituted with p occurrences of R 7 .
- a 1 is pyrimidinyl substituted with p occurrences of R 7 .
- a 1 is a 5-membered monocyclic heteroaryl having one nitrogen atom and 0, 1, or 2 additional heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said heteroaryl is substituted with p occurrences of R 7 .
- a 1 is a 5-membered monocyclic heteroaryl having 1, 2, or 3 nitrogen atoms; wherein said heteroaryl is substituted with p occurrences of R 7 .
- a 1 is imidazolyl or pyrazolyl; each of which is substituted with p occurrences of R 7 .
- a 1 is imidazolyl substituted with p occurrences of R 7 .
- a 1 is pyrazolyl substituted with p occurrences of R 7 .
- a 1 is selected from the groups depicted in the compounds in Table 1, below.
- X 1 is C(H)2, C(R 4 )(H), or N(R 4 ). In certain embodiments,
- X 1 is C(H) 2 or C(R 4 )(H). In certain embodiments, X 1 is C(R 4 )(H) or N(R 4 ). In certain embodiments, X 1 is C(H)2. In certain embodiments, X 1 is C(R 4 )(H). In certain embodiments, X 1 is N(R 4 ). In certain embodiments, X 1 is selected from the groups depicted in the compounds in Table 1, below. [0156] As defined generally above, X 2 is N or C(CN). In certain embodiments, X 2 is N. In certain embodiments, X 2 is C(CN). In certain embodiments, X 2 is selected from the groups depicted in the compounds in Table 1, below.
- X 3 is N or C(H). In certain embodiments, X 3 is N. In certain embodiments, X 3 is C(H). In certain embodiments, X 3 is selected from the groups depicted in the compounds in Table 1, below.
- X 4 is C(O) or C(H)2. In certain embodiments, X 4 is C(O).
- X 4 is C(H)2. In certain embodiments, X 4 is selected from the groups depicted in the compounds in Table 1, below.
- L is a covalent bond or a Ci-4 bivalent saturated or unsaturated, straight or branched hydrocarbon chain wherein one or two methylene units of the chain are optionally and independently replaced by -0-, -N(R 9 )-, or -C(O)-. In certain embodiments, L is a covalent bond.
- L is a Ci-4 bivalent saturated or unsaturated, straight or branched hydrocarbon chain wherein one or two methylene units of the chain are optionally and independently replaced by -0-, -N(R 9 )-, or -C(O)-.
- L is a Ci-4 bivalent saturated, straight or branched hydrocarbon chain wherein one or two methylene units of the chain are optionally and independently replaced by -0-, -N(R 9 )-, or -C(O)-.
- L is a C1-4 bivalent saturated, straight hydrocarbon chain wherein one or two methylene units of the chain are optionally and independently replaced by -0-, -N(R 9 )-, or - C(O)-. In certain embodiments, L is a C2-3 bivalent saturated, straight hydrocarbon chain wherein one or two methylene units of the chain are optionally and independently replaced by - 0-, -N(R 9 )-, or -C(O)-.
- L is a C 1-4 bivalent saturated, straight hydrocarbon chain wherein one methylene unit of the chain is optionally replaced by -0-, -N(R 9 )-, or -C(O)-.
- L is a C 2-3 bivalent saturated, straight hydrocarbon chain wherein one methylene unit of the chain is optionally replaced by -0-, -N(R 9 )-, or -C(O)-.
- L is a Ci- 4 bivalent saturated, straight hydrocarbon chain wherein one methylene unit of the chain is replaced by -O- or -N(R 9 )-.
- L is a C 2-3 bivalent saturated, straight hydrocarbon chain wherein one methylene unit of the chain is replaced by -O- or -N(R 9 )-.
- L is -0-CH 2 -, -0-(CH 2 ) 2 -, -N(R 9 )-CH 2 -, or -N(R 9 )-(CH 2 ) 2 -, wherein the terminal carbon atom of L is attached to R 2 .
- L is -0-CH 2 - or -0-(CH 2 ) 2 -, wherein the terminal carbon atom of L is attached to R 2 .
- L is -N(R 9 )-CH 2 - or -N(R 9 )-(CH 2 ) 2 -, wherein the terminal carbon atom of L is attached to R 2 .
- L is -0-CH 2 -, wherein the carbon atom of L is attached to R 2 .
- L is -0-(CH 2 ) 2 -, wherein the terminal carbon atom of L is attached to R 2 .
- L is -N(R 9 )-CH 2 -, wherein the carbon atom of L is attached to R 2 .
- L is -N(R 9 )-(CH 2 ) 2 -, wherein the terminal carbon atom of L is attached to R 2 .
- L is selected from the groups depicted in the compounds in Table 1, below.
- Y 1 is a C1-3 bivalent saturated or unsaturated, straight hydrocarbon chain wherein one or two methylene units of the chain are optionally and independently replaced by -0-, -C(H)(R 7 )-, or -C(R 7 ) 2 -.
- Y 1 is a C 2 -3 bivalent unsaturated, straight hydrocarbon chain wherein one methylene unit of the chain is optionally replaced by -0-, -C(H)(R 7 )-, or -C(R 7 ) 2 -. In certain embodiments, Y 1 is a C 2 -3 bivalent unsaturated, straight hydrocarbon chain.
- Y 1 is a C1-3 bivalent saturated, straight hydrocarbon chain wherein one or two methylene units of the chain are optionally and independently replaced by - 0-, -C(H)(R 7 )-, or -C(R 7 ) 2 -. In certain embodiments, Y 1 is a C1-3 bivalent saturated, straight hydrocarbon chain wherein one methylene unit of the chain is optionally replaced by -0-, - C(H)(R 7 )-, or -C(R 7 ) 2 -.
- Y 1 is a C1-3 bivalent saturated, straight hydrocarbon chain wherein one methylene unit of the chain is replaced by -0-, -C(H)(R 7 )-, or - C(R 7 ) 2 -. In certain embodiments, Y 1 is a C1-3 bivalent saturated, straight hydrocarbon chain.
- Y 1 is a C 2 -3 bivalent saturated, straight hydrocarbon chain wherein one or two methylene units of the chain are optionally and independently replaced by - 0-, -C(H)(R 7 )-, or -C(R 7 ) 2 -.
- Y 1 is a C 2 -3 bivalent saturated, straight hydrocarbon chain wherein one methylene unit of the chain is optionally replaced by -0-, - C(H)(R 7 )-, or -C(R 7 ) 2 -.
- Y 1 is a C 2 -3 bivalent saturated, straight hydrocarbon chain wherein one methylene unit of the chain is replaced by -0-, -C(H)(R 7 )-, or - C(R 7 ) 2 -. In certain embodiments, Y 1 is a C 2-3 bivalent saturated, straight hydrocarbon chain.
- Y 1 is -(CH 2 )-, -(CH 2 ) 2 -, -CH 2 -C(H)(OH)-, -(CH 2 ) 3 -, -CH 2 -0- CH 2 -, or -CH 2 -CF 2 -CH 2 -.
- Y 1 is -(CH 2 )-, -(CH 2 ) 2 -, -CH 2 -C(H)(OH)-, - (CH 2 ) 3 -, or -CH 2 -CF 2 -CH 2 -.
- Y 1 is -(CH 2 ) 2 -, -CH 2 -C(H)(OH)-, -(CH 2 ) 3 -, or -CH 2 -CF 2 -CH 2 -. In certain embodiments, Y 1 is -(CH 2 ) 2 - or -(CH 2 ) 3 -. In certain embodiments, Y 1 is -CH 2 -C(H)(OH)- or -CH 2 -CF 2 -CH 2 -. In certain embodiments, Y 1 is -(CH 2 )-, -(CH 2 ) 2 -, or - (CH 2 ) 3 -.
- Y 1 is -(CH 2 ) 2 - or -CH 2 -C(H)(OH)-. In certain embodiments, Y 1 is -(CH 2 ) 3 -, -CH 2 -0-CH 2 -, or -CH 2 -CF 2 -CH 2 -.
- Y 1 is -(CH 2 )-. In certain embodiments, Y 1 is -(CH 2 ) 2 -. In certain embodiments, Y 1 is -CH 2 -C(H)(OH)-. In certain embodiments, Y 1 is -(CH 2 ) 3 -. In certain embodiments, Y 1 is -CH 2 -0-CH 2 -. In certain embodiments, Y 1 is -CH 2 -CF 2 -CH 2 -. In certain embodiments, Y 1 is selected from the groups depicted in the compounds in Table 1, below.
- Y 2 is a C 1-3 bivalent saturated or unsaturated, straight hydrocarbon chain wherein one or two methylene units of the chain are optionally and independently replaced by -0-, -C(H)(R 7 )-, or -C(R 7 ) 2 -.
- Y 2 is a C 2-3 bivalent unsaturated, straight hydrocarbon chain wherein one methylene unit of the chain is optionally replaced by -0-, -C(H)(R 7 )-, or -C(R 7 ) 2 -.
- Y 2 is a C 2-3 bivalent unsaturated, straight hydrocarbon chain.
- Y 2 is a C 1-3 bivalent saturated, straight hydrocarbon chain wherein one or two methylene units of the chain are optionally and independently replaced by - 0-, -C(H)(R 7 )-, or -C(R 7 ) 2 -.
- Y 2 is a C 1-3 bivalent saturated, straight hydrocarbon chain wherein one methylene unit of the chain is optionally replaced by -0-, - C(H)(R 7 )-, or -C(R 7 ) 2 -.
- Y 2 is a C 1-3 bivalent saturated, straight hydrocarbon chain wherein one methylene unit of the chain is replaced by -0-, -C(H)(R 7 )-, or - C(R 7 ) 2 -. In certain embodiments, Y 2 is a C 1-3 bivalent saturated, straight hydrocarbon chain.
- Y 2 is a C 2-3 bivalent saturated, straight hydrocarbon chain wherein one or two methylene units of the chain are optionally and independently replaced by - 0-, -C(H)(R 7 )-, or -C(R 7 ) 2 -. In certain embodiments, Y 2 is a C 2-3 bivalent saturated, straight hydrocarbon chain wherein one methylene unit of the chain is optionally replaced by -0-, - C(H)(R 7 )-, or -C(R 7 ) 2 -.
- Y 2 is a C 2-3 bivalent saturated, straight hydrocarbon chain wherein one methylene unit of the chain is replaced by -0-, -C(H)(R 7 )-, or - C(R 7 ) 2 -. In certain embodiments, Y 2 is a C 2-3 bivalent saturated, straight hydrocarbon chain.
- Y 2 is -(CH 2 )-, -(CH 2 ) 2 -, -CH 2 -C(H)(OH)-, -(CH 2 ) 3 -, -CH 2 -0- CH 2 -, or -CH 2 -CF 2 -CH 2 -.
- Y 2 is -(CH 2 )-, -(CH 2 ) 2 -, -CH 2 -C(H)(OH)-, - (CH 2 ) 3 -, or -CH 2 -CF 2 -CH 2 -.
- Y 2 is -(CH 2 ) 2 -, -CH 2 -C(H)(OH)-, -(CH 2 ) 3 -, or -CH 2 -CF 2 -CH 2 -. In certain embodiments, Y 2 is -(CH 2 ) 2 - or -(CH 2 ) 3 -. In certain embodiments, Y 2 is -CH 2 -C(H)(OH)- or -CH 2 -CF 2 -CH 2 -. In certain embodiments, Y 2 is -(CH 2 )-, -(CH 2 ) 2 -, or - (CH 2 ) 3 -.
- Y 2 is -(CH 2 ) 2 - or -CH 2 -C(H)(OH)-. In certain embodiments, Y 2 is -(CH 2 ) 3 -, -CH 2 -0-CH 2 -, or -CH 2 -CF 2 -CH 2 -.
- Y 2 is -(CH 2 )-. In certain embodiments, Y 2 is -(CH 2 ) 2 -. In certain embodiments, Y 2 is -CH 2 -C(H)(OH)-. In certain embodiments, Y 2 is -(CH 2 ) 3 -. In certain embodiments, Y 2 is -CH 2 -0-CH 2 -. In certain embodiments, Y 2 is -CH 2 -CF 2 -CH 2 -. In certain embodiments, Y 2 is selected from the groups depicted in the compounds in Table 1, below.
- Y 3 is a C 1-3 bivalent saturated or unsaturated, straight hydrocarbon chain wherein one or two methylene units of the chain are optionally and independently replaced by -0-, -C(H)(R 7 )-, or -C(R 7 ) 2 -.
- Y 3 is a C 2-3 bivalent unsaturated, straight hydrocarbon chain wherein one methylene unit of the chain is optionally replaced by -0-, -C(H)(R 7 )-, or -C(R 7 ) 2 -.
- Y 3 is a C 2-3 bivalent unsaturated, straight hydrocarbon chain.
- Y 3 is a C 1-3 bivalent saturated, straight hydrocarbon chain wherein one or two methylene units of the chain are optionally and independently replaced by - 0-, -C(H)(R 7 )-, or -C(R 7 ) 2 -. In certain embodiments, Y 3 is a C 1-3 bivalent saturated, straight hydrocarbon chain wherein one methylene unit of the chain is optionally replaced by -0-, - C(H)(R 7 )-, or -C(R 7 ) 2 -.
- Y 3 is a C 1-3 bivalent saturated, straight hydrocarbon chain wherein one methylene unit of the chain is replaced by -0-, -C(H)(R 7 )-, or - C(R 7 ) 2 -. In certain embodiments, Y 3 is a C 1-3 bivalent saturated, straight hydrocarbon chain. [0179] In certain embodiments, Y 3 is a C2-3 bivalent saturated, straight hydrocarbon chain wherein one or two methylene units of the chain are optionally and independently replaced by - 0-, -C(H)(R 7 )-, or -C(R 7 ) 2 -.
- Y 3 is a C2-3 bivalent saturated, straight hydrocarbon chain wherein one methylene unit of the chain is optionally replaced by -0-, - C(H)(R 7 )-, or -C(R 7 ) 2 -. In certain embodiments, Y 3 is a C2-3 bivalent saturated, straight hydrocarbon chain wherein one methylene unit of the chain is replaced by -0-, -C(H)(R 7 )-, or - C(R 7 ) 2 -. In certain embodiments, Y 3 is a C2-3 bivalent saturated, straight hydrocarbon chain.
- Y 3 is -(CH 2 )-, -(CH 2 ) 2 -, -CH 2 -C(H)(OH)-, -(CH 2 ) 3 -, -CH2-O- CH2-, or -CH2-CF2-CH2-.
- Y 3 is -(CH 2 )-, -(CH 2 ) 2 -, -CH 2 -C(H)(OH)-, - (CH 2 ) 3 -, or -CH2-CF2-CH2-.
- Y 3 is -(CH 2 ) 2 -, -CH 2 -C(H)(OH)-, -(CH 2 ) 3 -, or -CH2-CF2-CH2-. In certain embodiments, Y 3 is -(CH2)2- or -(CH2)3-. In certain embodiments, Y 3 is -CH 2 -C(H)(OH)- or -CH2-CF2-CH2-. In certain embodiments, Y 3 is -(CH 2 )-, -(CH 2 ) 2 -, or - (CH2)3-. In certain embodiments, Y 3 is -(CH2)2- or -CH2-C(H)(OH)-. In certain embodiments, Y 3 is -(CH 2 ) 3 -, -CH2-O-CH2-, or -CH2-CF2-CH2-.
- Y 3 is -(CH2)-. In certain embodiments, Y 3 is -(CH2)2-. In certain embodiments, Y 3 is -CH2-C(H)(OH)-. In certain embodiments, Y 3 is -(CH2)3-. In certain embodiments, Y 3 is -CH2-O-CH2-. In certain embodiments, Y 3 is -CH2-CF2-CH2-. In certain embodiments, Y 3 is selected from the groups depicted in the compounds in Table 1, below.
- m is 0, 1, 2, or 3. In certain embodiments, m is 0. In certain embodiments, m is 1. In certain embodiments, m is 2. In certain embodiments, m is 3. In certain embodiments, m is 0 or 1. In certain embodiments, m is 1 or 2. In certain embodiments, m is 2 or 3. In certain embodiments, m is 0, 1, or 2. In certain embodiments, m is 1, 2, or 3. In certain embodiments, m is selected from the values represented in the compounds in Table 1, below.
- n is 0, 1, 2, or 3. In certain embodiments, n is 0. In certain embodiments, n is 1. In certain embodiments, n is 2. In certain embodiments, n is 3. In certain embodiments, n is 0 or 1. In certain embodiments, n is 1 or 2. In certain embodiments, n is 2 or 3. In certain embodiments, n is 0, 1, or 2. In certain embodiments, n is 1, 2, or 3. In certain embodiments, n is selected from the values represented in the compounds in Table 1, below. [0184] As defined generally above, p is 0, 1, 2, or 3. In certain embodiments, p is 0. In certain embodiments, p is 1. In certain embodiments, p is 2. In certain embodiments, p is 3.
- p is 0 or 1. In certain embodiments, p is 1 or 2. In certain embodiments, p is 2 or 3. In certain embodiments, p is 0, 1, or 2. In certain embodiments, p is 1, 2, or 3. In certain embodiments, p is selected from the values represented in the compounds in Table 1, below.
- Another aspect of the invention provides a compound represented by Formula II: or a pharmaceutically acceptable salt thereof; wherein:
- R 1 is naphthyl; an 8-10 membered saturated or partially unsaturated bicyclic heterocyclyl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; an 8-10 membered bicyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 5-6 membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or phenyl; each of which is substituted with m occurrences of R 5 ;
- R 2 is an 8-10 membered saturated or partially unsaturated bicyclic heterocyclyl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 3-7 membered saturated or partially unsaturated monocyclic heterocyclyl having 1 or 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 5-6 membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; phenyl; or Ci- 6 aliphatic; each of which is substituted with n occurrences of R 6 ;
- R 3 is C M alkyl
- R 4 is hydrogen, halo, or C1-4 alkyl
- R 5 represents independently for each occurrence C2-6 alkynyl, C2-6 alkenyl, Ci- 6 alkyl, hydroxyl, Ci- 6 alkoxyl, halo, or cyano;
- R 6 and R 7 each represent independently for each occurrence halo, hydroxyl, Ci- 6 alkoxyl, Ci- 6 haloalkoxyl, Ci- 6 alkyl, Ci- 6 haloalkyl, Ci- 6 hydroxyalkyl, or -N(R 9 )2;
- R 8 and R 9 each represent independently for each occurrence hydrogen, C 1-4 alkyl, or C3-5 cycloalkyl; or two occurrences of R 9 attached to the same nitrogen atom are taken together with the nitrogen atom to which they are attached to form a 4-7 membered saturated ring having one nitrogen atom;
- a 1 is a 4-7 membered saturated monocyclic heterocyclyl having 1 or 2 nitrogen atoms; a 6-11 membered saturated spirocyclic heterocyclyl having 1 or 2 nitrogen atoms; a 6-11 membered saturated ortho- fused heterocyclyl having 1 or 2 nitrogen atoms; or a 5-6 membered monocyclic heteroaryl having one nitrogen atom and 0, 1, or 2 additional heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted with p
- X 1 is C(H) or N
- X 2 is N, C(CN), or C(R 4 );
- L is a covalent bond or a C1-4 bivalent saturated or unsaturated, straight or branched hydrocarbon chain wherein one or two methylene units of the chain are optionally and independently replaced by -0-, -N(R 9 )-, or -C(O)-;
- Y 1 , Y 2 , and Y 3 represent independently a C1-3 bivalent saturated or unsaturated, straight hydrocarbon chain wherein one or two methylene units of the chain are optionally and independently replaced by -0-, -C(H)(R 7 )-, or -C(R 7 )2-; and m, n, and p are each independently 0, 1, 2, or 3.
- the definitions of variables in Formula II above encompass multiple chemical groups.
- the definition of a variable is a single chemical group selected from those chemical groups set forth above
- the definition of a variable is a collection of two or more of the chemical groups selected from those set forth above
- the compound is defined by a combination of variables in which the variables are defined by (i) or (ii).
- the compound is a compound of Formula II.
- R 1 is naphthyl; an 8-10 membered saturated or partially unsaturated bicyclic heterocyclyl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; an 8-10 membered bicyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 5-6 membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or phenyl; each of which is substituted with m occurrences of R 5 .
- R 1 is naphthyl, an 8-10 membered saturated or partially unsaturated bicyclic heterocyclyl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or an 8-10 membered bicyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted with m occurrences of R 5 .
- R 1 is phenyl or a 5-6 membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted with m occurrences of R 5 .
- R 1 is naphthyl or phenyl; each of which is substituted with m occurrences of R 5 .
- R 1 is an 8-10 membered saturated or partially unsaturated bicyclic heterocyclyl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; an 8-10 membered bicyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or a 5-6 membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted with m occurrences of R 5 .
- R 1 is naphthyl or an 8-10 membered bicyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted with m occurrences of R 5 .
- R 1 is an 8-10 membered saturated or partially unsaturated bicyclic heterocyclyl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or an 8-10 membered bicyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted with m occurrences of R 5 .
- R 1 is naphthyl substituted with m occurrences of R 5 . In certain embodiments, R 1 is 1-naphthyl substituted with m occurrences of R 5 . In certain embodiments,
- R 1 is In certain embodiments, R 1 is
- R 1 is an 8-10 membered saturated or partially unsaturated bicyclic heterocyclyl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said heterocyclyl is substituted with m occurrences of R 5 .
- R 1 is an 8-10 membered saturated or partially unsaturated bicyclic heterocyclyl having 1 or 2 heteroatoms independently selected from nitrogen and oxygen; wherein said heterocyclyl is substituted with m occurrences of R 5 .
- R 1 is certain embodiments, R 1 is In certain embodiments, R 1 is In certain embodiments, R 1 is In certain embodiments, R 1 is
- R 1 is an 8-10 membered bicyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said heteroaryl is substituted with m occurrences of R 5 .
- R 1 is an 8-10 membered bicyclic heteroaryl having 1 or 2 heteroatoms independently selected from nitrogen and oxygen, and sulfur; wherein said heteroaryl is substituted with m occurrences of R 5 .
- R 1 is quinolinyl, isoquinolinyl, or indazolyl; each of which is substituted with m occurrences of R 5 .
- R 1 is quinolinyl substituted with m occurrences of R 5 .
- R 1 is quinoline-4-yl substituted with m occurrences of R 5 .
- R 1 is isoquinolinyl substituted with m occurrences of R 5 .
- R 1 is isoquinolin-l-yl substituted with m occurrences of R 5 .
- R 1 is indazolyl substituted with m occurrences of R 5 .
- R 1 is phenyl substituted with m occurrences of R 5 . In certain embodiments, R 1 is In certain embodiments, R 1 is
- R 1 is a 5-6 membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said heteroaryl is substituted with m occurrences of R 5 .
- R 1 is a 6-membered monocyclic heteroaryl having 1, 2, or 3 nitrogen atoms; wherein said heteroaryl is substituted with m occurrences of R 5 .
- R 1 is a 5-membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said heteroaryl is substituted with m occurrences of R 5 .
- R 1 is selected from the groups depicted in the compounds in Table 2, below.
- R 2 is an 8-10 membered saturated or partially unsaturated bicyclic heterocyclyl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 3-7 membered saturated or partially unsaturated monocyclic heterocyclyl having 1 or 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 5-6 membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; phenyl; or Ci- 6 aliphatic; each of which is substituted with n occurrences of R 6 .
- R 2 is an 8-10 membered saturated or partially unsaturated bicyclic heterocyclyl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 3-7 membered saturated or partially unsaturated monocyclic heterocyclyl having 1 or 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or a 5-6 membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted with n occurrences of R 6 .
- R 2 is phenyl or Ci- 6 aliphatic; each of which is substituted with n occurrences of R 6 .
- R 2 is an 8-10 membered saturated or partially unsaturated bicyclic heterocyclyl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or a 3-7 membered saturated or partially unsaturated monocyclic heterocyclyl having 1 or 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted with n occurrences of R 6 .
- R 2 is a 3-7 membered saturated or partially unsaturated monocyclic heterocyclyl having 1 or 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or a 5-6 membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted with n occurrences of R 6 .
- R 2 is a 3-7 membered saturated or partially unsaturated monocyclic heterocyclyl having 1 or 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 5-6 membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; phenyl; or Ci- 6 aliphatic; each of which is substituted with n occurrences of R 6 .
- R 2 is a 3-7 membered saturated or partially unsaturated monocyclic heterocyclyl having 1 or 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or Ci- 6 aliphatic; each of which is substituted with n occurrences of R 6 .
- R 2 is a 5-6 membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or phenyl; each of which is substituted with n occurrences of R 6 .
- R 2 is an 8-10 membered saturated or partially unsaturated bicyclic heterocyclyl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said heterocyclyl is substituted with n occurrences of R 6 .
- R 2 is an 8-10 membered saturated bicyclic heterocyclyl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said heterocyclyl is substituted with n occurrences of R 6 .
- R 2 is an 8-10 membered partially unsaturated bicyclic heterocyclyl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said heterocyclyl is substituted with n occurrences of R 6 .
- R 2 is an 8-10 membered saturated or partially unsaturated bicyclic heterocyclyl having 1 or 2 heteroatoms independently selected from nitrogen and oxygen; wherein said heterocyclyl is substituted with n occurrences of R 6 .
- R 2 is an 8-10 membered saturated or partially unsaturated bicyclic heterocyclyl having 1 nitrogen atom; wherein said heterocyclyl is substituted with n occurrences of R 6 .
- R 2 is an 8-10 membered saturated bicyclic heterocyclyl having 1 nitrogen atom; wherein said heterocyclyl is substituted with n occurrences of R 6 .
- R 2 is an 8-10 membered saturated bicyclic heterocyclyl having 1 nitrogen atom; wherein said heterocyclyl is substituted with n occurrences of R 6 .
- R 2 is substituted with n occurrences of R 6 .
- R 2 is an 8-10 membered saturated or partially unsaturated bicyclic heterocyclyl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In certain embodiments, R 2 is an 8-10 membered saturated bicyclic heterocyclyl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In certain embodiments, R 2 is an 8-10 membered partially unsaturated bicyclic heterocyclyl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur.
- R 2 is an 8-10 membered saturated or partially unsaturated bicyclic heterocyclyl having 1 or 2 heteroatoms independently selected from nitrogen and oxygen. In certain embodiments, R 2 is an 8-10 membered saturated or partially unsaturated bicyclic heterocyclyl having 1 nitrogen atom. In certain embodiments, R 2 is an 8-10 membered saturated bicyclic heterocyclyl having 1 nitrogen atom. In certain embodiments, R 2 is [0209] In certain embodiments, R 2 is a 3-7 membered saturated or partially unsaturated monocyclic heterocyclyl having 1 or 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said heterocyclyl is substituted with n occurrences of R 6 .
- R 2 is a 4-6 membered saturated or partially unsaturated monocyclic heterocyclyl having 1 or 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said heterocyclyl is substituted with n occurrences of R 6 .
- R 2 is a 5-6 membered saturated or partially unsaturated monocyclic heterocyclyl having 1 or 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said heterocyclyl is substituted with n occurrences of R 6 .
- R 2 is a 5-membered saturated or partially unsaturated monocyclic heterocyclyl having 1 or 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said heterocyclyl is substituted with n occurrences of R 6 .
- R 2 is a 6-membered saturated or partially unsaturated monocyclic heterocyclyl having 1 or 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said heterocyclyl is substituted with n occurrences of R 6 .
- R 2 is a 3-7 membered saturated monocyclic heterocyclyl having 1 or 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said heterocyclyl is substituted with n occurrences of R 6 .
- R 2 is a 5-6 membered saturated monocyclic heterocyclyl having 1 or 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said heterocyclyl is substituted with n occurrences of R 6 .
- R 2 is a 3-7 membered partially unsaturated monocyclic heterocyclyl having 1 or 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said heterocyclyl is substituted with n occurrences of R 6 .
- R 2 is a 5-6 membered partially unsaturated monocyclic heterocyclyl having 1 or 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said heterocyclyl is substituted with n occurrences of R 6 .
- R 2 is a 3-7 membered saturated or partially unsaturated monocyclic heterocyclyl having 1 or 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said heterocyclyl is substituted with n occurrences of R 6 .
- R 2 is a 5-6 membered saturated or partially unsaturated monocyclic heterocyclyl having 1 or 2 heteroatoms independently selected from nitrogen and oxygen; wherein said heterocyclyl is substituted with n occurrences of R 6 .
- R 2 is a 5-6 membered saturated monocyclic heterocyclyl having 1 or 2 heteroatoms independently selected from nitrogen and oxygen; wherein said heterocyclyl is substituted with n occurrences of R 6 .
- R 2 is azetidinyl, pyrrolidinyl, piperidinyl, or morpholinyl; each of which is substituted with n occurrences of R 6 .
- R 2 is azetidinyl substituted with n occurrences of R 6 .
- R 2 is pyrrolidinyl substituted with n occurrences of R 6 .
- R 2 is pyrrolidin-2-yl substituted with n occurrences of R 6 .
- R 2 is pyrrolidin-2-yl substituted with a single occurrence of R 6 at the 1-position.
- R 2 is piperidinyl substituted with n occurrences of R 6 .
- R 2 is morpholinyl substituted with n occurrences of R 6 .
- R 2 is azetidinyl, pyrrolidinyl, piperidinyl, or morpholinyl. In certain embodiments, R 2 is azetidinyl. In certain embodiments, R 2 is pyrrolidinyl. In certain embodiments, R 2 is pyrrolidin-2-yl. In certain embodiments, R 2 is l-methyl-pyrrolidin-2-yl. In certain embodiments, R 2 is piperidinyl. In certain embodiments, R 2 is morpholinyl.
- R 2 is a 5-6 membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said heteroaryl is substituted with n occurrences of R 6 .
- R 2 is phenyl substituted with n occurrences of R 6 . In certain embodiments, R 2 is phenyl.
- R 2 is Ci- 6 aliphatic substituted with n occurrences of R 6 . In certain embodiments, R 2 is C3-6 cycloaliphatic substituted with n occurrences of R 6 . In certain embodiments, R 2 is a Ci- 6 aliphatic chain substituted with n occurrences of R 6 . In certain embodiments, R 2 is C3-6 cycloalkyl substituted with n occurrences of R 6 . In certain embodiments, R 2 is Ci- 6 alkyl substituted with n occurrences of R 6 .
- R 2 is Ci- 6 aliphatic. In certain embodiments, R 2 is C3-6 cycloaliphatic. In certain embodiments, R 2 is a Ci- 6 aliphatic chain. In certain embodiments, R 2 is C3-6 cycloalkyl. In certain embodiments, R 2 is Ci- 6 alkyl.
- R 2 is selected from the groups depicted in the compounds in Table 2, below.
- R 3 is Ci-4 alkyl. In certain embodiments, R 3 is methyl. In certain embodiments, R 3 is selected from the groups depicted in the compounds in Table 2, below.
- R 4 is hydrogen, halo, or Ci-4 alkyl. In certain embodiments, R 4 is hydrogen. In certain embodiments, R 4 is halo. In certain embodiments, R 4 is fluoro or chloro. In certain embodiments, R 4 is fluoro. In certain embodiments, R 4 is chloro. In certain embodiments, R 4 is C M alkyl. In certain embodiments, R 4 is methyl. In certain embodiments,
- R 4 is selected from the groups depicted in the compounds in Table 2, below.
- R 5 represents independently for each occurrence C2-6 alkynyl, C2-6 alkenyl, Ci- 6 alkyl, hydroxyl, Ci- 6 alkoxyl, halo, or cyano.
- R 5 represents independently for each occurrence C2-6 alkynyl, C2-6 alkenyl, Ci- 6 alkyl, or hydroxyl. In certain embodiments, R 5 represents independently for each occurrence ethynyl, ethenyl, C1-3 alkyl, or hydroxyl. In certain embodiments, R 5 represents independently for each occurrence C2-6 alkynyl or hydroxyl. In certain embodiments, R 5 represents independently for each occurrence ethynyl or hydroxyl. In certain embodiments, one occurrence of R 5 is ethynyl. In certain embodiments, one occurrence of R 5 is hydroxyl.
- R 5 represents independently for each occurrence C 2-6 alkynyl, C 2-6 alkenyl, or Ci- 6 alkyl. In certain embodiments, R 5 represents independently for each occurrence ethynyl, ethenyl, or C 1-3 alkyl. In certain embodiments, R 5 represents independently for each occurrence hydroxyl or Ci- 6 alkoxyl. In certain embodiments, R 5 represents independently for each occurrence halo or cyano.
- R 5 represents independently for each occurrence C 2-6 alkynyl. In certain embodiments, R 5 is ethynyl. In certain embodiments, R 5 represents independently for each occurrence C 2-6 alkenyl. In certain embodiments, R 5 is ethenyl. In certain embodiments, R 5 represents independently for each occurrence Ci- 6 alkyl. In certain embodiments, R 5 represents independently for each occurrence C 1-3 alkyl. In certain embodiments, R 5 is methyl. In certain embodiments, R 5 is hydroxyl. In certain embodiments, R 5 represents independently for each occurrence Ci- 6 alkoxyl. In certain embodiments, R 5 represents independently for each occurrence halo.
- R 5 represents independently for each occurrence fluoro or chloro. In certain embodiments, R 5 is fluoro. In certain embodiments, R 5 is chloro. In certain embodiments, R 5 is cyano. In certain embodiments, R 5 is selected from the groups depicted in the compounds in Table 2, below.
- R 6 represents independently for each occurrence halo, hydroxyl, Ci- 6 alkoxyl, Ci- 6 haloalkoxyl, Ci- 6 alkyl, Ci- 6 haloalkyl, Ci- 6 hydroxyalkyl, or -N(R 9 )2.
- R 6 represents independently for each occurrence halo, hydroxyl, Ci- 6 alkoxyl, Ci- 6 alkyl, or Ci- 6 haloalkyl. In certain embodiments, R 6 represents independently for each occurrence halo, Ci- 6 alkyl, or Ci- 6 haloalkyl. In certain embodiments, R 6 represents independently for each occurrence halo or Ci- 6 alkyl. In certain embodiments, R 6 represents independently for each occurrence halo, hydroxyl, or Ci- 6 alkyl.
- R 6 represents independently for each occurrence halo, hydroxyl, Ci- 6 alkoxyl, Ci- 6 haloalkoxyl, or -N(R 9 )2. In certain embodiments, R 6 represents independently for each occurrence halo, hydroxyl, or -N(R 9 )2. In certain embodiments, R 6 represents independently for each occurrence halo, Ci- 6 alkoxyl, or Ci- 6 haloalkoxyl. In certain embodiments, R 6 represents independently for each occurrence halo, Ci- 6 alkyl, Ci- 6 haloalkyl, or Ci- 6 hydroxyalkyl.
- R 6 represents independently for each occurrence Ci- 6 alkyl, Ci- 6 haloalkyl, or Ci- 6 hydroxyalkyl. In certain embodiments, R 6 represents independently for each occurrence Ci- 6 alkyl or Ci- 6 haloalkyl.
- R 6 represents independently for each occurrence halo. In certain embodiments, R 6 represents independently for each occurrence fluoro or chloro. In certain embodiments, R 6 is fluoro. In certain embodiments, R 6 is chloro. In certain embodiments, R 6 is hydroxyl. In certain embodiments, R 6 represents independently for each occurrence Ci- 6 alkoxyl. In certain embodiments, R 6 is methoxy. In certain embodiments, R 6 represents independently for each occurrence Ci- 6 haloalkoxyl. In certain embodiments, R 6 is trifluoromethoxy. In certain embodiments, R 6 represents independently for each occurrence Ci- 6 alkyl. In certain embodiments, R 6 represents independently for each occurrence C1-3 alkyl.
- R 6 is methyl. In certain embodiments, R 6 represents independently for each occurrence Ci- 6 haloalkyl. In certain embodiments, R 6 is trifluoromethyl. In certain embodiments, R 6 represents independently for each occurrence Ci- 6 hydroxyalkyl. In certain embodiments, R 6 represents independently for each occurrence -N(R 9 )2. In certain embodiments, R 6 is -NH2. In certain embodiments, R 6 is selected from the groups depicted in the compounds in Table 2, below.
- R 7 represents independently for each occurrence halo, hydroxyl, Ci- 6 alkoxyl, Ci- 6 haloalkoxyl, Ci- 6 alkyl, Ci- 6 haloalkyl, Ci- 6 hydroxyalkyl, or -N(R 9 )2.
- R 7 represents independently for each occurrence halo, hydroxyl, Ci- 6 alkoxyl, Ci- 6 alkyl, or Ci- 6 haloalkyl. In certain embodiments, R 7 represents independently for each occurrence halo, Ci- 6 alkyl, or Ci- 6 haloalkyl. In certain embodiments, R 7 represents independently for each occurrence halo or Ci- 6 alkyl. In certain embodiments, R 7 represents independently for each occurrence halo, hydroxyl, or Ci- 6 alkyl.
- R 7 represents independently for each occurrence halo, hydroxyl, Ci- 6 alkoxyl, Ci- 6 haloalkoxyl, or -N(R 9 )2. In certain embodiments, R 7 represents independently for each occurrence halo, hydroxyl, or -N(R 9 )2. In certain embodiments, R 7 represents independently for each occurrence halo, Ci- 6 alkoxyl, or Ci- 6 haloalkoxyl. In certain embodiments, R 7 represents independently for each occurrence halo, Ci- 6 alkyl, Ci- 6 haloalkyl, or Ci- 6 hydroxyalkyl.
- R 7 represents independently for each occurrence Ci- 6 alkyl, Ci- 6 haloalkyl, or Ci- 6 hydroxyalkyl. In certain embodiments, R 7 represents independently for each occurrence Ci- 6 alkyl or Ci- 6 haloalkyl.
- R 7 represents independently for each occurrence halo. In certain embodiments, R 7 represents independently for each occurrence fluoro or chloro. In certain embodiments, R 7 is fluoro. In certain embodiments, R 7 is chloro. In certain embodiments, R 7 is hydroxyl. In certain embodiments, R 7 represents independently for each occurrence Ci- 6 alkoxyl. In certain embodiments, R 7 is methoxy. In certain embodiments, R 7 represents independently for each occurrence Ci- 6 haloalkoxyl. In certain embodiments, R 7 is trifluoromethoxy. In certain embodiments, R 7 represents independently for each occurrence Ci- 6 alkyl. In certain embodiments, R 7 represents independently for each occurrence C1-3 alkyl.
- R 7 is methyl. In certain embodiments, R 7 represents independently for each occurrence Ci- 6 haloalkyl. In certain embodiments, R 7 is trifluoromethyl. In certain embodiments, R 7 represents independently for each occurrence Ci- 6 hydroxyalkyl. In certain embodiments, R 7 represents independently for each occurrence -N(R 9 )2. In certain embodiments, R 7 is -NH2. In certain embodiments, R 7 is selected from the groups depicted in the compounds in Table 2, below.
- R 8 is hydrogen, C1-4 alkyl, or C3-5 cycloalkyl. In certain embodiments, R 8 is hydrogen or C 1-4 alkyl. In certain embodiments, R 8 is hydrogen or methyl.
- R 8 is C IM alkyl or C3-5 cycloalkyl.
- R 8 is hydrogen. In certain embodiments, R 8 is C IM alkyl. In certain embodiments, R 8 is methyl. In certain embodiments, R 8 is C3-5 cycloalkyl. In certain embodiments, R 8 is cyclopropyl. In certain embodiments, R 8 is selected from the groups depicted in the compounds in Table 2, below.
- R 9 represents independently for each occurrence hydrogen, Ci-4 alkyl, or C3-5 cycloalkyl; or two occurrences of R 9 attached to the same nitrogen atom are taken together with the nitrogen atom to which they are attached to form a 4-7 membered saturated ring having one nitrogen atom.
- R 9 represents independently for each occurrence hydrogen, C1-4 alkyl, or C3-5 cycloalkyl. In certain embodiments, R 9 represents independently for each occurrence hydrogen or C1-4 alkyl. In certain embodiments, R 9 represents independently for each occurrence hydrogen or methyl. In certain embodiments, R 9 represents independently for each occurrence C1-4 alkyl or C3-5 cycloalkyl.
- two occurrences of R 9 attached to the same nitrogen atom are taken together with the nitrogen atom to which they are attached to form a 4-7 membered saturated ring having one nitrogen atom.
- R 9 is hydrogen. In certain embodiments, R 9 represents independently for each occurrence C1-4 alkyl. In certain embodiments, R 9 is methyl. In certain embodiments, R 9 represents independently for each occurrence C3-5 cycloalkyl. In certain embodiments, R 9 is cyclopropyl. In certain embodiments, R 9 is selected from the groups depicted in the compounds in Table 2, below.
- a 1 is a 4-7 membered saturated monocyclic heterocyclyl having 1 or 2 nitrogen atoms; a 6-11 membered saturated spirocyclic heterocyclyl having 1 or 2 nitrogen atoms; a 6-11 membered saturated ortho- fused heterocyclyl having 1 or 2 nitrogen atoms; or a 5-6 membered monocyclic heteroaryl having one nitrogen atom and 0, 1, or 2 additional heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted with p occurrences of R 7 ; or A 1 is , ,
- a 1 is In certain embodiments, A 1 is i n certain embodiments, A 1 is In certain embodiments, A 1 is
- a 1 is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
- a 1 is a 4-7 membered saturated monocyclic heterocyclyl having 1 or 2 nitrogen atoms; a 6-11 membered saturated spirocyclic heterocyclyl having 1 or 2 nitrogen atoms; a 6-11 membered saturated ortho- fused heterocyclyl having 1 or 2 nitrogen atoms; or a 5- 6 membered monocyclic heteroaryl having one nitrogen atom and 0, 1, or 2 additional heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted with p occurrences of R 7 .
- a 1 is a 4-7 membered saturated monocyclic heterocyclyl having 1 or 2 nitrogen atoms; a 6-11 membered saturated spirocyclic heterocyclyl having 1 or 2 nitrogen atoms; or a 6-11 membered saturated ortho- fused heterocyclyl having 1 or 2 nitrogen atoms; each of which is substituted with p occurrences of R 7 ; or A 1 is [0243] In certain embodiments, A 1 is a 4-7 membered saturated monocyclic heterocyclyl having 1 or 2 nitrogen atoms; a 6-11 membered saturated spirocyclic heterocyclyl having 1 or 2 nitrogen atoms; or a 6-11 membered saturated ortho- fused heterocyclyl having 1 or 2 nitrogen atoms; each of which is substituted with p occurrences of R 7 .
- a 1 is a 6-11 membered saturated spirocyclic heterocyclyl having 1 or 2 nitrogen atoms; or a 6-11 membered saturated ortho- fused heterocyclyl having 1 or 2 nitrogen atoms; each of which is substituted with p occurrences of R 7 ; or A 1 is or
- a 1 is a 6-11 membered saturated spirocyclic heterocyclyl having 1 or 2 nitrogen atoms; or a 6-11 membered saturated ortho- fused heterocyclyl having 1 or 2 nitrogen atoms; each of which is substituted with p occurrences of R 7 .
- a 1 is a 4-7 membered saturated monocyclic heterocyclyl having 1 or 2 nitrogen atoms; or a 5-6 membered monocyclic heteroaryl having one nitrogen atom and 0, 1, or 2 additional heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted with p occurrences of R 7 .
- a 1 is a 4-7 membered saturated monocyclic heterocyclyl having 1 or 2 nitrogen atoms; a 6-11 membered saturated spirocyclic heterocyclyl having 1 or 2 nitrogen atoms; a 6-11 membered saturated ortho- fused heterocyclyl having 1 or 2 nitrogen atoms; or a 5- 6 membered monocyclic heteroaryl having one nitrogen atom and 0, 1, or 2 additional heteroatoms independently selected from nitrogen, oxygen, and sulfur.
- a 1 is a 4-7 membered saturated monocyclic heterocyclyl having 1 or 2 nitrogen atoms; a 6-11 membered saturated spirocyclic heterocyclyl having 1 or 2 nitrogen atoms; or a 6-11 membered saturated ortho- fused heterocyclyl having 1 or 2 nitrogen atoms; or
- a 1 is a 4-7 membered saturated monocyclic heterocyclyl having 1 or 2 nitrogen atoms; a 6-11 membered saturated spirocyclic heterocyclyl having 1 or 2 nitrogen atoms; or a 6-11 membered saturated ortho- fused heterocyclyl having 1 or 2 nitrogen atoms.
- a 1 is a 6-11 membered saturated spirocyclic heterocyclyl having 1 or 2 nitrogen atoms; or a 6-11 membered saturated ortho- fused heterocyclyl having 1 or 2
- a 1 is a 6-11 membered saturated spirocyclic heterocyclyl having 1 or 2 nitrogen atoms; or a 6-11 membered saturated ortho- fused heterocyclyl having 1 or 2 nitrogen atoms.
- a 1 is a 4-7 membered saturated monocyclic heterocyclyl having 1 or 2 nitrogen atoms; or a 5-6 membered monocyclic heteroaryl having one nitrogen atom and 0, 1, or 2 additional heteroatoms independently selected from nitrogen, oxygen, and sulfur.
- a 1 is a 4-7 membered saturated monocyclic heterocyclyl having 1 or 2 nitrogen atoms; wherein said heterocyclyl is substituted with p occurrences of R 7 .
- a 1 is a 5-6 membered saturated monocyclic heterocyclyl having 1 or 2 nitrogen atoms; wherein said heterocyclyl is substituted with p occurrences of R 7 .
- a 1 is a 4-7 membered saturated monocyclic heterocyclyl having 1 or 2 nitrogen atoms.
- a 1 is a 5-6 membered saturated monocyclic heterocyclyl having 1 or 2 nitrogen atoms.
- a 1 is 1,4-diazepanyl, piperidinyl, piperazinyl, pyrrolidinyl, or azetidinyl; each of which is substituted with p occurrences of R 7 .
- a 1 is 1,4-diazepanyl substituted with p occurrences of R 7 .
- a 1 is piperidinyl substituted with p occurrences of R 7 .
- a 1 is piperazinyl substituted with p occurrences of R 7 .
- a 1 is pyrrolidinyl substituted with p occurrences of R 7 .
- a 1 is azetidinyl substituted with p occurrences of R 7 .
- a 1 is 1,4-diazepanyl, piperidinyl, piperazinyl, pyrrolidinyl, or azetidinyl. In certain embodiments, A 1 is 1,4-diazepanyl. In certain embodiments, A 1 is piperidinyl. In certain embodiments, A 1 is piperazinyl. In certain embodiments, A 1 is pyrrolidinyl. In certain embodiments, A 1 is azetidinyl.
- a 1 is 1,4-diazepan-l-yl, piperidin-4-yl, piperazin-l-yl, pyrrolidin-3-yl, or azetidin-3-yl; each of which is substituted with p occurrences of R 7 .
- a 1 is 1,4-diazepan-l-yl substituted with p occurrences of R 7 .
- a 1 is piperidin-4-yl substituted with p occurrences of R 7 .
- a 1 is piperazin-l-yl substituted with p occurrences of R 7 .
- a 1 is pyrrolidin-3-yl substituted with p occurrences of R 7 .
- a 1 is azetidin-3-yl substituted with p occurrences of R 7 .
- a 1 is 1,4-diazepan-l-yl, piperidin-4-yl, piperazin-l-yl, pyrrolidin-3-yl, or azetidin-3-yl. In certain embodiments, A 1 is 1,4-diazepan-l-yl. In certain embodiments, A 1 is piperidin-4-yl. In certain embodiments, A 1 is piperazin-l-yl. In certain embodiments, A 1 is pyrrolidin-3-yl. In certain embodiments, A 1 is azetidin-3-yl.
- a 1 is a 6-11 membered saturated spirocyclic heterocyclyl having 1 or 2 nitrogen atoms; wherein said heterocyclyl is substituted with p occurrences of R 7 .
- a 1 is a 7-10 membered saturated spirocyclic heterocyclyl having 1 or 2 nitrogen atoms; wherein said heterocyclyl is substituted with p occurrences of R 7 .
- a 1 is a 6-11 membered saturated spirocyclic heterocyclyl having 2 nitrogen atoms; wherein said heterocyclyl is substituted with p occurrences of R 7 .
- a 1 is a 6-11 membered saturated spirocyclic heterocyclyl having 1 or 2 nitrogen atoms. In certain embodiments, A 1 is a 7-10 membered saturated spirocyclic heterocyclyl having 1 or 2 nitrogen atoms. In certain embodiments, A 1 is a 6-11 membered saturated spirocyclic heterocyclyl having 2 nitrogen atoms. In certain embodiments, A 1 is or In certain embodiments, A 1 is In certain embodiments, A 1 is
- a 1 is a 6-11 membered saturated ortho- fused heterocyclyl having 1 or 2 nitrogen atoms; wherein said heterocyclyl is substituted with p occurrences of R 7 .
- a 1 is a 7-10 membered saturated ortho- fused heterocyclyl having 1 or 2 nitrogen atoms; wherein said heterocyclyl is substituted with p occurrences of R 7 .
- a 1 is a 6-11 membered saturated ortho- fused heterocyclyl having 1 or 2 nitrogen atoms.
- a 1 is a 7-10 membered saturated ortho- fused heterocyclyl having 1 or 2 nitrogen atoms.
- a 1 is a 5-6 membered monocyclic heteroaryl having one nitrogen atom and 0, 1, or 2 additional heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said heteroaryl is substituted with p occurrences of R 7 .
- a 1 is a 6-membered monocyclic heteroaryl having 1, 2, or 3 nitrogen atoms; wherein said heteroaryl is substituted with p occurrences of R 7 .
- a 1 is pyridinyl or pyrimidinyl; each of which is substituted with p occurrences of R 7 .
- a 1 is pyridinyl substituted with p occurrences of R 7 .
- a 1 is pyridin-4-yl substituted with p occurrences of R 7 .
- a 1 is pyrimidinyl substituted with p occurrences of R 7 .
- a 1 is a 5-membered monocyclic heteroaryl having one nitrogen atom and 0, 1, or 2 additional heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said heteroaryl is substituted with p occurrences of R 7 .
- a 1 is a 5-membered monocyclic heteroaryl having 1, 2, or 3 nitrogen atoms; wherein said heteroaryl is substituted with p occurrences of R 7 .
- a 1 is imidazolyl or pyrazolyl; each of which is substituted with p occurrences of R 7 .
- a 1 is imidazolyl substituted with p occurrences of R 7 .
- a 1 is pyrazolyl substituted with p occurrences of R 7 .
- a 1 is selected from the groups depicted in the compounds in Table 2, below.
- X 1 is C(H) or N. In certain embodiments, X 1 is C(H). In certain embodiments, X 1 is N. In certain embodiments, X 1 is selected from the groups depicted in the compounds in Table 2, below.
- X 2 is N, C(CN), or C(R 4 ). In certain embodiments, X 2 is N. In certain embodiments, X 2 is C(CN) or C(R 4 ). In certain embodiments, X 2 is C(CN) or C(H).
- X 2 is C(CN). In certain embodiments, X 2 is C(R 4 ). In certain embodiments, X 2 is C(H). In certain embodiments, X 2 is selected from the groups depicted in the compounds in Table 2, below.
- L is a covalent bond or a Ci-4 bivalent saturated or unsaturated, straight or branched hydrocarbon chain wherein one or two methylene units of the chain are optionally and independently replaced by -0-, -N(R 9 )-, or -C(O)-. In certain embodiments, L is a covalent bond.
- L is a Ci-4 bivalent saturated or unsaturated, straight or branched hydrocarbon chain wherein one or two methylene units of the chain are optionally and independently replaced by -0-, -N(R 9 )-, or -C(O)-.
- L is a Ci-4 bivalent saturated, straight or branched hydrocarbon chain wherein one or two methylene units of the chain are optionally and independently replaced by -0-, -N(R 9 )-, or -C(O)-.
- L is a CM bivalent saturated, straight hydrocarbon chain wherein one or two methylene units of the chain are optionally and independently replaced by -0-, -N(R 9 )-, or - C(O)-.
- L is a C2-3 bivalent saturated, straight hydrocarbon chain wherein one or two methylene units of the chain are optionally and independently replaced by - 0-, -N(R 9 )-, or -C(O)-.
- L is a C1-4 bivalent saturated, straight hydrocarbon chain wherein one methylene unit of the chain is optionally replaced by -0-, -N(R 9 )-, or -C(O)-.
- L is a C2-3 bivalent saturated, straight hydrocarbon chain wherein one methylene unit of the chain is optionally replaced by -0-, -N(R 9 )-, or -C(O)-.
- L is a Ci- 4 bivalent saturated, straight hydrocarbon chain wherein one methylene unit of the chain is replaced by -O- or -N(R 9 )-.
- L is a C 2-3 bivalent saturated, straight hydrocarbon chain wherein one methylene unit of the chain is replaced by -O- or -N(R 9 )-.
- L is -O-CH2-, -0-(CH 2 ) 2 -, -N(R 9 )-CH 2 -, or -N(R 9 )-(CH 2 ) 2 -, wherein the terminal carbon atom of L is attached to R 2 .
- L is -O-CH2- or -0-(CH 2 ) 2 -, wherein the terminal carbon atom of L is attached to R 2 .
- L is -N(R 9 )-CH2- or -N(R 9 )-(CH2)2-, wherein the terminal carbon atom of L is attached to R 2 .
- L is -O-CH2-, wherein the carbon atom of L is attached to R 2 .
- L is -0-(CH 2 ) 2 -, wherein the terminal carbon atom of L is attached to R 2 .
- L is -N(R 9 )-CH2-, wherein the carbon atom of L is attached to R 2 .
- L is -N(R 9 )-(CH2)2-, wherein the terminal carbon atom of L is attached to R 2 .
- L is selected from the groups depicted in the compounds in Table 2, below.
- Y 1 is a C1-3 bivalent saturated or unsaturated, straight hydrocarbon chain wherein one or two methylene units of the chain are optionally and independently replaced by -O-, -C(H)(R 7 )-, or -C(R 7 )2-.
- Y 1 is a C 2-3 bivalent unsaturated, straight hydrocarbon chain wherein one methylene unit of the chain is optionally replaced by -O-, -C(H)(R 7 )-, or -C(R 7 ) 2 -. In certain embodiments, Y 1 is a C 2-3 bivalent unsaturated, straight hydrocarbon chain.
- Y 1 is a C 1-3 bivalent saturated, straight hydrocarbon chain wherein one or two methylene units of the chain are optionally and independently replaced by - O-, -C(H)(R 7 )-, or -C(R 7 ) 2 -.
- Y 1 is a C 1-3 bivalent saturated, straight hydrocarbon chain wherein one methylene unit of the chain is optionally replaced by -O-, - C(H)(R 7 )-, or -C(R 7 ) 2 -.
- Y 1 is a C 1-3 bivalent saturated, straight hydrocarbon chain wherein one methylene unit of the chain is replaced by -0-, -C(H)(R 7 )-, or - C(R 7 ) 2 -. In certain embodiments, Y 1 is a C 1-3 bivalent saturated, straight hydrocarbon chain. [0275] In certain embodiments, Y 1 is a C 2-3 bivalent saturated, straight hydrocarbon chain wherein one or two methylene units of the chain are optionally and independently replaced by - 0-, -C(H)(R 7 )-, or -C(R 7 ) 2 -.
- Y 1 is a C 2-3 bivalent saturated, straight hydrocarbon chain wherein one methylene unit of the chain is optionally replaced by -0-, - C(H)(R 7 )-, or -C(R 7 ) 2 -. In certain embodiments, Y 1 is a C 2-3 bivalent saturated, straight hydrocarbon chain wherein one methylene unit of the chain is replaced by -0-, -C(H)(R 7 )-, or - C(R 7 ) 2 -. In certain embodiments, Y 1 is a C 2-3 bivalent saturated, straight hydrocarbon chain.
- Y 1 is -(CH 2 )-, -(CH 2 ) 2 -, -CH 2 -C(H)(OH)-, -(CH 2 ) 3 -, -CH 2 -O- CH 2 -, or -CH 2 -CF 2 -CH 2 -.
- Y 1 is -(CH 2 )-, -(CH 2 ) 2 -, -CH 2 -C(H)(OH)-, - (CH 2 ) 3 -, or -CH2-CF2-CH2-.
- Y 1 is -(CH 2 ) 2 -, -CH 2 -C(H)(OH)-, -(CH 2 ) 3 -, or -CH 2 -CF 2 -CH 2 -. In certain embodiments, Y 1 is -(CH2) 2 - or -(CH2) 3 -. In certain embodiments, Y 1 is -CH 2 -C(H)(OH)- or -CH 2 -CF 2 -CH 2 -. In certain embodiments, Y 1 is -(CH 2 )-, -(CH 2 ) 2 -, or - (CH2) 3 -.
- Y 1 is -(CH 2 ) 2 - or -CH 2 -C(H)(OH)-. In certain embodiments, Y 1 is -(CH 2 ) 3 -, -CH2-O-CH2-, or -CH2-CF2-CH2-.
- Y 1 is -(CH2)-. In certain embodiments, Y 1 is -(CH2) 2 -. In certain embodiments, Y 1 is -CH 2 -C(H)(OH)-. In certain embodiments, Y 1 is -(CH2) 3 -. In certain embodiments, Y 1 is -CH 2 -O-CH 2 -. In certain embodiments, Y 1 is -CH 2 -CF 2 -CH 2 -. In certain embodiments, Y 1 is selected from the groups depicted in the compounds in Table 2, below.
- Y 2 is a C 1-3 bivalent saturated or unsaturated, straight hydrocarbon chain wherein one or two methylene units of the chain are optionally and independently replaced by -0-, -C(H)(R 7 )-, or -C(R 7 ) 2 -.
- Y 2 is a C 2-3 bivalent unsaturated, straight hydrocarbon chain wherein one methylene unit of the chain is optionally replaced by -0-, -C(H)(R 7 )-, or -C(R 7 ) 2 -.
- Y 2 is a C 2-3 bivalent unsaturated, straight hydrocarbon chain.
- Y 2 is a C 1-3 bivalent saturated, straight hydrocarbon chain wherein one or two methylene units of the chain are optionally and independently replaced by - 0-, -C(H)(R 7 )-, or -C(R 7 ) 2 -.
- Y 2 is a C 1-3 bivalent saturated, straight hydrocarbon chain wherein one methylene unit of the chain is optionally replaced by -0-, - C(H)(R 7 )-, or -C(R 7 ) 2 -.
- Y 2 is a C 1-3 bivalent saturated, straight hydrocarbon chain wherein one methylene unit of the chain is replaced by -0-, -C(H)(R 7 )-, or - C(R 7 ) 2 -. In certain embodiments, Y 2 is a C1-3 bivalent saturated, straight hydrocarbon chain.
- Y 2 is a C2-3 bivalent saturated, straight hydrocarbon chain wherein one or two methylene units of the chain are optionally and independently replaced by - 0-, -C(H)(R 7 )-, or -C(R 7 ) 2 -.
- Y 2 is a C 2 -3 bivalent saturated, straight hydrocarbon chain wherein one methylene unit of the chain is optionally replaced by -0-, - C(H)(R 7 )-, or -C(R 7 ) 2 -.
- Y 2 is a C 2 -3 bivalent saturated, straight hydrocarbon chain wherein one methylene unit of the chain is replaced by -0-, -C(H)(R 7 )-, or - C(R 7 ) 2 -. In certain embodiments, Y 2 is a C 2 -3 bivalent saturated, straight hydrocarbon chain.
- Y 2 is -(CH 2 )-, -(CH 2 ) 2 -, -CH 2 -C(H)(OH)-, -(CH 2 ) -, -CH 2 -0- CH 2 -, or -CH 2 -CF 2 -CH 2 -.
- Y 2 is -(CH 2 )-, -(CH 2 ) 2 -, -CH 2 -C(H)(OH)-, - (CH 2 ) -, or -CH 2 -CF 2 -CH 2 -.
- Y 2 is -(CH 2 ) 2 -, -CH 2 -C(H)(OH)-, -(CH 2 ) -, or -CH 2 -CF 2 -CH 2 -. In certain embodiments, Y 2 is -(CH 2 ) 2 - or -(CH 2 )3-. In certain embodiments, Y 2 is -CH 2 -C(H)(OH)- or -CH 2 -CF 2 -CH 2 -. In certain embodiments, Y 2 is -(CH 2 )-, -(CH 2 ) 2 -, or - (CH 2 ) -.
- Y 2 is -(CH 2 ) 2 - or -CH 2 -C(H)(OH)-. In certain embodiments, Y 2 is -(CH 2 ) -, -CH 2 -0-CH 2 -, or -CH 2 -CF 2 -CH 2 -.
- Y 2 is -(CH 2 )-. In certain embodiments, Y 2 is -(CH 2 ) 2 -. In certain embodiments, Y 2 is -CH 2 -C(H)(OH)-. In certain embodiments, Y 2 is -(CH 2 )3-. In certain embodiments, Y 2 is -CH 2 -0-CH 2 -. In certain embodiments, Y 2 is -CH 2 -CF 2 -CH 2 -. In certain embodiments, Y 2 is selected from the groups depicted in the compounds in Table 2, below.
- Y 3 is a C1-3 bivalent saturated or unsaturated, straight hydrocarbon chain wherein one or two methylene units of the chain are optionally and independently replaced by -0-, -C(H)(R 7 )-, or -C(R 7 ) 2 -.
- Y 3 is a C 2 -3 bivalent unsaturated, straight hydrocarbon chain wherein one methylene unit of the chain is optionally replaced by -0-, -C(H)(R 7 )-, or -C(R 7 ) 2 -.
- Y 3 is a C 2 -3 bivalent unsaturated, straight hydrocarbon chain.
- Y 3 is a C1-3 bivalent saturated, straight hydrocarbon chain wherein one or two methylene units of the chain are optionally and independently replaced by - 0-, -C(H)(R 7 )-, or -C(R 7 ) 2 -. In certain embodiments, Y 3 is a C1-3 bivalent saturated, straight hydrocarbon chain wherein one methylene unit of the chain is optionally replaced by -0-, - C(H)(R 7 )-, or -C(R 7 ) 2 -.
- Y 3 is a C1-3 bivalent saturated, straight hydrocarbon chain wherein one methylene unit of the chain is replaced by -0-, -C(H)(R 7 )-, or - C(R 7 ) 2 -. In certain embodiments, Y 3 is a C1-3 bivalent saturated, straight hydrocarbon chain.
- Y 3 is a C 2 -3 bivalent saturated, straight hydrocarbon chain wherein one or two methylene units of the chain are optionally and independently replaced by - 0-, -C(H)(R 7 )-, or -C(R 7 ) 2 -. In certain embodiments, Y 3 is a C 2 -3 bivalent saturated, straight hydrocarbon chain wherein one methylene unit of the chain is optionally replaced by -0-, - C(H)(R 7 )-, or -C(R 7 ) 2 -.
- Y 3 is a C 2 -3 bivalent saturated, straight hydrocarbon chain wherein one methylene unit of the chain is replaced by -0-, -C(H)(R 7 )-, or - C(R 7 ) 2 -. In certain embodiments, Y 3 is a C 2 -3 bivalent saturated, straight hydrocarbon chain.
- Y 3 is -(CH 2 )-, -(CH 2 ) 2 -, -CH 2 -C(H)(OH)-, -(CH 2 ) 3 -, -CH 2 -0- CH 2 -, or -CH 2 -CF 2 -CH 2 -. In certain embodiments, Y 3 is -(CH 2 )-, -(CH 2 ) 2 -, -CH 2 -C(H)(OH)-, - (CH 2 )3-, or -CH 2 -CF 2 -CH 2 -.
- Y 3 is -(CH 2 ) 2 -, -CH 2 -C(H)(OH)-, -(CH 2 ) 3 -, or -CH 2 -CF 2 -CH 2 -. In certain embodiments, Y 3 is -(CH 2 ) 2 - or -(CH 2 )3-. In certain embodiments, Y 3 is -CH 2 -C(H)(OH)- or -CH 2 -CF 2 -CH 2 -. In certain embodiments, Y 3 is -(CH 2 )-, -(CH 2 ) 2 -, or - (CH 2 ) 3 -.
- Y 3 is -(CH 2 ) 2 - or -CH 2 -C(H)(OH)-. In certain embodiments, Y 3 is -(CH 2 ) 3 -, -CH 2 -0-CH 2 -, or -CH 2 -CF 2 -CH 2 -.
- Y 3 is -(CH 2 )-. In certain embodiments, Y 3 is -(CH 2 ) 2 -. In certain embodiments, Y 3 is -CH 2 -C(H)(OH)-. In certain embodiments, Y 3 is -(CH 2 )3-. In certain embodiments, Y 3 is -CH 2 -0-CH 2 -. In certain embodiments, Y 3 is -CH 2 -CF 2 -CH 2 -. In certain embodiments, Y 3 is selected from the groups depicted in the compounds in Table 2, below.
- m is 0, 1, 2, or 3. In certain embodiments, m is 0. In certain embodiments, m is 1. In certain embodiments, m is 2. In certain embodiments, m is 3. In certain embodiments, m is 0 or 1. In certain embodiments, m is 1 or 2. In certain embodiments, m is 2 or 3. In certain embodiments, m is 0, 1, or 2. In certain embodiments, m is 1, 2, or 3. In certain embodiments, m is selected from the values represented in the compounds in Table 2, below.
- n is 0, 1, 2, or 3. In certain embodiments, n is 0. In certain embodiments, n is 1. In certain embodiments, n is 2. In certain embodiments, n is 3. In certain embodiments, n is 0 or 1. In certain embodiments, n is 1 or 2. In certain embodiments, n is 2 or 3. In certain embodiments, n is 0, 1, or 2. In certain embodiments, n is 1, 2, or 3. In certain embodiments, n is selected from the values represented in the compounds in Table 2, below.
- p is 0, 1, 2, or 3. In certain embodiments, p is 0. In certain embodiments, p is 1. In certain embodiments, p is 2. In certain embodiments, p is 3. In certain embodiments, p is 0 or 1. In certain embodiments, p is 1 or 2. In certain embodiments, p is 2 or 3. In certain embodiments, p is 0, 1, or 2. In certain embodiments, p is 1, 2, or 3. In certain embodiments, p is selected from the values represented in the compounds in Table 2, below.
- Another aspect of the invention provides a compound represented by Formula III: or a pharmaceutically acceptable salt thereof; wherein:
- R 1 is naphthyl; an 8-10 membered saturated or partially unsaturated bicyclic heterocyclyl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; an 8-10 membered bicyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 5-6 membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or phenyl; each of which is substituted with m occurrences of R 5 ;
- R 2 is an 8-10 membered saturated or partially unsaturated bicyclic heterocyclyl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 3-7 membered saturated or partially unsaturated monocyclic heterocyclyl having 1 or 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 5-6 membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; phenyl; or Ci- 6 aliphatic; each of which is substituted with n occurrences of R 6 ;
- R 4 is hydrogen, halo, or C1-4 alkyl
- R 5 represents independently for each occurrence C2-6 alkynyl, C2-6 alkenyl, Ci- 6 alkyl, hydroxyl, Ci- 6 alkoxyl, halo, or cyano;
- R 6 and R 7 each represent independently for each occurrence halo, hydroxyl, Ci- 6 alkoxyl, Ci- 6 haloalkoxyl, Ci- 6 alkyl, Ci- 6 haloalkyl, Ci- 6 hydroxyalkyl, or -N(R 9 )2;
- R 8 and R 9 each represent independently for each occurrence hydrogen, C1-4 alkyl, or C3-5 cycloalkyl; or two occurrences of R 9 attached to the same nitrogen atom are taken together with the nitrogen atom to which they are attached to form a 4-7 membered saturated ring having one nitrogen atom;
- a 1 is a 4-7 membered saturated monocyclic heterocyclyl having 1 or 2 nitrogen atoms; a 6-11 membered saturated spirocyclic heterocyclyl having 1 or 2 nitrogen atoms; a 6-11 membered saturated ortho- fused heterocyclyl having 1 or 2 nitrogen atoms; or a 5-6 membered monocyclic heteroaryl having one nitrogen atom and 0, 1, or 2 additional heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted with p
- X 2 is N, C(CN), or C(R 4 );
- L is a covalent bond or a CM bivalent saturated or unsaturated, straight or branched hydrocarbon chain wherein one or two methylene units of the chain are optionally and independently replaced by -0-, -N(R 9 )-, or -C(O)-;
- Y 1 , Y 2 , and Y 3 represent independently a C1-3 bivalent saturated or unsaturated, straight hydrocarbon chain wherein one or two methylene units of the chain are optionally and independently replaced by -0-, -C(H)(R 7 )-, or -C(R 7 )2-; and m, n, and p are each independently 0, 1, 2, or 3.
- the definitions of variables in Formula III above encompass multiple chemical groups.
- the definition of a variable is a single chemical group selected from those chemical groups set forth above
- the definition of a variable is a collection of two or more of the chemical groups selected from those set forth above
- the compound is defined by a combination of variables in which the variables are defined by (i) or (ii).
- the compound is a compound of Formula III.
- R 1 is naphthyl; an 8-10 membered saturated or partially unsaturated bicyclic heterocyclyl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; an 8-10 membered bicyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 5-6 membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or phenyl; each of which is substituted with m occurrences of R 5 .
- R 1 is naphthyl, an 8-10 membered saturated or partially unsaturated bicyclic heterocyclyl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or an 8-10 membered bicyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted with m occurrences of R 5 .
- R 1 is phenyl or a 5-6 membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted with m occurrences of R 5 .
- R 1 is naphthyl or phenyl; each of which is substituted with m occurrences of R 5 .
- R 1 is an 8-10 membered saturated or partially unsaturated bicyclic heterocyclyl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; an 8-10 membered bicyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or a 5-6 membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted with m occurrences of R 5 .
- R 1 is naphthyl or an 8-10 membered bicyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted with m occurrences of R 5 .
- R 1 is an 8-10 membered saturated or partially unsaturated bicyclic heterocyclyl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or an 8-10 membered bicyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted with m occurrences of R 5 .
- R 1 is naphthyl substituted with m occurrences of R 5 . In certain embodiments, R 1 is 1-naphthyl substituted with m occurrences of R 5 . In certain embodiments,
- R 1 is In certain embodiments, R 1 is
- R 1 is an 8-10 membered saturated or partially unsaturated bicyclic heterocyclyl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said heterocyclyl is substituted with m occurrences of R 5 .
- R 1 is an 8-10 membered saturated or partially unsaturated bicyclic heterocyclyl having 1 or 2 heteroatoms independently selected from nitrogen and oxygen; wherein said heterocyclyl is substituted with m occurrences of R 5 .
- R 1 is certain embodiments, R 1 is In certain embodiments, R 1 is In certain embodiments, R 1 is In certain embodiments, R 1 is
- R 1 is an 8-10 membered bicyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said heteroaryl is substituted with m occurrences of R 5 .
- R 1 is an 8-10 membered bicyclic heteroaryl having 1 or 2 heteroatoms independently selected from nitrogen and oxygen, and sulfur; wherein said heteroaryl is substituted with m occurrences of R 5 .
- R 1 is quinolinyl, isoquinolinyl, or indazolyl; each of which is substituted with m occurrences of R 5 .
- R 1 is quinolinyl substituted with m occurrences of R 5 .
- R 1 is quinoline-4-yl substituted with m occurrences of R 5 .
- R 1 is isoquinolinyl substituted with m occurrences of R 5 .
- R 1 is isoquinolin-l-yl substituted with m occurrences of R 5 .
- R 1 is indazolyl substituted with m occurrences of R 5 .
- R 1 is phenyl substituted with m occurrences of R 5 . In certain embodiments, R 1 is In certain embodiments, R 1 is
- R 1 is a 5-6 membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said heteroaryl is substituted with m occurrences of R 5 .
- R 1 is a 6-membered monocyclic heteroaryl having 1, 2, or 3 nitrogen atoms; wherein said heteroaryl is substituted with m occurrences of R 5 .
- R 1 is a 5-membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said heteroaryl is substituted with m occurrences of R 5 .
- R 1 is selected from the groups depicted in the compounds in Table 3, below.
- R 2 is an 8-10 membered saturated or partially unsaturated bicyclic heterocyclyl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 3-7 membered saturated or partially unsaturated monocyclic heterocyclyl having 1 or 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 5-6 membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; phenyl; or Ci- 6 aliphatic; each of which is substituted with n occurrences of R 6 .
- R 2 is an 8-10 membered saturated or partially unsaturated bicyclic heterocyclyl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 3-7 membered saturated or partially unsaturated monocyclic heterocyclyl having 1 or 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or a 5-6 membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted with n occurrences of R 6 .
- R 2 is phenyl or Ci- 6 aliphatic; each of which is substituted with n occurrences of R 6 .
- R 2 is an 8-10 membered saturated or partially unsaturated bicyclic heterocyclyl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or a 3-7 membered saturated or partially unsaturated monocyclic heterocyclyl having 1 or 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted with n occurrences of R 6 .
- R 2 is a 3-7 membered saturated or partially unsaturated monocyclic heterocyclyl having 1 or 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or a 5-6 membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted with n occurrences of R 6 .
- R 2 is a 3-7 membered saturated or partially unsaturated monocyclic heterocyclyl having 1 or 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 5-6 membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; phenyl; or Ci- 6 aliphatic; each of which is substituted with n occurrences of R 6 .
- R 2 is a 3-7 membered saturated or partially unsaturated monocyclic heterocyclyl having 1 or 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or Ci- 6 aliphatic; each of which is substituted with n occurrences of R 6 .
- R 2 is a 5-6 membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or phenyl; each of which is substituted with n occurrences of R 6 .
- R 2 is an 8-10 membered saturated or partially unsaturated bicyclic heterocyclyl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said heterocyclyl is substituted with n occurrences of R 6 .
- R 2 is an 8-10 membered saturated bicyclic heterocyclyl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said heterocyclyl is substituted with n occurrences of R 6 .
- R 2 is an 8-10 membered partially unsaturated bicyclic heterocyclyl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said heterocyclyl is substituted with n occurrences of R 6 .
- R 2 is an 8-10 membered saturated or partially unsaturated bicyclic heterocyclyl having 1 or 2 heteroatoms independently selected from nitrogen and oxygen; wherein said heterocyclyl is substituted with n occurrences of R 6 .
- R 2 is an 8-10 membered saturated or partially unsaturated bicyclic heterocyclyl having 1 nitrogen atom; wherein said heterocyclyl is substituted with n occurrences of R 6 .
- R 2 is an 8-10 membered saturated bicyclic heterocyclyl having 1 nitrogen atom; wherein said heterocyclyl is substituted with n occurrences of R 6 .
- R 2 is an 8-10 membered saturated bicyclic heterocyclyl having 1 nitrogen atom; wherein said heterocyclyl is substituted with n occurrences of R 6 .
- R 2 is substituted with n occurrences of R 6 .
- R 2 is an 8-10 membered saturated or partially unsaturated bicyclic heterocyclyl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In certain embodiments, R 2 is an 8-10 membered saturated bicyclic heterocyclyl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In certain embodiments, R 2 is an 8-10 membered partially unsaturated bicyclic heterocyclyl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur.
- R 2 is an 8-10 membered saturated or partially unsaturated bicyclic heterocyclyl having 1 or 2 heteroatoms independently selected from nitrogen and oxygen. In certain embodiments, R 2 is an 8-10 membered saturated or partially unsaturated bicyclic heterocyclyl having 1 nitrogen atom. In certain embodiments, R 2 is an 8-10 membered saturated bicyclic heterocyclyl having 1 nitrogen atom. In certain embodiments, R 2 is [0317] In certain embodiments, R 2 is a 3-7 membered saturated or partially unsaturated monocyclic heterocyclyl having 1 or 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said heterocyclyl is substituted with n occurrences of R 6 .
- R 2 is a 4-6 membered saturated or partially unsaturated monocyclic heterocyclyl having 1 or 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said heterocyclyl is substituted with n occurrences of R 6 .
- R 2 is a 5-6 membered saturated or partially unsaturated monocyclic heterocyclyl having 1 or 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said heterocyclyl is substituted with n occurrences of R 6 .
- R 2 is a 5-membered saturated or partially unsaturated monocyclic heterocyclyl having 1 or 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said heterocyclyl is substituted with n occurrences of R 6 .
- R 2 is a 6-membered saturated or partially unsaturated monocyclic heterocyclyl having 1 or 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said heterocyclyl is substituted with n occurrences of R 6 .
- R 2 is a 3-7 membered saturated monocyclic heterocyclyl having 1 or 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said heterocyclyl is substituted with n occurrences of R 6 .
- R 2 is a 5-6 membered saturated monocyclic heterocyclyl having 1 or 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said heterocyclyl is substituted with n occurrences of R 6 .
- R 2 is a 3-7 membered partially unsaturated monocyclic heterocyclyl having 1 or 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said heterocyclyl is substituted with n occurrences of R 6 .
- R 2 is a 5-6 membered partially unsaturated monocyclic heterocyclyl having 1 or 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said heterocyclyl is substituted with n occurrences of R 6 .
- R 2 is a 3-7 membered saturated or partially unsaturated monocyclic heterocyclyl having 1 or 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said heterocyclyl is substituted with n occurrences of R 6 .
- R 2 is a 5-6 membered saturated or partially unsaturated monocyclic heterocyclyl having 1 or 2 heteroatoms independently selected from nitrogen and oxygen; wherein said heterocyclyl is substituted with n occurrences of R 6 .
- R 2 is a 5-6 membered saturated monocyclic heterocyclyl having 1 or 2 heteroatoms independently selected from nitrogen and oxygen; wherein said heterocyclyl is substituted with n occurrences of R 6 .
- R 2 is azetidinyl, pyrrolidinyl, piperidinyl, or morpholinyl; each of which is substituted with n occurrences of R 6 .
- R 2 is azetidinyl substituted with n occurrences of R 6 .
- R 2 is pyrrolidinyl substituted with n occurrences of R 6 .
- R 2 is pyrrolidin-2-yl substituted with n occurrences of R 6 .
- R 2 is pyrrolidin-2-yl substituted with a single occurrence of R 6 at the 1-position.
- R 2 is piperidinyl substituted with n occurrences of R 6 .
- R 2 is morpholinyl substituted with n occurrences of R 6 .
- R 2 is azetidinyl, pyrrolidinyl, piperidinyl, or morpholinyl. In certain embodiments, R 2 is azetidinyl. In certain embodiments, R 2 is pyrrolidinyl. In certain embodiments, R 2 is pyrrolidin-2-yl. In certain embodiments, R 2 is l-methyl-pyrrolidin-2-yl. In certain embodiments, R 2 is piperidinyl. In certain embodiments, R 2 is morpholinyl.
- R 2 is a 5-6 membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said heteroaryl is substituted with n occurrences of R 6 .
- R 2 is phenyl substituted with n occurrences of R 6 . In certain embodiments, R 2 is phenyl.
- R 2 is Ci- 6 aliphatic substituted with n occurrences of R 6 . In certain embodiments, R 2 is C3-6 cycloaliphatic substituted with n occurrences of R 6 . In certain embodiments, R 2 is a Ci- 6 aliphatic chain substituted with n occurrences of R 6 . In certain embodiments, R 2 is C3-6 cycloalkyl substituted with n occurrences of R 6 . In certain embodiments, R 2 is Ci- 6 alkyl substituted with n occurrences of R 6 .
- R 2 is Ci- 6 aliphatic. In certain embodiments, R 2 is C3-6 cycloaliphatic. In certain embodiments, R 2 is a Ci- 6 aliphatic chain. In certain embodiments, R 2 is C3-6 cycloalkyl. In certain embodiments, R 2 is Ci- 6 alkyl.
- R 2 is selected from the groups depicted in the compounds in Table 3, below.
- R 4 is hydrogen, halo, or Ci- 4 alkyl. In certain embodiments, R 4 is hydrogen. In certain embodiments, R 4 is halo. In certain embodiments, R 4 is fluoro or chloro. In certain embodiments, R 4 is fluoro. In certain embodiments, R 4 is chloro. In certain embodiments, R 4 is C 1-4 alkyl. In certain embodiments, R 4 is methyl. In certain embodiments,
- R 4 is selected from the groups depicted in the compounds in Table 3, below.
- R 5 represents independently for each occurrence C 2-6 alkynyl, C 2-6 alkenyl, C1-6 alkyl, hydroxyl, C1-6 alkoxyl, halo, or cyano.
- R 5 represents independently for each occurrence C 2-6 alkynyl, C 2-6 alkenyl, C1-6 alkyl, or hydroxyl. In certain embodiments, R 5 represents independently for each occurrence ethynyl, ethenyl, C 1-3 alkyl, or hydroxyl. In certain embodiments, R 5 represents independently for each occurrence C 2-6 alkynyl or hydroxyl. In certain embodiments, R 5 represents independently for each occurrence ethynyl or hydroxyl. In certain embodiments, one occurrence of R 5 is ethynyl. In certain embodiments, one occurrence of R 5 is hydroxyl.
- R 5 represents independently for each occurrence C 2-6 alkynyl, C 2-6 alkenyl, or C1-6 alkyl. In certain embodiments, R 5 represents independently for each occurrence ethynyl, ethenyl, or C 1-3 alkyl. In certain embodiments, R 5 represents independently for each occurrence hydroxyl or C1-6 alkoxyl. In certain embodiments, R 5 represents independently for each occurrence halo or cyano.
- R 5 represents independently for each occurrence C 2-6 alkynyl. In certain embodiments, R 5 is ethynyl. In certain embodiments, R 5 represents independently for each occurrence C 2-6 alkenyl. In certain embodiments, R 5 is ethenyl. In certain embodiments, R 5 represents independently for each occurrence Ci-6 alkyl. In certain embodiments, R 5 represents independently for each occurrence C 1-3 alkyl. In certain embodiments, R 5 is methyl. In certain embodiments, R 5 is hydroxyl. In certain embodiments, R 5 represents independently for each occurrence C1-6 alkoxyl. In certain embodiments, R 5 represents independently for each occurrence halo.
- R 5 represents independently for each occurrence fluoro or chloro. In certain embodiments, R 5 is fluoro. In certain embodiments, R 5 is chloro. In certain embodiments, R 5 is cyano. In certain embodiments, R 5 is selected from the groups depicted in the compounds in Table 3, below. [0332] As defined generally above, R 6 represents independently for each occurrence halo, hydroxyl, Ci- 6 alkoxyl, Ci- 6 haloalkoxyl, Ci- 6 alkyl, Ci- 6 haloalkyl, Ci- 6 hydroxyalkyl, or -N(R 9 )2.
- R 6 represents independently for each occurrence halo, hydroxyl, Ci- 6 alkoxyl, Ci- 6 alkyl, or Ci- 6 haloalkyl. In certain embodiments, R 6 represents independently for each occurrence halo, Ci- 6 alkyl, or Ci- 6 haloalkyl. In certain embodiments, R 6 represents independently for each occurrence halo or Ci- 6 alkyl. In certain embodiments, R 6 represents independently for each occurrence halo, hydroxyl, or Ci- 6 alkyl.
- R 6 represents independently for each occurrence halo, hydroxyl, Ci- 6 alkoxyl, Ci- 6 haloalkoxyl, or -N(R 9 )2. In certain embodiments, R 6 represents independently for each occurrence halo, hydroxyl, or -N(R 9 )2. In certain embodiments, R 6 represents independently for each occurrence halo, Ci- 6 alkoxyl, or Ci- 6 haloalkoxyl. In certain embodiments, R 6 represents independently for each occurrence halo, Ci- 6 alkyl, Ci- 6 haloalkyl, or Ci- 6 hydroxyalkyl.
- R 6 represents independently for each occurrence Ci- 6 alkyl, Ci- 6 haloalkyl, or Ci- 6 hydroxyalkyl. In certain embodiments, R 6 represents independently for each occurrence Ci- 6 alkyl or Ci- 6 haloalkyl.
- R 6 represents independently for each occurrence halo. In certain embodiments, R 6 represents independently for each occurrence fluoro or chloro. In certain embodiments, R 6 is fluoro. In certain embodiments, R 6 is chloro. In certain embodiments, R 6 is hydroxyl. In certain embodiments, R 6 represents independently for each occurrence Ci- 6 alkoxyl. In certain embodiments, R 6 is methoxy. In certain embodiments, R 6 represents independently for each occurrence Ci- 6 haloalkoxyl. In certain embodiments, R 6 is trifluoromethoxy. In certain embodiments, R 6 represents independently for each occurrence Ci- 6 alkyl. In certain embodiments, R 6 represents independently for each occurrence C1-3 alkyl.
- R 6 is methyl. In certain embodiments, R 6 represents independently for each occurrence Ci- 6 haloalkyl. In certain embodiments, R 6 is trifluoromethyl. In certain embodiments, R 6 represents independently for each occurrence Ci- 6 hydroxyalkyl. In certain embodiments, R 6 represents independently for each occurrence -N(R 9 )2. In certain embodiments, R 6 is -NH2. In certain embodiments, R 6 is selected from the groups depicted in the compounds in Table 3, below.
- R 7 represents independently for each occurrence halo, hydroxyl, Ci- 6 alkoxyl, Ci- 6 haloalkoxyl, Ci- 6 alkyl, Ci- 6 haloalkyl, Ci- 6 hydroxyalkyl, or -N(R 9 )2.
- R 7 represents independently for each occurrence halo, hydroxyl, Ci- 6 alkoxyl, Ci- 6 alkyl, or Ci- 6 haloalkyl. In certain embodiments, R 7 represents independently for each occurrence halo, Ci- 6 alkyl, or Ci- 6 haloalkyl. In certain embodiments, R 7 represents independently for each occurrence halo or Ci- 6 alkyl. In certain embodiments, R 7 represents independently for each occurrence halo, hydroxyl, or Ci- 6 alkyl.
- R 7 represents independently for each occurrence halo, hydroxyl, Ci- 6 alkoxyl, Ci- 6 haloalkoxyl, or -N(R 9 )2. In certain embodiments, R 7 represents independently for each occurrence halo, hydroxyl, or -N(R 9 )2. In certain embodiments, R 7 represents independently for each occurrence halo, Ci- 6 alkoxyl, or Ci- 6 haloalkoxyl. In certain embodiments, R 7 represents independently for each occurrence halo, Ci- 6 alkyl, Ci- 6 haloalkyl, or Ci- 6 hydroxyalkyl.
- R 7 represents independently for each occurrence Ci- 6 alkyl, Ci- 6 haloalkyl, or Ci- 6 hydroxyalkyl. In certain embodiments, R 7 represents independently for each occurrence Ci- 6 alkyl or Ci- 6 haloalkyl.
- R 7 represents independently for each occurrence halo. In certain embodiments, R 7 represents independently for each occurrence fluoro or chloro. In certain embodiments, R 7 is fluoro. In certain embodiments, R 7 is chloro. In certain embodiments, R 7 is hydroxyl. In certain embodiments, R 7 represents independently for each occurrence Ci- 6 alkoxyl. In certain embodiments, R 7 is methoxy. In certain embodiments, R 7 represents independently for each occurrence Ci- 6 haloalkoxyl. In certain embodiments, R 7 is trifluoromethoxy. In certain embodiments, R 7 represents independently for each occurrence Ci- 6 alkyl. In certain embodiments, R 7 represents independently for each occurrence C1-3 alkyl.
- R 7 is methyl. In certain embodiments, R 7 represents independently for each occurrence Ci- 6 haloalkyl. In certain embodiments, R 7 is trifluoromethyl. In certain embodiments, R 7 represents independently for each occurrence Ci- 6 hydroxyalkyl. In certain embodiments, R 7 represents independently for each occurrence -N(R 9 )2. In certain embodiments, R 7 is -NH2. In certain embodiments, R 7 is selected from the groups depicted in the compounds in Table 3, below. [0340] As defined generally above, R 8 is hydrogen, Ci alkyl, or C3-5 cycloalkyl. In certain embodiments, R 8 is hydrogen or C M alkyl. In certain embodiments, R 8 is hydrogen or methyl.
- R 8 is C IM alkyl or C3-5 cycloalkyl.
- R 8 is hydrogen. In certain embodiments, R 8 is C IM alkyl. In certain embodiments, R 8 is methyl. In certain embodiments, R 8 is C3-5 cycloalkyl. In certain embodiments, R 8 is cyclopropyl. In certain embodiments, R 8 is selected from the groups depicted in the compounds in Table 3, below.
- R 9 represents independently for each occurrence hydrogen, Ci-4 alkyl, or C3-5 cycloalkyl; or two occurrences of R 9 attached to the same nitrogen atom are taken together with the nitrogen atom to which they are attached to form a 4-7 membered saturated ring having one nitrogen atom.
- R 9 represents independently for each occurrence hydrogen, C1-4 alkyl, or C3-5 cycloalkyl. In certain embodiments, R 9 represents independently for each occurrence hydrogen or C1-4 alkyl. In certain embodiments, R 9 represents independently for each occurrence hydrogen or methyl. In certain embodiments, R 9 represents independently for each occurrence C1-4 alkyl or C3-5 cycloalkyl.
- two occurrences of R 9 attached to the same nitrogen atom are taken together with the nitrogen atom to which they are attached to form a 4-7 membered saturated ring having one nitrogen atom.
- R 9 is hydrogen. In certain embodiments, R 9 represents independently for each occurrence C1-4 alkyl. In certain embodiments, R 9 is methyl. In certain embodiments, R 9 represents independently for each occurrence C3-5 cycloalkyl. In certain embodiments, R 9 is cyclopropyl. In certain embodiments, R 9 is selected from the groups depicted in the compounds in Table 3, below.
- a 1 is a 4-7 membered saturated monocyclic heterocyclyl having 1 or 2 nitrogen atoms; a 6-11 membered saturated spirocyclic heterocyclyl having 1 or 2 nitrogen atoms; a 6-11 membered saturated ortho- fused heterocyclyl having 1 or 2 nitrogen atoms; or a 5-6 membered monocyclic heteroaryl having one nitrogen atom and 0, 1, or 2 additional heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted with p occurrences of R 7 ; or A 1 is
- a 1 is In certain embodiments, A 1 is In certain embodiments, A 1 is In certain embodiments, A 1 is in certain embodiments, A 1 is
- a 1 is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
- a 1 is a 4-7 membered saturated monocyclic heterocyclyl having 1 or 2 nitrogen atoms; a 6-11 membered saturated spirocyclic heterocyclyl having 1 or 2 nitrogen atoms; a 6-11 membered saturated ortho- fused heterocyclyl having 1 or 2 nitrogen atoms; or a 5- 6 membered monocyclic heteroaryl having one nitrogen atom and 0, 1, or 2 additional heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted with p occurrences of R 7 .
- a 1 is a 4-7 membered saturated monocyclic heterocyclyl having 1 or 2 nitrogen atoms; a 6-11 membered saturated spirocyclic heterocyclyl having 1 or 2 nitrogen atoms; or a 6-11 membered saturated ortho- fused heterocyclyl having 1 or 2 nitrogen atoms; each of which is substituted with p occurrences of R 7 ; or A 1 is [0350] In certain embodiments, A 1 is a 4-7 membered saturated monocyclic heterocyclyl having 1 or 2 nitrogen atoms; a 6-11 membered saturated spirocyclic heterocyclyl having 1 or 2 nitrogen atoms; or a 6-11 membered saturated ortho- fused heterocyclyl having 1 or 2 nitrogen atoms; each of which is substituted with p occurrences of R 7 .
- a 1 is a 6-11 membered saturated spirocyclic heterocyclyl having 1 or 2 nitrogen atoms; or a 6-11 membered saturated ortho- fused heterocyclyl having 1 or 2 nitrogen atoms; each of which is substituted with p occurrences of R 7 ; or A 1 is or
- a 1 is a 6-11 membered saturated spirocyclic heterocyclyl having 1 or 2 nitrogen atoms; or a 6-11 membered saturated ortho- fused heterocyclyl having 1 or 2 nitrogen atoms; each of which is substituted with p occurrences of R 7 .
- a 1 is a 4-7 membered saturated monocyclic heterocyclyl having 1 or 2 nitrogen atoms; or a 5-6 membered monocyclic heteroaryl having one nitrogen atom and 0, 1, or 2 additional heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted with p occurrences of R 7 .
- a 1 is a 4-7 membered saturated monocyclic heterocyclyl having 1 or 2 nitrogen atoms; a 6-11 membered saturated spirocyclic heterocyclyl having 1 or 2 nitrogen atoms; a 6-11 membered saturated ortho- fused heterocyclyl having 1 or 2 nitrogen atoms; or a 5- 6 membered monocyclic heteroaryl having one nitrogen atom and 0, 1, or 2 additional heteroatoms independently selected from nitrogen, oxygen, and sulfur.
- a 1 is a 4-7 membered saturated monocyclic heterocyclyl having 1 or 2 nitrogen atoms; a 6-11 membered saturated spirocyclic heterocyclyl having 1 or 2 nitrogen atoms; or a 6-11 membered saturated ortho- fused heterocyclyl having 1 or 2 nitrogen atoms; or
- a 1 is a 4-7 membered saturated monocyclic heterocyclyl having 1 or 2 nitrogen atoms; a 6-11 membered saturated spirocyclic heterocyclyl having 1 or 2 nitrogen atoms; or a 6-11 membered saturated ortho- fused heterocyclyl having 1 or 2 nitrogen atoms.
- a 1 is a 6-11 membered saturated spirocyclic heterocyclyl having 1 or 2 nitrogen atoms; or a 6-11 membered saturated ortho- fused heterocyclyl having 1 or 2
- a 1 is a 6-11 membered saturated spirocyclic heterocyclyl having 1 or 2 nitrogen atoms; or a 6-11 membered saturated ortho- fused heterocyclyl having 1 or 2 nitrogen atoms.
- a 1 is a 4-7 membered saturated monocyclic heterocyclyl having 1 or 2 nitrogen atoms; or a 5-6 membered monocyclic heteroaryl having one nitrogen atom and 0, 1, or 2 additional heteroatoms independently selected from nitrogen, oxygen, and sulfur.
- a 1 is a 4-7 membered saturated monocyclic heterocyclyl having 1 or 2 nitrogen atoms; wherein said heterocyclyl is substituted with p occurrences of R 7 .
- a 1 is a 5-6 membered saturated monocyclic heterocyclyl having 1 or 2 nitrogen atoms; wherein said heterocyclyl is substituted with p occurrences of R 7 .
- a 1 is a 4-7 membered saturated monocyclic heterocyclyl having 1 or 2 nitrogen atoms.
- a 1 is a 5-6 membered saturated monocyclic heterocyclyl having 1 or 2 nitrogen atoms.
- a 1 is 1,4-diazepanyl, piperidinyl, piperazinyl, pyrrolidinyl, or azetidinyl; each of which is substituted with p occurrences of R 7 .
- a 1 is 1,4-diazepanyl substituted with p occurrences of R 7 .
- a 1 is piperidinyl substituted with p occurrences of R 7 .
- a 1 is piperazinyl substituted with p occurrences of R 7 .
- a 1 is pyrrolidinyl substituted with p occurrences of R 7 .
- a 1 is azetidinyl substituted with p occurrences of R 7 .
- a 1 is 1,4-diazepanyl, piperidinyl, piperazinyl, pyrrolidinyl, or azetidinyl. In certain embodiments, A 1 is 1,4-diazepanyl. In certain embodiments, A 1 is piperidinyl. In certain embodiments, A 1 is piperazinyl. In certain embodiments, A 1 is pyrrolidinyl. In certain embodiments, A 1 is azetidinyl.
- a 1 is 1,4-diazepan-l-yl, piperidin-4-yl, piperazin-l-yl, pyrrolidin-3-yl, or azetidin-3-yl; each of which is substituted with p occurrences of R 7 .
- a 1 is 1,4-diazepan-l-yl substituted with p occurrences of R 7 .
- a 1 is piperidin-4-yl substituted with p occurrences of R 7 .
- a 1 is piperazin-l-yl substituted with p occurrences of R 7 .
- a 1 is pyrrolidin-3-yl substituted with p occurrences of R 7 .
- a 1 is azetidin-3-yl substituted with p occurrences of R 7 .
- a 1 is 1,4-diazepan-l-yl, piperidin-4-yl, piperazin-l-yl, pyrrolidin-3-yl, or azetidin-3-yl. In certain embodiments, A 1 is 1,4-diazepan-l-yl. In certain embodiments, A 1 is piperidin-4-yl. In certain embodiments, A 1 is piperazin-l-yl. In certain embodiments, A 1 is pyrrolidin-3-yl. In certain embodiments, A 1 is azetidin-3-yl.
- a 1 is a 6-11 membered saturated spirocyclic heterocyclyl having 1 or 2 nitrogen atoms; wherein said heterocyclyl is substituted with p occurrences of R 7 .
- a 1 is a 7-10 membered saturated spirocyclic heterocyclyl having 1 or 2 nitrogen atoms; wherein said heterocyclyl is substituted with p occurrences of R 7 .
- a 1 is a 6-11 membered saturated spirocyclic heterocyclyl having 2 nitrogen atoms; wherein said heterocyclyl is substituted with p occurrences of R 7 .
- a 1 is a 6-11 membered saturated spirocyclic heterocyclyl having 1 or 2 nitrogen atoms. In certain embodiments, A 1 is a 7-10 membered saturated spirocyclic heterocyclyl having 1 or 2 nitrogen atoms. In certain embodiments, A 1 is a 6-11 membered saturated spirocyclic heterocyclyl having 2 nitrogen atoms. In certain embodiments, A 1 is or In certain embodiments, A 1 is In certain embodiments, A 1 i s
- a 1 is a 6-11 membered saturated ortho- fused heterocyclyl having 1 or 2 nitrogen atoms; wherein said heterocyclyl is substituted with p occurrences of R 7 .
- a 1 is a 7-10 membered saturated ortho- fused heterocyclyl having 1 or 2 nitrogen atoms; wherein said heterocyclyl is substituted with p occurrences of R 7 .
- a 1 is a 6-11 membered saturated ortho- fused heterocyclyl having 1 or 2 nitrogen atoms.
- a 1 is a 7-10 membered saturated ortho- fused heterocyclyl having 1 or 2 nitrogen atoms.
- a 1 is a 5-6 membered monocyclic heteroaryl having one nitrogen atom and 0, 1, or 2 additional heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said heteroaryl is substituted with p occurrences of R 7 .
- a 1 is a 6-membered monocyclic heteroaryl having 1, 2, or 3 nitrogen atoms; wherein said heteroaryl is substituted with p occurrences of R 7 .
- a 1 is pyridinyl or pyrimidinyl; each of which is substituted with p occurrences of R 7 .
- a 1 is pyridinyl substituted with p occurrences of R 7 .
- a 1 is pyridin-4-yl substituted with p occurrences of R 7 .
- a 1 is pyrimidinyl substituted with p occurrences of R 7 .
- a 1 is a 5-membered monocyclic heteroaryl having one nitrogen atom and 0, 1, or 2 additional heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said heteroaryl is substituted with p occurrences of R 7 .
- a 1 is a 5-membered monocyclic heteroaryl having 1, 2, or 3 nitrogen atoms; wherein said heteroaryl is substituted with p occurrences of R 7 .
- a 1 is imidazolyl or pyrazolyl; each of which is substituted with p occurrences of R 7 .
- a 1 is imidazolyl substituted with p occurrences of R 7 .
- a 1 is pyrazolyl substituted with p occurrences of R 7 .
- a 1 is selected from the groups depicted in the compounds in Table 3, below.
- X 2 is N, C(CN), or C(R 4 ). In certain embodiments, X 2 is N. In certain embodiments, X 2 is C(CN) or C(R 4 ). In certain embodiments, X 2 is C(CN) or C(H).
- X 2 is C(CN). In certain embodiments, X 2 is C(R 4 ). In certain embodiments, X 2 is C(H). In certain embodiments, X 2 is selected from the groups depicted in the compounds in Table 3, below.
- L is a covalent bond or a Ci-4 bivalent saturated or unsaturated, straight or branched hydrocarbon chain wherein one or two methylene units of the chain are optionally and independently replaced by -0-, -N(R 9 )-, or -C(O)-. In certain embodiments, L is a covalent bond.
- L is a Ci-4 bivalent saturated or unsaturated, straight or branched hydrocarbon chain wherein one or two methylene units of the chain are optionally and independently replaced by -0-, -N(R 9 )-, or -C(O)-.
- L is a Ci-4 bivalent saturated, straight or branched hydrocarbon chain wherein one or two methylene units of the chain are optionally and independently replaced by -0-, -N(R 9 )-, or -C(O)-.
- L is a C 1-4 bivalent saturated, straight hydrocarbon chain wherein one or two methylene units of the chain are optionally and independently replaced by -0-, -N(R 9 )-, or - C(O)-. In certain embodiments, L is a C2-3 bivalent saturated, straight hydrocarbon chain wherein one or two methylene units of the chain are optionally and independently replaced by - 0-, -N(R 9 )-, or -C(O)-.
- L is a C1-4 bivalent saturated, straight hydrocarbon chain wherein one methylene unit of the chain is optionally replaced by -0-, -N(R 9 )-, or -C(O)-.
- L is a C2-3 bivalent saturated, straight hydrocarbon chain wherein one methylene unit of the chain is optionally replaced by -0-, -N(R 9 )-, or -C(O)-.
- L is a Ci-4 bivalent saturated, straight hydrocarbon chain wherein one methylene unit of the chain is replaced by -O- or -N(R 9 )-.
- L is a C2-3 bivalent saturated, straight hydrocarbon chain wherein one methylene unit of the chain is replaced by -O- or -N(R 9 )-.
- L is -0-CH 2 -, -0-(CH 2 ) 2 -, -N(R 9 )-CH 2 -, or -N(R 9 )-(CH 2 ) 2 -, wherein the terminal carbon atom of L is attached to R 2 .
- L is -0-CH 2 - or -0-(CH 2 ) 2 -, wherein the terminal carbon atom of L is attached to R 2 .
- L is -N(R 9 )-CH 2 - or -N(R 9 )-(CH 2 ) 2 -, wherein the terminal carbon atom of L is attached to R 2 .
- L is -0-CH 2 -, wherein the carbon atom of L is attached to R 2 .
- L is -0-(CH 2 ) 2 -, wherein the terminal carbon atom of L is attached to R 2 .
- L is -N(R 9 )-CH 2 -, wherein the carbon atom of L is attached to R 2 .
- L is -N(R 9 )-(CH 2 ) 2 -, wherein the terminal carbon atom of L is attached to R 2 .
- L is selected from the groups depicted in the compounds in Table 3, below.
- Y 1 is a C1-3 bivalent saturated or unsaturated, straight hydrocarbon chain wherein one or two methylene units of the chain are optionally and independently replaced by -0-, -C(H)(R 7 )-, or -C(R 7 ) 2 -.
- Y 1 is a C 2 -3 bivalent unsaturated, straight hydrocarbon chain wherein one methylene unit of the chain is optionally replaced by -0-, -C(H)(R 7 )-, or -C(R 7 ) 2 -. In certain embodiments, Y 1 is a C 2 -3 bivalent unsaturated, straight hydrocarbon chain.
- Y 1 is a C1-3 bivalent saturated, straight hydrocarbon chain wherein one or two methylene units of the chain are optionally and independently replaced by - 0-, -C(H)(R 7 )-, or -C(R 7 ) 2 -. In certain embodiments, Y 1 is a C1-3 bivalent saturated, straight hydrocarbon chain wherein one methylene unit of the chain is optionally replaced by -0-, - C(H)(R 7 )-, or -C(R 7 ) 2 -.
- Y 1 is a C1-3 bivalent saturated, straight hydrocarbon chain wherein one methylene unit of the chain is replaced by -0-, -C(H)(R 7 )-, or - C(R 7 ) 2 -. In certain embodiments, Y 1 is a C1-3 bivalent saturated, straight hydrocarbon chain.
- Y 1 is a C 2 -3 bivalent saturated, straight hydrocarbon chain wherein one or two methylene units of the chain are optionally and independently replaced by - 0-, -C(H)(R 7 )-, or -C(R 7 ) 2 -.
- Y 1 is a C 2 -3 bivalent saturated, straight hydrocarbon chain wherein one methylene unit of the chain is optionally replaced by -0-, - C(H)(R 7 )-, or -C(R 7 ) 2 -.
- Y 1 is a C 2 -3 bivalent saturated, straight hydrocarbon chain wherein one methylene unit of the chain is replaced by -0-, -C(H)(R 7 )-, or - C(R 7 ) 2 -. In certain embodiments, Y 1 is a C2-3 bivalent saturated, straight hydrocarbon chain.
- Y 1 is -(CH 2 )-, -(CH 2 ) 2 -, -CH 2 -C(H)(OH)-, -(CH 2 ) 3 -, -CH 2 -0- CH 2 -, or -CH 2 -CF 2 -CH 2 -. In certain embodiments, Y 1 is -(CH 2 )-, -(CH 2 ) 2 -, -CH 2 -C(H)(OH)-, - (CH 2 )3-, or -CH 2 -CF 2 -CH 2 -.
- Y 1 is -(CH 2 ) 2 -, -CH 2 -C(H)(OH)-, -(CH 2 ) 3 -, or -CH 2 -CF 2 -CH 2 -. In certain embodiments, Y 1 is -(CH 2 ) 2 - or -(CH 2 )3-. In certain embodiments, Y 1 is -CH 2 -C(H)(OH)- or -CH 2 -CF 2 -CH 2 -. In certain embodiments, Y 1 is -(CH 2 )-, -(CH 2 ) 2 -, or - (CH 2 ) 3 -.
- Y 1 is -(CH 2 ) 2 - or -CH 2 -C(H)(OH)-. In certain embodiments, Y 1 is -(CH 2 ) 3 -, -CH 2 -0-CH 2 -, or -CH 2 -CF 2 -CH 2 -.
- Y 1 is -(CH 2 )-. In certain embodiments, Y 1 is -(CH 2 ) 2 -. In certain embodiments, Y 1 is -CH 2 -C(H)(OH)-. In certain embodiments, Y 1 is -(CH 2 )3-. In certain embodiments, Y 1 is -CH 2 -0-CH 2 -. In certain embodiments, Y 1 is -CH 2 -CF 2 -CH 2 -. In certain embodiments, Y 1 is selected from the groups depicted in the compounds in Table 3, below.
- Y 2 is a C1-3 bivalent saturated or unsaturated, straight hydrocarbon chain wherein one or two methylene units of the chain are optionally and independently replaced by -0-, -C(H)(R 7 )-, or -C(R 7 ) 2 -.
- Y 2 is a C 2 -3 bivalent unsaturated, straight hydrocarbon chain wherein one methylene unit of the chain is optionally replaced by -0-, -C(H)(R 7 )-, or -C(R 7 ) 2 -.
- Y 2 is a C 2 -3 bivalent unsaturated, straight hydrocarbon chain.
- Y 2 is a C1-3 bivalent saturated, straight hydrocarbon chain wherein one or two methylene units of the chain are optionally and independently replaced by - 0-, -C(H)(R 7 )-, or -C(R 7 ) 2 -. In certain embodiments, Y 2 is a C1-3 bivalent saturated, straight hydrocarbon chain wherein one methylene unit of the chain is optionally replaced by -0-, - C(H)(R 7 )-, or -C(R 7 ) 2 -.
- Y 2 is a C1-3 bivalent saturated, straight hydrocarbon chain wherein one methylene unit of the chain is replaced by -0-, -C(H)(R 7 )-, or - C(R 7 ) 2 -. In certain embodiments, Y 2 is a C1-3 bivalent saturated, straight hydrocarbon chain.
- Y 2 is a C 2 -3 bivalent saturated, straight hydrocarbon chain wherein one or two methylene units of the chain are optionally and independently replaced by - 0-, -C(H)(R 7 )-, or -C(R 7 ) 2 -.
- Y 2 is a C 2 -3 bivalent saturated, straight hydrocarbon chain wherein one methylene unit of the chain is optionally replaced by -0-, - C(H)(R 7 )-, or -C(R 7 ) 2 -.
- Y 2 is a C2-3 bivalent saturated, straight hydrocarbon chain wherein one methylene unit of the chain is replaced by -0-, -C(H)(R 7 )-, or - C(R 7 ) 2 -. In certain embodiments, Y 2 is a C 2 -3 bivalent saturated, straight hydrocarbon chain.
- Y 2 is -(CH 2 )-, -(CH 2 ) 2 -, -CH 2 -C(H)(OH)-, -(CH 2 ) 3 -, -CH 2 -0- CH 2 -, or -CH 2 -CF 2 -CH 2 -.
- Y 2 is -(CH 2 )-, -(CH 2 ) 2 -, -CH 2 -C(H)(OH)-, - (CH 2 ) 3 -, or -CH 2 -CF 2 -CH 2 -.
- Y 2 is -(CH 2 ) 2 -, -CH 2 -C(H)(OH)-, -(CH 2 ) 3 -, or -CH 2 -CF 2 -CH 2 -. In certain embodiments, Y 2 is -(CH 2 ) 2 - or -(CH 2 )3-. In certain embodiments, Y 2 is -CH 2 -C(H)(OH)- or -CH 2 -CF 2 -CH 2 -. In certain embodiments, Y 2 is -(CH 2 )-, -(CH 2 ) 2 -, or - (CH 2 ) 3 -.
- Y 2 is -(CH 2 ) 2 - or -CH 2 -C(H)(OH)-. In certain embodiments, Y 2 is -(CH 2 ) 3 -, -CH 2 -0-CH 2 -, or -CH 2 -CF 2 -CH 2 -.
- Y 2 is -(CH 2 )-. In certain embodiments, Y 2 is -(CH 2 ) 2 -. In certain embodiments, Y 2 is -CH 2 -C(H)(OH)-. In certain embodiments, Y 2 is -(CH 2 )3-. In certain embodiments, Y 2 is -CH 2 -0-CH 2 -. In certain embodiments, Y 2 is -CH 2 -CF 2 -CH 2 -. In certain embodiments, Y 2 is selected from the groups depicted in the compounds in Table 3, below.
- Y 3 is a C1-3 bivalent saturated or unsaturated, straight hydrocarbon chain wherein one or two methylene units of the chain are optionally and independently replaced by -0-, -C(H)(R 7 )-, or -C(R 7 ) 2 -.
- Y 3 is a C 2 -3 bivalent unsaturated, straight hydrocarbon chain wherein one methylene unit of the chain is optionally replaced by -0-, -C(H)(R 7 )-, or -C(R 7 ) 2 -.
- Y 3 is a C 2 -3 bivalent unsaturated, straight hydrocarbon chain.
- Y 3 is a C1-3 bivalent saturated, straight hydrocarbon chain wherein one or two methylene units of the chain are optionally and independently replaced by - 0-, -C(H)(R 7 )-, or -C(R 7 ) 2 -. In certain embodiments, Y 3 is a C1-3 bivalent saturated, straight hydrocarbon chain wherein one methylene unit of the chain is optionally replaced by -0-, - C(H)(R 7 )-, or -C(R 7 ) 2 -.
- Y 3 is a C1-3 bivalent saturated, straight hydrocarbon chain wherein one methylene unit of the chain is replaced by -0-, -C(H)(R 7 )-, or - C(R 7 ) 2 -. In certain embodiments, Y 3 is a C1-3 bivalent saturated, straight hydrocarbon chain. [0393] In certain embodiments, Y 3 is a C2-3 bivalent saturated, straight hydrocarbon chain wherein one or two methylene units of the chain are optionally and independently replaced by - 0-, -C(H)(R 7 )-, or -C(R 7 ) 2 -.
- Y 3 is a C2-3 bivalent saturated, straight hydrocarbon chain wherein one methylene unit of the chain is optionally replaced by -0-, - C(H)(R 7 )-, or -C(R 7 ) 2 -. In certain embodiments, Y 3 is a C2-3 bivalent saturated, straight hydrocarbon chain wherein one methylene unit of the chain is replaced by -0-, -C(H)(R 7 )-, or - C(R 7 ) 2 -. In certain embodiments, Y 3 is a C2-3 bivalent saturated, straight hydrocarbon chain.
- Y 3 is -(CH 2 )-, -(CH 2 ) 2 -, -CH 2 -C(H)(OH)-, -(CH 2 ) 3 -, -CH2-O- CH2-, or -CH2-CF2-CH2-.
- Y 3 is -(CH 2 )-, -(CH 2 ) 2 -, -CH 2 -C(H)(OH)-, - (CH 2 ) 3 -, or -CH2-CF2-CH2-.
- Y 3 is -(CH 2 ) 2 -, -CH 2 -C(H)(OH)-, -(CH 2 ) 3 -, or -CH2-CF2-CH2-. In certain embodiments, Y 3 is -(CH2)2- or -(CH2)3-. In certain embodiments, Y 3 is -CH 2 -C(H)(OH)- or -CH2-CF2-CH2-. In certain embodiments, Y 3 is -(CH 2 )-, -(CH 2 ) 2 -, or - (CH2)3-. In certain embodiments, Y 3 is -(CH2)2- or -CH2-C(H)(OH)-. In certain embodiments, Y 3 is -(CH 2 ) 3 -, -CH2-O-CH2-, or -CH2-CF2-CH2-.
- Y 3 is -(CH2)-. In certain embodiments, Y 3 is -(CH2)2-. In certain embodiments, Y 3 is -CH2-C(H)(OH)-. In certain embodiments, Y 3 is -(CH2)3-. In certain embodiments, Y 3 is -CH2-O-CH2-. In certain embodiments, Y 3 is -CH2-CF2-CH2-. In certain embodiments, Y 3 is selected from the groups depicted in the compounds in Table 3, below.
- m is 0, 1, 2, or 3. In certain embodiments, m is 0. In certain embodiments, m is 1. In certain embodiments, m is 2. In certain embodiments, m is 3. In certain embodiments, m is 0 or 1. In certain embodiments, m is 1 or 2. In certain embodiments, m is 2 or 3. In certain embodiments, m is 0, 1, or 2. In certain embodiments, m is 1, 2, or 3. In certain embodiments, m is selected from the values represented in the compounds in Table 3, below.
- n is 0, 1, 2, or 3. In certain embodiments, n is 0. In certain embodiments, n is 1. In certain embodiments, n is 2. In certain embodiments, n is 3. In certain embodiments, n is 0 or 1. In certain embodiments, n is 1 or 2. In certain embodiments, n is 2 or 3. In certain embodiments, n is 0, 1, or 2. In certain embodiments, n is 1, 2, or 3. In certain embodiments, n is selected from the values represented in the compounds in Table 3, below. [0398] As defined generally above, p is 0, 1, 2, or 3. In certain embodiments, p is 0. In certain embodiments, p is 1. In certain embodiments, p is 2. In certain embodiments, p is 3.
- p is 0 or 1. In certain embodiments, p is 1 or 2. In certain embodiments, p is 2 or 3. In certain embodiments, p is 0, 1, or 2. In certain embodiments, p is 1, 2, or 3. In certain embodiments, p is selected from the values represented in the compounds in Table 3, below.
- the compound is a compound in Table 1, 1-A, 2, or 3 below, or a pharmaceutically acceptable salt thereof. In certain embodiments, the compound is a compound in Table 1, 1-A, 2, or 3 below. In certain embodiments, the compound is a compound in Table 1, 2, or 3 below, or a pharmaceutically acceptable salt thereof. In certain embodiments, the compound is a compound in Table 1, 2, or 3 below. In certain embodiments, the compound is a compound in Table 1 or 2 below, or a pharmaceutically acceptable salt thereof. In certain embodiments, the compound is a compound in Table 1 or 2 below. In certain embodiments, the compound is a compound in Table 1 or 1-A below, or a pharmaceutically acceptable salt thereof. In certain embodiments, the compound is a compound in Table 1 or 1-A below.
- the compound is a compound in Table 1 below, or a pharmaceutically acceptable salt thereof. In certain embodiments, the compound is a compound in Table 1 below. In certain embodiments, the compound is a compound in Table 1-A below, or a pharmaceutically acceptable salt thereof. In certain embodiments, the compound is a compound in Table 1-A below. In certain embodiments, the compound is a compound in Table 2 below, or a pharmaceutically acceptable salt thereof. In certain embodiments, the compound is a compound in Table 2 below. In certain embodiments, the compound is a compound in Table 3 below, or a pharmaceutically acceptable salt thereof. In certain embodiments, the compound is a compound in Table 3 below. TABLE 1.
- Schemes 4 and 5 depict methods that may be used for preparing specific compounds described herein, based on methods described in Schemes 1-3 above, and in the Examples below.
- Scheme 4 depicts methods that may be used to prepare compounds 1-5 and 1-8.
- compound 1-26 may be prepared according to the methods depicted for compound 1-8, but using tert - butyl azetidin-3-ylcarbamate instead of tert -butyl 3,8-diazabicyclo[3.2.1]octane-8- carboxylate in the first step.
- compound 1-23 may be prepared according to the methods depicted for compound 1-5, but using 4-bromo-2-(methoxymethoxy)quinoline instead of the substituted naphthyl triflate in the Pd coupling step.
- Scheme 5 depicts methods that may be used to prepare compounds II-3 and II-4.
- compounds II-9 and II- 10 may be prepared according to the methods depicted for compounds II-3 and II-4, respectively, but using tert-butyl 1,4-diazepane-l-carboxylate or tert- butyl azetidin-3-ylcarbamate instead of tert-butyl 3,8-diazabicyclo[3.2.1]octane-8-carboxylate in the first step.
- SCHEME 5 tert-butyl 1,4-diazepane-l-carboxylate or tert- butyl azetidin-3-ylcarbamate instead of tert-butyl 3,8-diazabicyclo[3.2.1]octane-8-carboxylate in the first step.
- one aspect of the invention provides a method of treating a disorder mediated by K- Ras in a subject.
- the method comprises administering a therapeutically effective amount of a compound described herein, such as a compound of Formula I, II, or III, to a subject in need thereof to treat the disorder.
- Another aspect of the invention provides a method of treating a disorder mediated by K-Ras G12D in a subject.
- the method comprises administering a therapeutically effective amount of a compound described herein, such as a compound of Formula I, II, or III, to a subject in need thereof to treat the disorder.
- a compound described herein such as a compound of Formula I, II, or III
- the compound is a compound of Formula I, II, or III defined by one of the embodiments described above.
- K-Ras Kirsten Rat Sarcoma 2 Viral Oncogene Homolog
- GDP-bound inactive
- GTP-bound active
- cellular proliferation e.g ., see Alamgeer et al., (2013) Current Opin Pharmcol.13:394-401).
- K-Ras The role of activated K-Ras in malignancy was observed over thirty years ago (e.g., see Santos et al., (1984) Science 223:661-664). Aberrant expression of K-Ras has been reported to account for up to 20% of all cancers, and oncogenic K-Ras mutations that stabilize GTP binding and lead to constitutive activation of K-Ras and downstream signaling have been reported in 25 - 30% of lung adenocarcinomas (e.g., see Samatar and Poulikakos (2014) Nat Rev Drug Disc 13(12): 928- 942 doi: 10.1038/nrd428).
- K-Ras G12D mutation has been reported to be present in 25.0% of all pancreatic ductal adenocarcinoma patients, 13.3% of all colorectal carcinoma patients, 10.1% of all rectal carcinoma patients, 4.1% of all non- small cell lung carcinoma patients, and 1.7% of all small cell lung carcinoma patients (e.g., see The AACR Project GENIE Consortium, (2017) Cancer Discovery;7(8):818-831. Dataset Version 4).
- the provided compounds are inhibitors of K-Ras and are therefore useful for treating one or more disorders associated with activity of K-Ras.
- the present invention provides a method for treating a K-Ras -mediated disorder comprising the step of administering to a patient in need thereof a therapeutically effective compound of the present invention, or pharmaceutically acceptable composition thereof.
- K-Ras-mediated disorders, diseases, and/or conditions means any disease or other deleterious condition in which K-Ras, or a variant or mutant thereof, is known to play a role.
- another aspect or embodiment of the present invention relates to treating or lessening the severity of one or more diseases in which K-Ras is known to play a role.
- provided herein are methods of treating, reducing the severity of, delaying the onset of, or inhibiting the progress of a disease or disorder, or one or more symptoms thereof, of a disease or disorder characterized by or associated with increased K- Ras expression and/or increased K-Ras activity, comprising the step of administering to a patient in need thereof a therapeutically effective amount of a compound of the present invention, or pharmaceutically acceptable composition thereof.
- provided herein are methods of treating, reducing the severity of, delaying the onset of, or inhibiting the progress of a disease or disorder, or one or more symptoms thereof of a disease or disorder in which inhibition or antagonizing of K-Ras activity is beneficial, comprising the step of administering to a patient in need thereof a therapeutically effective amount of a compound of the present invention, or pharmaceutically acceptable composition thereof.
- the present invention provides a method for treating one or more disorders, diseases, and/or conditions wherein the disorder, disease, or condition includes, but is not limited to, a cellular proliferative disorder, comprising administering to a patient in need thereof, a K-Ras inhibitor compound as described herein, or a pharmaceutical salt or composition thereof.
- the cellular proliferative disorder is cancer.
- the cancer is characterized by increased K-Ras expression and/or increased K-Ras activity, i.e., “increased activated K-Ras.”
- the K-Ras is a mutant K-Ras. In some embodiments, the K- Ras is an activated mutant K-Ras. In some embodiments, the K-Ras is a G12 mutant K-Ras. In some embodiments, the K-Ras is K-Ras G12D, K-Ras G12V, or K-Ras G12C. In some embodiments, the K-Ras is K-Ras G12D. In some embodiments, the K-Ras is K-Ras G12V. In some embodiments, the K-Ras is K-Ras G12C.
- the provided compounds are inhibitors of K-Ras G12D and are therefore useful for treating one or more disorders associated with activity of K-Ras G12D.
- the present invention provides a method for treating a K-Ras G12D-mediated disorder comprising the step of administering to a patient in need thereof a therapeutically effective compound of the present invention, or pharmaceutically acceptable composition thereof.
- K-Ras G12D-mediated disorders, diseases, and/or conditions means any disease or other deleterious condition in which K-Ras G12D is known to play a role.
- another aspect or embodiment of the present invention relates to treating or lessening the severity of one or more diseases in which K-Ras G12D is known to play a role.
- kits for treating, reducing the severity of, delaying the onset of, or inhibiting the progress of a disease or disorder, or one or more symptoms thereof, of a disease or disorder characterized by or associated with increased K- Ras G12D expression and/or increased K-Ras G12D activity comprising the step of administering to a patient in need thereof a therapeutically effective amount of a compound of the present invention, or pharmaceutically acceptable composition thereof.
- provided herein are methods of treating, reducing the severity of, delaying the onset of, or inhibiting the progress of a disease or disorder, or one or more symptoms thereof of a disease or disorder in which inhibition or antagonizing of K-Ras G12D activity is beneficial, comprising the step of administering to a patient in need thereof a therapeutically effective amount of a compound of the present invention, or pharmaceutically acceptable composition thereof.
- the present invention provides a method for treating one or more disorders, diseases, and/or conditions wherein the disorder, disease, or condition includes, but is not limited to, a cellular proliferative disorder, comprising administering to a patient in need thereof, an K-Ras G12D inhibitor compound as described herein, or a pharmaceutical salt or composition thereof.
- the cellular proliferative disorder is cancer.
- the cancer is characterized by increased K-Ras G12D expression and/or increased K-Ras G12D activity, i.e., “increased activated K-Ras G12D.”
- an increase can be by at least about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, about 96%, about 97%, about 98%, about 99%, about 100%, about 2-fold, about 3- fold, about 4-fold, about 5-fold, about 6-fold, about 7-fold, about 8-fold, about 9-fold, about 10- fold, about 20-fold, about 25-fold, about 50-fold, about 100-fold, or higher, relative to a control or baseline amount of a function, or activity, or concentration.
- the terms "increased expression” and/or “increased activity" of a substance, such as K-Ras G12D, in a sample or cancer or patient refers to an increase in the amount of the substance, such as K-Ras G12D, of about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, about 96%, about 97%, about 98%, about 99%, about 100%, about 2-fold, about 3-fold, about 4-fold, about 5-fold, about 6-fold, about 7-fold, about 8-fold, about 9-fold, about 10-fold, about 20-fold, about 25-fold, about 50-fold, about 100-fold, or higher, relative to the amount of the substance, such as K-Ras G12D, in a control sample or control samples, such as an individual or
- a subject can also be determined to have an "increased expression” or “increased activity” of a substance, such as K-Ras G12D, if the expression and/or activity of the substance, such as K-Ras G12D, is increased by one standard deviation, two standard deviations, three standard deviations, four standard deviations, five standard deviations, or more, relative to the mean (average) or median amount of the substance, such as K-Ras G12D, in a control group of samples or a baseline group of samples or a retrospective analysis of patient samples.
- control or baseline expression levels can be previously determined, or measured prior to the measurement in the sample or cancer or subject, or can be obtained from a database of such control samples.
- a proliferative disease refers to a disease that occurs due to abnormal growth or extension by the multiplication of cells (Walker, Cambridge Dictionary of Biology, Cambridge University Press: Cambridge, UK, 1990).
- a proliferative disease can be associated with: 1) the pathological proliferation of normally quiescent cells; 2) the pathological migration of cells from their normal location ( e.g ., metastasis of neoplastic cells); 3) the pathological expression of proteolytic enzymes, such as the matrix metalloproteinases (e.g., collagenases, gelatinases, and elastases); or 4) the pathological angiogenesis, as in proliferative retinopathy and tumor metastasis.
- proteolytic enzymes such as the matrix metalloproteinases (e.g., collagenases, gelatinases, and elastases)
- the pathological angiogenesis as in proliferative retinopathy and tumor metastasis.
- Exemplary proliferative diseases include cancers (i.e., "malignant neoplasms"), benign neoplasms, angiogenesis, inflammatory diseases, and autoimmune diseases.
- the disorder is cancer.
- the cancer or proliferative disorder or tumor to be treated using the compounds and methods and uses described herein include, but are not limited to, a hematological cancer, a lymphoma, a myeloma, a leukemia, a neurological cancer, skin cancer, breast cancer, a prostate cancer, a colorectal cancer, lung cancer, head and neck cancer, a gastrointestinal cancer, a liver cancer, a pancreatic cancer, a genitourinary cancer, a bone cancer, renal cancer, and a vascular cancer.
- a cancer is treated by inhibiting or reducing or decreasing or arresting further growth or spread of the cancer or tumor.
- a cancer is treated by inhibiting or reducing the size (e.g., volume or mass) of the cancer or tumor by at least 5%, at least 10%, at least 25%, at least 50%, at least 75%, at least 90% or at least 99% relative to the size of the cancer or tumor prior to treatment.
- a cancer is treated by reducing the quantity of the cancers or tumors in the patient by at least 5%, at least 10%, at least 25%, at least 50%, at least 75%, at least 90% or at least 99% relative to the quantity of the cancers or tumors prior to treatment.
- the cancer is selected from is non-small cell lung cancer (NSCLC), small cell lung cancer, colorectal cancer, rectal cancer, and pancreatic cancer. In some embodiments, the cancer is selected from non-small cell lung cancer (NSCLC), pancreatic cancer, and colorectal cancer. In some embodiments, the cancer is selected from non-small cell lung cancer (NSCLC) and pancreatic cancer.
- the cancer is a solid tumor. In certain embodiments, the cancer is a melanoma, carcinoma, or blastoma. In certain embodiments, the cancer is a melanoma. In certain embodiments, the cancer is a carcinoma. In certain embodiments, the cancer is an adenocarcinoma. In certain embodiments, the cancer is a blastoma.
- the cancer is lung cancer, pancreatic cancer, colorectal cancer, breast cancer, cervical cancer, prostate cancer, gastric cancer, skin cancer, liver cancer, bile duct cancer, or nervous system cancer.
- the cancer is lung cancer.
- the cancer is pancreatic cancer.
- the cancer is colorectal cancer.
- the cancer is breast cancer.
- the cancer is cervical cancer.
- the cancer is prostate cancer.
- the cancer is gastric cancer.
- the cancer is skin cancer.
- the cancer is liver cancer.
- the cancer is bile duct cancer.
- the cancer is nervous system cancer.
- the cancer is breast adenocarcinoma, lung adenocarcinoma, pancreatic adenocarcinoma, cervical adenocarcinoma, colorectal adenocarcinoma, prostate adenocarcinoma, gastric adenocarcinoma, melanoma, lung squamous cell carcinoma, hepatocellular carcinoma, cholangiocarcinoma, glioblastoma, or neuroblastoma.
- the cancer is breast adenocarcinoma.
- the cancer is lung adenocarcinoma.
- the cancer is pancreatic adenocarcinoma.
- the cancer is cervical adenocarcinoma.
- the cancer is prostate adenocarcinoma.
- the cancer is gastric adenocarcinoma.
- the cancer is melanoma.
- the cancer is lung squamous cell carcinoma, hepatocellular carcinoma, or cholangiocarcinoma. In certain embodiments, the cancer is lung squamous cell carcinoma. In certain embodiments, the cancer is hepatocellular carcinoma. In certain embodiments, the cancer is cholangiocarcinoma.
- the cancer is glioblastoma or neuroblastoma. In certain embodiments, the cancer is glioblastoma. In certain embodiments, the cancer is neuroblastoma. [0429] In certain embodiments, the cancer is lung cancer, pancreatic cancer, or colorectal cancer. In certain embodiments, the cancer is non-small cell lung cancer, pancreatic cancer, or colorectal cancer. In certain embodiments, the cancer is lung cancer. In certain embodiments, the cancer is non-small cell lung cancer.
- the cancer has elevated K-Ras activity. In certain embodiments, the cancer overexpresses K-Ras. In some embodiments, a subject having a disorder associated with or mediated by K-Ras has been identified or diagnosed as having a cancer having a K-Ras mutation (e.g., as determined using a regulatory agency-approved, e.g., FDA-approved, assay or kit). In some embodiments, the subject has a tumor that is positive for a K-Ras mutation (e.g., as determined using a regulatory agency-approved assay or kit).
- the subject can be a subject who has one or more tumor that is positive for a K-Ras mutation (e.g., identified as positive using a regulatory agency-approved, e.g., FDA-approved, assay or kit).
- the subject can be a subject whose tumor(s) have a K-Ras mutation (e.g., where the tumor is identified as such using a regulatory agency-approved, e.g., FDA-approved, kit or assay).
- the subject is suspected of having a K-Ras gene-associated cancer.
- the subject has a clinical record indicating that the subject has a tumor that has a K-Ras mutation (and, for example, the clinical record indicates that the subject should be treated with any of the compounds or compositions provided herein).
- an assay is used to determine whether the patient has a K-Ras mutation using a sample (e.g., a biological sample or a biopsy sample (e.g., a paraffin-embedded biopsy sample) from a patient (e.g., a patient suspected of having a K-Ras-associated cancer, a patient having one or more symptoms of a K- Ras-associated cancer, and/or a patient that has an increased risk of developing a K-Ras- associated cancer).
- a sample e.g., a biological sample or a biopsy sample (e.g., a paraffin-embedded biopsy sample) from a patient (e.g., a patient suspected of having a K-Ras-associated cancer, a patient having one or more symptoms of a K- Ras-associated cancer, and/or a patient that has an increased risk of developing a K-Ras- associated cancer).
- Non-limiting examples of such assays that can be used to determine whether a patient or subject has a K-Ras mutation include next generation sequencing (NGS), immunohistochemistry, fluorescence microscopy, break apart FISH analysis, Southern blotting, Western blotting, FACS analysis, Northern blotting, and PCR-based amplification (e.g., RT-PCR and quantitative real-time RT-PCR).
- NGS next generation sequencing
- the assays are typically performed, e.g., with at least one labelled nucleic acid probe or at least one labelled antibody or antigen-binding fragment thereof.
- regulatory agency is a country’s agency for the approval of the medical use of pharmaceutical agents with the country.
- a non limiting example of a regulatory agency is the U.S. Food and Drug Administration (FDA).
- the K-Ras mutation is a G12 mutation. In some embodiments, the K-Ras mutation is G12D, G12V, or G12C. In some embodiments, the K-Ras mutation is G12D. In some embodiments, the K-Ras mutation is G12V. In some embodiments, the K-Ras mutation is G12C.
- the cancer has elevated K-Ras G12D activity. In certain embodiments, the cancer overexpresses K-Ras G12D.
- a subject having a disorder associated with or mediated by K-Ras G12D has been identified or diagnosed as having a cancer having a K-Ras G12D mutation (e.g ., as determined using a regulatory agency- approved, e.g., FDA-approved, assay or kit).
- the subject has a tumor that is positive for a K-Ras G12D mutation (e.g., as determined using a regulatory agency-approved assay or kit).
- the subject can be a subject who has one or more tumor that is positive for a K-Ras G12D mutation (e.g., identified as positive using a regulatory agency-approved, e.g., FDA- approved, assay or kit).
- the subject can be a subject whose tumor(s) have a K-Ras G12D mutation (e.g., where the tumor is identified as such using a regulatory agency-approved, e.g., FDA-approved, kit or assay).
- the subject is suspected of having a K-Ras G12D gene-associated cancer.
- the subject has a clinical record indicating that the subject has a tumor that has a K-Ras G12D mutation (and, for example, the clinical record indicates that the subject should be treated with any of the compounds or compositions provided herein).
- an assay is used to determine whether the patient has a K-Ras G12D mutation using a sample (e.g., a biological sample or a biopsy sample (e.g., a paraffin-embedded biopsy sample) from a patient (e.g., a patient suspected of having a K-Ras G12D-associated cancer, a patient having one or more symptoms of a K-Ras G12D-associated cancer, and/or a patient that has an increased risk of developing a K-Ras G12D-associated cancer).
- a sample e.g., a biological sample or a biopsy sample (e.g., a paraffin-embedded biopsy sample) from a patient (e.g., a patient suspected of having a K-Ras G12D-associated cancer, a patient having one or more symptoms of a K-Ras G12D-associated cancer, and/or a patient that has an increased risk of developing a K-Ras G12D-
- Non-limiting examples of such assays that can be used to determine whether a patient or subject has a K-Ras G12D mutation include next generation sequencing (NGS), immunohistochemistry, fluorescence microscopy, break apart FISH analysis, Southern blotting, Western blotting, FACS analysis, Northern blotting, and PCR- based amplification (e.g ., RT-PCR and quantitative real-time RT-PCR).
- NGS next generation sequencing
- the assays are typically performed, e.g., with at least one labelled nucleic acid probe or at least one labelled antibody or antigen-binding fragment thereof.
- regulatory agency is a country’s agency for the approval of the medical use of pharmaceutical agents with the country.
- a non-limiting example of a regulatory agency is the U.S. Food and Drug Administration (FDA).
- the cancer is a leukemia (e.g., acute leukemia, acute lymphocytic leukemia, acute myelocytic leukemia, acute myeloblastic leukemia, acute promyelocytic leukemia, acute myelomonocytic leukemia, acute monocytic leukemia, acute erythroleukemia, chronic leukemia, chronic myelocytic leukemia, chronic lymphocytic leukemia), polycythemia vera, lymphoma (e.g., Hodgkin’s disease or non-Hodgkin’s disease), Waldenstrom's macroglobulinemia, multiple myeloma, heavy chain disease, or a solid tumor such as a sarcoma or carcinoma (e.g., fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteogenic sarcoma, chordoma, angiosarcoma
- a leukemia
- the cancer is glioma, astrocytoma, glioblastoma multiforme (GBM, also known as glioblastoma), medulloblastoma, craniopharyngioma, ependymoma, pinealoma, hemangioblastoma, acoustic neuroma, oligodendroglioma, schwannoma, neurofibrosarcoma, meningioma, melanoma, neuroblastoma, or retinoblastoma.
- the cancer is acoustic neuroma, astrocytoma ( e.g .
- Grade I Pilocytic Astrocytoma, Grade II - Low-grade Astrocytoma, Grade III - Anaplastic Astrocytoma, or Grade IV - Glioblastoma (GBM)), chordoma, CNS lymphoma, craniopharyngioma, brain stem glioma, ependymoma, mixed glioma, optic nerve glioma, subependymoma, medulloblastoma, meningioma, metastatic brain tumor, oligodendroglioma, pituitary tumors, primitive neuroectodermal (PNET) tumor, or schwannoma.
- GBM Glioblastoma
- the cancer is a type found more commonly in children than adults, such as brain stem glioma, craniopharyngioma, ependymoma, juvenile pilocytic astrocytoma (JPA), medulloblastoma, optic nerve glioma, pineal tumor, primitive neuroectodermal tumors (PNET), or rhabdoid tumor.
- the cancer is mesothelioma, hepatobilliary (hepatic and billiary duct), bone cancer, pancreatic cancer, skin cancer, cancer of the head or neck, cutaneous or intraocular melanoma, ovarian cancer, colon cancer, rectal cancer, cancer of the anal region, stomach cancer, gastrointestinal (gastric, colorectal, and duodenal), uterine cancer, carcinoma of the fallopian tubes, carcinoma of the endometrium, carcinoma of the cervix, carcinoma of the vagina, carcinoma of the vulva, Hodgkin’s Disease, cancer of the esophagus, cancer of the small intestine, cancer of the endocrine system, cancer of the thyroid gland, cancer of the parathyroid gland, cancer of the adrenal gland, sarcoma of soft tissue, cancer of the urethra, cancer of the penis, prostate cancer, testicular cancer, chronic or acute leukemia, chronic myeloid leukemia, lymphoc
- the cancer is hepatocellular carcinoma, ovarian cancer, ovarian epithelial cancer, fallopian tube cancer, papillary serous cystadenocarcinoma, uterine papillary serous carcinoma (UPSC), prostate cancer, testicular cancer, gallbladder cancer, hepatocholangiocarcinoma, soft tissue and bone synovial sarcoma, rhabdomyosarcoma, osteosarcoma, chondrosarcoma, Ewing sarcoma, anaplastic thyroid cancer, adrenocortical adenoma, pancreatic cancer, pancreatic ductal carcinoma, pancreatic adenocarcinoma, gastrointestinal/stomach (GIST) cancer, lymphoma, squamous cell carcinoma of the head and neck (SCCHN), salivary gland cancer, glioma, or brain cancer, neurofibromatosis- 1 associated malignant peripheral nerve sheath tumors (MPNST),
- MPNST neurofibromat
- the cancer is hepatocellular carcinoma (HCC), hepatoblastoma, colon cancer, rectal cancer, ovarian cancer, ovarian epithelial cancer, fallopian tube cancer, papillary serous cystadenocarcinoma, uterine papillary serous carcinoma (UPSC), hepatocholangiocarcinoma, soft tissue and bone synovial sarcoma, rhabdomyosarcoma, osteosarcoma, anaplastic thyroid cancer, adrenocortical adenoma, pancreatic cancer, pancreatic ductal carcinoma, pancreatic adenocarcinoma, glioma, neurofibromatosis- 1 associated malignant peripheral nerve sheath tumors (MPNST), Waldenstrom’s macroglobulinemia, or medulloblastoma.
- HCC hepatocellular carcinoma
- hepatoblastoma colon cancer
- rectal cancer ovarian cancer
- ovarian epithelial cancer
- the cancer is selected from renal cell carcinoma, or kidney cancer; hepatocellular carcinoma (HCC) or hepatoblastoma, or liver cancer; melanoma; breast cancer; colorectal carcinoma, or colorectal cancer; colon cancer; rectal cancer; anal cancer; lung cancer, such as non-small cell lung cancer (NSCLC) or small cell lung cancer (SCLC); ovarian cancer, ovarian epithelial cancer, ovarian carcinoma, or fallopian tube cancer; papillary serous cystadenocarcinoma or uterine papillary serous carcinoma (UPSC); prostate cancer; testicular cancer; gallbladder cancer; hepatocholangiocarcinoma; soft tissue and bone synovial sarcoma; rhabdomyosarcoma; osteosarcoma; chondrosarcoma; Ewing sarcoma; anaplastic thyroid cancer; adrenocortical carcinoma; pancreatic cancer; pancreatic duct
- the cancer is renal cell carcinoma, hepatocellular carcinoma (HCC), hepatoblastoma, colorectal carcinoma, colorectal cancer, colon cancer, rectal cancer, anal cancer, ovarian cancer, ovarian epithelial cancer, ovarian carcinoma, fallopian tube cancer, papillary serous cystadenocarcinoma, uterine papillary serous carcinoma (UPSC), hepatocholangiocarcinoma, soft tissue and bone synovial sarcoma, rhabdomyosarcoma, osteosarcoma, chondrosarcoma, anaplastic thyroid cancer, adrenocortical carcinoma, pancreatic cancer, pancreatic ductal carcinoma, pancreatic adenocarcinoma, glioma, brain cancer, neurofibromatosis- 1 associated malignant peripheral nerve sheath tumors (MPNST), Waldenstrom’s macroglobulinemia, or medulloblastoma.
- HCC hepatocellular
- the cancer is hepatocellular carcinoma (HCC), hepatoblastoma, colon cancer, rectal cancer, ovarian cancer, ovarian epithelial cancer, ovarian carcinoma, fallopian tube cancer, papillary serous cystadenocarcinoma, uterine papillary serous carcinoma (UPSC), hepatocholangiocarcinoma, soft tissue and bone synovial sarcoma, rhabdomyosarcoma, osteosarcoma, anaplastic thyroid cancer, adrenocortical carcinoma, pancreatic cancer, pancreatic ductal carcinoma, pancreatic adenocarcinoma, glioma, neurofibromatosis- 1 associated malignant peripheral nerve sheath tumors (MPNST), Waldenstrom’s macroglobulinemia, or medulloblastoma.
- HCC hepatocellular carcinoma
- hepatoblastoma colon cancer
- rectal cancer ovarian cancer
- ovarian cancer ovarian
- the cancer is hepatocellular carcinoma (HCC). In some embodiments, the cancer is hepatoblastoma. In some embodiments, the cancer is colon cancer.
- the cancer is rectal cancer. In some embodiments, the cancer is ovarian cancer, or ovarian carcinoma. In some embodiments, the cancer is ovarian epithelial cancer. In some embodiments, the cancer is fallopian tube cancer. In some embodiments, the cancer is papillary serous cystadenocarcinoma. In some embodiments, the cancer is uterine papillary serous carcinoma (UPSC). In some embodiments, the cancer is hepatocholangiocarcinoma. In some embodiments, the cancer is soft tissue and bone synovial sarcoma. In some embodiments, the cancer is rhabdomyosarcoma. In some embodiments, the cancer is osteosarcoma.
- UPSC papillary serous carcinoma
- the cancer is anaplastic thyroid cancer. In some embodiments, the cancer is adrenocortical carcinoma. In some embodiments, the cancer is pancreatic cancer, or pancreatic ductal carcinoma. In some embodiments, the cancer is pancreatic adenocarcinoma. In some embodiments, the cancer is glioma. In some embodiments, the cancer is malignant peripheral nerve sheath tumors (MPNST). In some embodiments, the cancer is neurofibromatosis- 1 associated MPNST. In some embodiments, the cancer is Waldenstrom’s macroglobulinemia. In some embodiments, the cancer is medulloblastoma.
- MPNST peripheral nerve sheath tumors
- the cancer is neurofibromatosis- 1 associated MPNST.
- the cancer is Waldenstrom’s macroglobulinemia. In some embodiments, the cancer is medulloblastoma.
- Another aspect of the invention provides for the use of a compound described herein (such as a compound of Formula I, II, or III, or other compounds in Section I) for treating a medical disorder, such as a medical disorder described herein (for example, cancer).
- a compound described herein such as a compound of Formula I, II, or III, or other compounds in Section I
- a medical disorder such as a medical disorder described herein (for example, cancer).
- the compounds described herein can inhibit K-Ras activity.
- another aspect of the invention provides a method of inhibiting K-Ras activity. The method comprises contacting K-Ras with an effective amount of a naphthyl-substituted quinolin-4( 1H)- one or related compound described herein, such as a compound of Formula I, II, or III, or other compounds in Section I, to inhibit K-Ras activity.
- the compound is a compound of Formula I, II, or III defined by one of the embodiments described above.
- the K-Ras is a mutant K-Ras. In some embodiments, the K-Ras is an activated mutant K-Ras. In some embodiments, the K-Ras is a G 12 mutant K-Ras. In some embodiments, the K-Ras is K-Ras G12D, K-Ras G12V, or K-Ras G12C. In some embodiments, the K-Ras is K-Ras G12D. In some embodiments, the K-Ras is K-Ras G12V. In some embodiments, the K-Ras is K-Ras G12C.
- the compounds described herein can inhibit K-Ras G12D activity.
- another aspect of the invention provides a method of inhibiting K-Ras G12D activity.
- the method comprises contacting K-Ras G12D with an effective amount of a naphthyl- substituted quinolin-4( 1H)-onc or related compound described herein, such as a compound of Formula I, II, or III, or other compounds in Section I, to inhibit K-Ras G12D activity.
- the compound is a compound of Formula I, II, or III defined by one of the embodiments described above.
- Compounds may be tested for ability to bind to and/or inhibit K-Ras activity according to any of various assays known in the art, including, for example, surface plasmon resonance binding assays, TR-FRET displacement binding assays, TR-FRET assays that detect Ras-Raf interaction, and cell-based phosphorylation inhibition assays.
- Compounds may be tested for ability to bind to and/or inhibit K-Ras G12D activity according to any of various assays known in the art, including, for example, surface plasmon resonance binding assays, TR-FRET displacement binding assays, TR-FRET assays that detect Ras-Raf interaction, and cell-based phosphorylation inhibition assays.
- Naphthyl-substituted quinolin-4( l//)-onc or related compounds described herein e.g., a compound of Formula I, II, or III, or other compounds in Section I
- additional therapeutic agents to treat medical disorders, such as a cancer.
- the present invention provides a method of treating a disclosed disease or condition comprising administering to a patient in need thereof an effective amount of a compound disclosed herein or a pharmaceutically acceptable salt thereof and co-administering simultaneously or sequentially an effective amount of one or more additional therapeutic agents, such as those described herein.
- the method includes co-administering one additional therapeutic agent.
- the method includes co-administering two additional therapeutic agents.
- the combination of the disclosed compound and the additional therapeutic agent or agents acts synergistically.
- One or more other therapeutic agents may be administered separately from a compound or composition of the invention, as part of a multiple dosage regimen.
- one or more other therapeutic agents may be part of a single dosage form, mixed together with a compound of this invention in a single composition.
- one or more other therapeutic agent and a compound or composition of the invention may be administered simultaneously, sequentially or within a period of time from one another, for example within 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 18, 20, 21, 22, 23, or 24 hours from one another.
- one or more other therapeutic agent and a compound or composition of the invention are administerd as a multiple dosage regimen more than 24 hours aparts.
- the term “combination,” “combined,” and related terms refers to the simultaneous or sequential administration of therapeutic agents in accordance with this invention.
- a compound of the present invention can be administered with one or more other therapeutic agent(s) simultaneously or sequentially in separate unit dosage forms or together in a single unit dosage form.
- the present invention provides a single unit dosage form comprising a compound of the current invention, one or more other therapeutic agent(s), and a pharmaceutically acceptable carrier, adjuvant, or vehicle.
- compositions which comprise an additional therapeutic agent, such as a second anti-cancer agent, as described above varies depending upon the host treated and the particular mode of administration.
- a composition of the invention should be formulated so that a dosage of between 0.01 - 100 mg/kg body weight/day of a compound of the invention can be administered.
- compositions which comprise one or more other therapeutic agent(s) can act synergistically. Therefore, the amount of the one or more other therapeutic agent(s) in such compositions may be less than that required in a monotherapy utilizing only that therapeutic agent. In such compositions a dosage of between 0.01 - 1,000 g/kg body weight/day of the one or more other therapeutic agent(s) can be administered.
- the amount of one or more other therapeutic agent(s) present in the compositions of this invention is preferably no more than the amount that would normally be administered in a composition comprising that therapeutic agent as the only active agent.
- the amount of one or more other therapeutic agent(s) in the presently disclosed compositions ranges from about 50% to 100% of the amount normally present in a composition comprising that agent as the only therapeutically active agent.
- one or more other therapeutic agent(s) is administered at a dosage of about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, or about 95% of the amount normally administered for that agent.
- the phrase "normally administered” means the amount an FDA- approved therapeutic agent is approved for dosing per the FDA label insert.
- another aspect of the invention provides a method of treating cancer in a patient.
- the method comprises administering to a subject in need thereof (i) a therapeutically effective amount of a naphthyl-substituted quinolin-4( l /7)-onc or related compound described herein and (ii) a second anti-cancer agent, in order to treat the cancer.
- the second anti-cancer agent is an EGFR inhibitor, a FAK inhibitor, a RAF/ERK/MAPK inhibitor, a mTOR Inhibitor, a MEK Inhibitor, or a Phosphoinositide 3-Kinase Inhibitor.
- the second anti-cancer agent is an ALK Inhibitor, an ATR Inhibitor, an A2A Antagonist, a Base Excision Repair Inhibitor, a Bcr-Abl Tyrosine Kinase Inhibitor, a Bruton's Tyrosine Kinase Inhibitor, a CDC7 Inhibitor, a CHK1 Inhibitor, a Cyclin-Dependent Kinase Inhibitor, a DNA-PK Inhibitor, an Inhibitor of both DNA-PK and mTOR, a DNMT1 Inhibitor, a DNMT1 Inhibitor plus 2-chloro-deoxy adenosine, an HD AC Inhibitor, a Hedgehog Signaling Pathway Inhibitor, an IDO Inhibitor, a JAK Inhibitor, a mTOR Inhibitor, a MEK Inhibitor, a MELK Inhibitor, a
- the second anti-cancer agent is an ALK Inhibitor. In certain embodiments, the second anti-cancer agent is an ALK Inhibitor comprisng ceritinib or crizotinib. In certain embodiments, the second anti-cancer agent is an ATR Inhibitor. In certain embodiments, the second anti-cancer agent is an ATR Inhibitor comprising AZD6738 or VX- 970. In certain embodiments, the second anti-cancer agent is an A2A Antagonist. In certain embodiments, the second anti-cancer agent is a Base Excision Repair Inhibitor comprising methoxyamine.
- the second anti-cancer agent is a Base Excision Repair Inhibitor, such as methoxyamine.
- the second anti-cancer agent is a Bcr- Abl Tyrosine Kinase Inhibitor.
- the second anti-cancer agent is a Bcr- Abl Tyrosine Kinase Inhibitor comprising dasatinib or nilotinib.
- the second anti-cancer agent is a Bruton's Tyrosine Kinase Inhibitor.
- the second anti-cancer agent is a Bruton's Tyrosine Kinase Inhibitor comprising ibrutinib.
- the second anti-cancer agent is a CDC7 Inhibitor.
- the second anti-cancer agent is a CDC7 Inhibitor comprising RXDX-103 or AS- 141.
- the second anti-cancer agent is a CHK1 Inhibitor. In certain embodiments, the second anti-cancer agent is a CHK1 Inhibitor comprising MK-8776, ARRY- 575, or SAR-020106. In certain embodiments, the second anti-cancer agent is a Cyclin- Dependent Kinase Inhibitor. In certain embodiments, the second anti-cancer agent is a Cyclin- Dependent Kinase Inhibitor comprising palbociclib. In certain embodiments, the second anti cancer agent is a DNA-PK Inhibitor. In certain embodiments, the second anti-cancer agent is a DNA-PK Inhibitor comprising MSC2490484A. In certain embodiments, the second anti-cancer agent is Inhibitor of both DNA-PK and mTOR. In certain embodiments, the second anti-cancer agent comprises CC-115.
- the second anti-cancer agent is a DNMT1 Inhibitor.
- the second anti-cancer agent is a DNMT1 Inhibitor comprising decitabine, RX- 3117, guadecitabine, NUC-8000, or azacytidine.
- the second anti-cancer agent comprises a DNMT1 Inhibitor and 2-chloro-deoxyadenosine.
- the second anti-cancer agent comprises ASTX-727.
- the second anti-cancer agent is a HD AC Inhibitor.
- the second anti-cancer agent is a HDAC Inhibitor comprising OBP-801, CHR- 3996, etinostate, resminostate, pracinostat, CG-200745, panobinostat, romidepsin, mocetinostat, belinostat, AR-42, ricolinostat, KA-3000, or ACY-241.
- the second anti-cancer agent is a Hedgehog Signaling Pathway Inhibitor. In certain embodiments, the second anti-cancer agent is a Hedgehog Signaling Pathway Inhibitor comprising sonidegib or vismodegib. In certain embodiments, the second anti-cancer agent is an IDO Inhibitor. In certain embodiments, the second anti-cancer agent is an IDO Inhibitor comprising INCB024360. In certain embodiments, the second anti-cancer agent is a JAK Inhibitor. In certain embodiments, the second anti-cancer agent is a JAK Inhibitor comprising ruxolitinib or tofacitinib.
- the second anti-cancer agent is a mTOR Inhibitor. In certain embodiments, the second anti-cancer agent is a mTOR Inhibitor comprising everolimus or temsirolimus. In certain embodiments, the second anti-cancer agent is a MEK Inhibitor. In certain embodiments, the second anti-cancer agent is a MEK Inhibitor comprising cobimetinib or trametinib. In certain embodiments, the second anti-cancer agent is a MELK Inhibitor. In certain embodiments, the second anti-cancer agent is a MELK Inhibitor comprising ARN-7016, APTO-500, or OTS-167.
- the second anti cancer agent is a MTH1 Inhibitor. In certain embodiments, the second anti-cancer agent is a MTH1 Inhibitor comprising (S)-crizotinib, TH287, or TH588.
- the second anti-cancer agent is a PARP Inhibitor.
- the second anti-cancer agent is a PARP Inhibitor comprising MP-124, olaparib, BGB-290, talazoparib, veliparib, niraparib, E7449, rucaparb, or ABT-767.
- the second anti-cancer agent is a Phosphoinositide 3-Kinase Inhibitor.
- the second anti-cancer agent is a Phosphoinositide 3-Kinase Inhibitor comprising idelalisib.
- the second anti-cancer agent is an inhibitor of both PARP1 and DHODH (i.e., an agent that inhibits both poly ADP ribose polymerase 1 and dihydroorotate dehydrogenase).
- the second anti-cancer agent is a Proteasome Inhibitor. In certain embodiments, the second anti-cancer agent is a Proteasome Inhibitor comprising bortezomib or carfilzomib. In certain embodiments, the second anti-cancer agent is a Topoisomerase-II Inhibitor. In certain embodiments, the second anti-cancer agent is a Topoisomerase-II Inhibitor comprising vosaroxin.
- the second anti-cancer agent is a Tyrosine Kinase Inhibitor. In certain embodiments, the second anti-cancer agent is a Tyrosine Kinase Inhibitor comprising bosutinib, cabozantinib, imatinib or ponatinib. In certain embodiments, the second anti-cancer agent is a VEGFR Inhibitor. In certain embodiments, the second anti-cancer agent is a VEGFR Inhibitor comprising regorafenib. In certain embodiments, the second anti-cancer agent is a WEE1 Inhibitor. In certain embodiments, the second anti-cancer agent is a WEE1 Inhibitor comprising AZD1775.
- the second anti-cancer agent is a compound targeting, decreasing or inhibiting the activity of members of the protein kinase C (PKC) and Raf family of serine/threonine kinases, members of the MEK, SRC, JAK/pan-JAK, FAK, PDK1, PKB/Akt, Ras/MAPK, PI3K, SYK, TYK2, BTK and TEC family, and/or members of the cyclin-dependent kinase family (CDK) including staurosporine derivatives, such as midostaurin; examples of further compounds include UCN-01, safingol, BAY 43-9006, Bryostatin 1, Perifosine; llmofosine; RO 318220 and RO 320432; GO 6976; Isis 3521; LY333531/LY379196; isochinoline compounds; FTIs; PD184352 or QAN697 (a P13K inhibitor) or
- the second anti-cancer agent is an agonist of 0X40, CD137, CD40, GITR, CD27, HVEM, TNFRSF25, or ICOS.
- the second anti cancer agent is an agonist of 0X40, CD137, CD40, or GITR.
- the second anti-cancer agent is an agonist of CD27, HVEM, TNFRSF25, or ICOS.
- the second anti-cancer agent is a therapeutic antibody.
- the therapeutic antibody targets one of the following: CD20, CD30, CD33, CD52, EpCAM, CEA, gpA33, a mucin, TAG-72, CAIX, PSMA, a folate-binding protein, a ganglioside, Le, VEGF, VEGFR, VEGFR2, integrin aVp3, integrin a5b1, EGFR, ERBB2, ERBB3, MET, IGF1R, EPHA3, TRAILR1, TRAILR2, RANKL, FAP, tenascin, CD19, KIR, NKG2A, CD47, CEACAM1, c-MET, VISTA, CD73, CD38, BAFF, interleukin- 1 beta, B4GALNT1, interleukin- 6, and interleukin-6 receptor.
- the second anti-cancer agent is a therapeutic antibody selected from the group consisting of rituximab, ibritumomab tiuxetan, tositumomab, obinutuzumab, ofatumumab, brentuximab vedotin, gemtuzumab ozogamicin, alemtuzumab, IGN101, adecatumumab, labetuzumab, huA33, pemtumomab, oregovomab, minetumomab, cG250, J591, Movl8, farletuzumab, 3F8, chl4.18, KW-2871, hu3S193, lgN311, bevacizumab, IM-2C6, pazopanib, sorafenib, axitinib, CDP791, lenvatinib, ramuci
- the second anti-cancer agent is a cytokine.
- the cytokine is IL-12, IL-15, GM-CSF, or G-CSF.
- the second anti-cancer agent is sipuleucel-T, aldesleukin (a human recombinant interleukin-2 product having the chemical name des-alanyl-1, serine- 125 human interleukin-2), dabrafenib (a kinase inhibitor having the chemical name N- ⁇ 3-[5-(2- aminopyri midi n-4-yl)-2-ter t -butyl- 1 ,3-thiazol-4-yl] -2- fluorophenyl ⁇ -2,6- difluorobenzenesulfonamide), vemurafenib (a kinase inhibitor having the chemical name propane- 1- sulfonic acid ⁇ 3-[5-(4-ch)
- the second anti-cancer agent is a placental growth factor, an antibody-drug conjugate, an oncolytic vims, or an anti-cancer vaccine.
- the second anti-cancer agent is a placental growth factor.
- the second anti-cancer agent is a placental growth factor comprising ziv-aflibercept.
- the second anti-cancer agent is an antibody-drug conjugate.
- the second anti-cancer agent is an antibody-drug conjugate selected from the group consisting of brentoxumab vedotin and trastuzumab emtransine.
- the second anti-cancer agent is an oncolytic virus. In certain embodiments, the second anti-cancer agent is the oncolytic vims talimogene laherparepvec. In certain embodiments, the second anti-cancer agent is an anti-cancer vaccine. In certain embodiments, the second anti-cancer agent is an anti-cancer vaccine selected from the group consistint of a GM-CSF tumor vaccine, a STING/GM-CSF tumor vaccine, and NY-ESO-1. In certain embodiments, the second anti-cancer agent is a cytokine selected from IL-12, IL-15, GM- CSF, and G-CSF.
- the second anti-cancer agent is an immune checkpoint inhibitor (also referred to as immune checkpoint blockers).
- Immune checkpoint inhibitors are a class of therapeutic agents that have the effect of blocking immune checkpoints. See, for example, Pardoll in Nature Reviews Cancer (2012) vol. 12, pages 252-264.
- the immune checkpoint inhibitor is an agent that inhibits one or more of (i) cytotoxic T- lymphocyte- associated antigen 4 (CTLA4), (ii) programmed cell death protein 1 (PD1), (iii) PDL1, (iv) LAB3, (v) B7-H3, (vi) B7-H4, and (vii) TIM3.
- CTLA4 cytotoxic T- lymphocyte- associated antigen 4
- PD1 programmed cell death protein 1
- PDL1 programmed cell death protein 1
- PDL1 programmed cell death protein 1
- PDL1 programmed cell death protein 1
- PD1 programmed cell death protein 1
- PDL1 programmed cell death protein 1
- PD1 programmed cell death
- the immune checkpoint inhibitor is pembrolizumab.
- the second anti-cancer agent is a monoclonal antibody that targets a non-checkpoint target (e.g., herceptin).
- the second anti-cancer agent is a non-cytoxic agent (e.g., a tyrosine -kinase inhibitor).
- the second anti-cancer agent is selected from mitomycin, ribomustin, vincristine, tretinoin, etoposide, cladribine, gemcitabine, mitobronitol, methotrexate, doxorubicin, carboquone, pentostatin, nitracrine, zinostatin, cetrorelix, letrozole, raltitrexed, daunombicin, fadrozole, fotemustine, thymalfasin, sobuzoxane, nedaplatin, aminoglutethimide, amsacrine, proglumide, elliptinium acetate, ketanserin, doxifluridine, etretinate, isotretinoin, streptozocin, nimustine, vindesine, cytarabine, bicalutamide, vinorelbine, vesnarin
- the second anti-cancer agent is radiation therapy.
- the second anti-cancer agent is a MEK Inhibitor.
- the second anti-cancer agent is binimetinib, cobimetinib, refametinib, selumetinib, trametinib, or a pharmaceutically acceptable salt and/or solvate of any of the foregoing.
- the second anti-cancer agent is binimetinib, cobimetinib, selumetinib, trametinib, or a pharmaceutically acceptable salt and/or solvate of any of the foregoing.
- the second anti-cancer agent is trametinib or a pharmaceutically acceptable salt and/or solvate thereof. In certain embodiments, the second anti-cancer agent is trametinib or a pharmaceutically acceptable solvate thereof. In certain embodiments, the second anti-cancer agent is trametinib dimethylsulfoxide. In certain embodiments, the second anti cancer agent is trametinib.
- the second anti-cancer agent is binimetinib or a pharmaceutically acceptable salt and/or solvate thereof. In certain embodiments, the second anti-cancer agent is cobimetinib or a pharmaceutically acceptable salt and/or solvate thereof. In certain embodiments, the second anti-cancer agent is refametinib or a pharmaceutically acceptable salt and/or solvate thereof. In certain embodiments, the second anti-cancer agent is selumetinib or a pharmaceutically acceptable salt and/or solvate thereof.
- the second anti-cancer agent is binimetinib. In certain embodiments, the second anti-cancer agent is cobimetinib. In certain embodiments, the second anti-cancer agent is refametinib. In certain embodiments, the second anti-cancer agent is selumetinib.
- the second anti-cancer agent is a TEAD inhibitor.
- the TEAD inhibitor is selected from those described in WO 2020/243415, the contents of which are herein incorporated by reference in their entirety.
- the TEAD inhibitor is selected from those described in WO 2020/243423, the contents of which are herein incorporated by reference in their entirety.
- the TEAD inhibitor is selected from those described in US Patent No. 11,274,082, the contents of which are herein incorporated by reference in their entirety.
- the second anti-cancer agent is an ERK5 inhibitor.
- the ERK5 inhibitor is selected from those described in WO 2022/051567, the contents of which are herein incorporated by reference in their entirety.
- the ERK5 inhibitor is selected from those described in WO 2022/051565, the contents of which are herein incorporated by reference in their entirety.
- the ERK5 inhibitor is selected from those described in WO 2022/051569, the contents of which are herein incorporated by reference in their entirety.
- the ERK5 inhibitor is selected from those described in WO 2022/051568, the contents of which are herein incorporated by reference in their entirety.
- the method further comprises administering to the subject a third anti-cancer agent. In certain embodiments, the method further comprises administering to the subject a fourth anti-cancer agent. In certain embodiments, the method further comprises administering to the subject a fifth anti-cancer agent.
- the third anti-cancer agent is one of the second anti-cancer agents described above.
- the fourth anti-cancer agent is one of the second anti-cancer agents described above.
- the fifth anti-cancer agent is one of the second anti-cancer agents described above.
- the doses and dosage regimen of the active ingredients used in the combination therapy may be determined by an attending clinician.
- the naphthyl-substituted quinolin-4( 1H)-onc or related compound described herein e.g., a compound of Formula I, II, or III, or other compounds in Section I
- the additional therapeutic agent(s) e.g. the second, third, or fourth, or fifth anti-cancer agent, described above
- the naphthyl-substituted quinolin-4( 1 H)-onc or related compound described herein e.g., a compound of Formula I, II, or III, or other compounds in Section I
- the additional therapeutic agent(s) e.g. the second, third, or fourth, or fifth anti-cancer agent, described above
- the naphthyl-substituted quinolin-4( 1H)-onc or related compound described herein e.g., a compound of Formula I, II, or III, or other compounds in Section I
- the additional therapeutic agent(s) e.g. the second, third, or fourth, or fifth anti-cancer agent, described above
- the naphthyl-substituted quinolin-4( 1 H)-onc or related compound described herein e.g., a compound of Formula I, II, or III, or other compounds in Section I
- the additional therapeutic agent(s) e.g. the second, third, or fourth, or fifth anticancer agent, described above
- a synergistic combination may allow the use of lower dosages of one or more agents and/or less frequent administration of one or more agents of a combination therapy.
- a lower dosage or less frequent administration of one or more agents may lower toxicity of the therapy without reducing the efficacy of the therapy.
- Another aspect of this invention is a kit comprising a therapeutically effective amount of the naphthyl-substituted quinolin-4( 1 H)-onc or related compound described herein (e.g., a compound of Formula I, II, or III, or other compounds in Section I), a pharmaceutically acceptable carrier, vehicle or diluent, and optionally at least one additional therapeutic agent listed above.
- a pharmaceutically acceptable carrier e.g., a compound of Formula I, II, or III, or other compounds in Section I
- vehicle or diluent e.g., a compound of Formula I, II, or III, or other compounds in Section I
- the invention provides pharmaceutical compositions, which comprise a therapeutically-effective amount of one or more of the compounds described above, formulated together with one or more pharmaceutically acceptable carriers (additives) and/or diluents.
- the pharmaceutical compositions may be specially formulated for administration in solid or liquid form, including those adapted for the following: (1) oral administration, for example, drenches (aqueous or non-aqueous solutions or suspensions), tablets, e.g., those targeted for buccal, sublingual, and systemic absorption, boluses, powders, granules, pastes for application to the tongue; (2) parenteral administration, for example, by subcutaneous, intramuscular, intravenous or epidural injection as, for example, a sterile solution or suspension, or sustained-release formulation; (3) topical application, for example, as a cream, ointment, or a controlled-release patch or spray applied to the skin; (4) intravaginally or intrarectally, for example, as a pessary
- a therapeutically effective amount means that amount of a compound, material, or composition comprising a compound of the present invention which is effective for producing some desired therapeutic effect in at least a sub-population of cells in an animal at a reasonable benefit/risk ratio applicable to any medical treatment.
- a therapeutically effective amount is an amount sufficient for inhibition of K-Ras G12D.
- a therapeutically effective amount is an amount sufficient for treating a proliferative disease, such as cancer.
- phrases “pharmaceutically acceptable” is employed herein to refer to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.
- Wetting agents, emulsifiers and lubricants, such as sodium lauryl sulfate and magnesium stearate, as well as coloring agents, release agents, coating agents, sweetening, flavoring and perfuming agents, preservatives and antioxidants can also be present in the compositions.
- antioxidants examples include: (1) water soluble antioxidants, such as ascorbic acid, cysteine hydrochloride, sodium bisulfate, sodium metabisulfite, sodium sulfite and the like; (2) oil-soluble antioxidants, such as ascorbyl palmitate, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), lecithin, propyl gallate, alpha-tocopherol, and the like; and (3) metal chelating agents, such as citric acid, ethylenediamine tetraacetic acid (EDTA), sorbitol, tartaric acid, phosphoric acid, and the like.
- water soluble antioxidants such as ascorbic acid, cysteine hydrochloride, sodium bisulfate, sodium metabisulfite, sodium sulfite and the like
- oil-soluble antioxidants such as ascorbyl palmitate, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), le
- Formulations of the present invention include those suitable for oral, nasal, topical (including buccal and sublingual), rectal, vaginal and/or parenteral administration.
- the formulations may conveniently be presented in unit dosage form and may be prepared by any methods well known in the art of pharmacy.
- the amount of active ingredient which can be combined with a carrier material to produce a single dosage form will vary depending upon the host being treated, the particular mode of administration.
- the amount of active ingredient which can be combined with a carrier material to produce a single dosage form will generally be that amount of the compound which produces a therapeutic effect. Generally, out of one hundred percent, this amount will range from about 0.1 percent to about ninety-nine percent of active ingredient, preferably from about 5 percent to about 70 percent, most preferably from about 10 percent to about 30 percent.
- a formulation of the present invention comprises an excipient selected from the group consisting of cyclodextrins, celluloses, liposomes, micelle forming agents, e.g., bile acids, and polymeric carriers, e.g., polyesters and poly anhydrides; and a compound of the present invention.
- an aforementioned formulation renders orally bioavailable a compound of the present invention.
- Methods of preparing these formulations or compositions include the step of bringing into association a compound of the present invention with the carrier and, optionally, one or more accessory ingredients.
- the formulations are prepared by uniformly and intimately bringing into association a compound of the present invention with liquid carriers, or finely divided solid carriers, or both, and then, if necessary, shaping the product.
- Formulations of the invention suitable for oral administration may be in the form of capsules, cachets, pills, tablets, lozenges (using a flavored basis, usually sucrose and acacia or tragacanth), powders, granules, or as a solution or a suspension in an aqueous or non-aqueous liquid, or as an oil-in-water or water-in-oil liquid emulsion, or as an elixir or syrup, or as pastilles (using an inert base, such as gelatin and glycerin, or sucrose and acacia) and/or as mouth washes and the like, each containing a predetermined amount of a compound of the present invention as an active ingredient.
- a compound of the present invention may also be administered as a bolus, electuary or paste.
- the active ingredient is mixed with one or more pharmaceutically-acceptable carriers, such as sodium citrate or dicalcium phosphate, and/or any of the following: (1) fillers or extenders, such as starches, lactose, sucrose, glucose, mannitol, and/or silicic acid; (2) binders, such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinyl pyrrolidone, sucrose and/or acacia; (3) humectants, such as glycerol; (4) disintegrating agents, such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate; (5) solution retarding agents, such as paraffin; (6) absorption accelerators, such as quaternary ammonium compounds and surfactants, such
- compositions may also comprise buffering agents.
- Solid compositions of a similar type may also be employed as fillers in soft and hard-shelled gelatin capsules using such excipients as lactose or milk sugars, as well as high molecular weight polyethylene glycols and the like.
- a tablet may be made by compression or molding, optionally with one or more accessory ingredients.
- Compressed tablets may be prepared using binder (for example, gelatin or hydroxypropylmethyl cellulose), lubricant, inert diluent, preservative, disintegrant (for example, sodium starch glycolate or cross-linked sodium carboxymethyl cellulose), surface-active or dispersing agent.
- Molded tablets may be made by molding in a suitable machine a mixture of the powdered compound moistened with an inert liquid diluent.
- the tablets, and other solid dosage forms of the pharmaceutical compositions of the present invention may optionally be scored or prepared with coatings and shells, such as enteric coatings and other coatings well known in the pharmaceutical-formulating art. They may also be formulated so as to provide slow or controlled release of the active ingredient therein using, for example, hydroxypropylmethyl cellulose in varying proportions to provide the desired release profile, other polymer matrices, liposomes and/or microspheres. They may be formulated for rapid release, e.g., freeze-dried.
- compositions may be sterilized by, for example, filtration through a bacteria-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved in sterile water, or some other sterile injectable medium immediately before use.
- These compositions may also optionally contain opacifying agents and may be of a composition that they release the active ingredient(s) only, or preferentially, in a certain portion of the gastrointestinal tract, optionally, in a delayed manner.
- embedding compositions which can be used include polymeric substances and waxes.
- the active ingredient can also be in micro-encapsulated form, if appropriate, with one or more of the above-described excipients.
- Liquid dosage forms for oral administration of the compounds of the invention include pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs.
- the liquid dosage forms may contain inert diluents commonly used in the art, such as, for example, water or other solvents, solubilizing agents and emulsifiers, such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor and sesame oils), glycerol, tetrahydrofuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof.
- inert diluents commonly used in the art, such as, for example, water or other solvents, solubilizing agents and
- the oral compositions can also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, coloring, perfuming and preservative agents.
- adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, coloring, perfuming and preservative agents.
- Suspensions in addition to the active compounds, may contain suspending agents as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth, and mixtures thereof.
- suspending agents as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth, and mixtures thereof.
- Formulations of the pharmaceutical compositions of the invention for rectal or vaginal administration may be presented as a suppository, which may be prepared by mixing one or more compounds of the invention with one or more suitable nonirritating excipients or carriers comprising, for example, cocoa butter, polyethylene glycol, a suppository wax or a salicylate, and which is solid at room temperature, but liquid at body temperature and, therefore, will melt in the rectum or vaginal cavity and release the active compound.
- suitable nonirritating excipients or carriers comprising, for example, cocoa butter, polyethylene glycol, a suppository wax or a salicylate, and which is solid at room temperature, but liquid at body temperature and, therefore, will melt in the rectum or vaginal cavity and release the active compound.
- Formulations of the present invention which are suitable for vaginal administration also include pessaries, tampons, creams, gels, pastes, foams or spray formulations containing such carriers as are known in the art to be appropriate.
- Dosage forms for the topical or transdermal administration of a compound of this invention include powders, sprays, ointments, pastes, creams, lotions, gels, solutions, patches and inhalants.
- the active compound may be mixed under sterile conditions with a pharmaceutically-acceptable carrier, and with any preservatives, buffers, or propellants which may be required.
- the ointments, pastes, creams and gels may contain, in addition to an active compound of this invention, excipients, such as animal and vegetable fats, oils, waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicic acid, talc and zinc oxide, or mixtures thereof.
- excipients such as animal and vegetable fats, oils, waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicic acid, talc and zinc oxide, or mixtures thereof.
- Powders and sprays can contain, in addition to a compound of this invention, excipients such as lactose, talc, silicic acid, aluminum hydroxide, calcium silicates and polyamide powder, or mixtures of these substances.
- Sprays can additionally contain customary propellants, such as chlorofluorohydrocarbons and volatile unsubstituted hydrocarbons, such as butane and propane.
- Transdermal patches have the added advantage of providing controlled delivery of a compound of the present invention to the body.
- dosage forms can be made by dissolving or dispersing the compound in the proper medium.
- Absorption enhancers can also be used to increase the flux of the compound across the skin. The rate of such flux can be controlled by either providing a rate controlling membrane or dispersing the compound in a polymer matrix or gel.
- Ophthalmic formulations are also contemplated as being within the scope of this invention.
- compositions of this invention suitable for parenteral administration comprise one or more compounds of the invention in combination with one or more pharmaceutically-acceptable sterile isotonic aqueous or nonaqueous solutions, dispersions, suspensions or emulsions, or sterile powders which may be reconstituted into sterile injectable solutions or dispersions just prior to use, which may contain sugars, alcohols, antioxidants, buffers, bacteriostats, solutes which render the formulation isotonic with the blood of the intended recipient or suspending or thickening agents.
- aqueous and nonaqueous carriers examples include water, ethanol, polyols (such as glycerol, propylene glycol, polyethylene glycol, and the like), and suitable mixtures thereof, vegetable oils, such as olive oil, and injectable organic esters, such as ethyl oleate.
- polyols such as glycerol, propylene glycol, polyethylene glycol, and the like
- vegetable oils such as olive oil
- injectable organic esters such as ethyl oleate.
- Proper fluidity can be maintained, for example, by the use of coating materials, such as lecithin, by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants.
- compositions may also contain adjuvants such as preservatives, wetting agents, emulsifying agents and dispersing agents. Prevention of the action of microorganisms upon the subject compounds may be ensured by the inclusion of various antibacterial and antifungal agents, for example, paraben, chlorobutanol, phenol sorbic acid, and the like. It may also be desirable to include isotonic agents, such as sugars, sodium chloride, and the like into the compositions. In addition, prolonged absorption of the injectable pharmaceutical form may be brought about by the inclusion of agents which delay absorption such as aluminum monostearate and gelatin.
- adjuvants such as preservatives, wetting agents, emulsifying agents and dispersing agents.
- Injectable depot forms are made by forming microencapsule matrices of the subject compounds in biodegradable polymers such as polylactide-polyglycolide. Depending on the ratio of drug to polymer, and the nature of the particular polymer employed, the rate of drug release can be controlled. Examples of other biodegradable polymers include poly(orthoesters) and poly(anhydrides). Depot injectable formulations are also prepared by entrapping the drug in liposomes or microemulsions which are compatible with body tissue.
- biodegradable polymers such as polylactide-polyglycolide.
- Depot injectable formulations are also prepared by entrapping the drug in liposomes or microemulsions which are compatible with body tissue.
- the compounds of the present invention are administered as pharmaceuticals, to humans and animals, they can be given per se or as a pharmaceutical composition containing, for example, 0.1 to 99% (more preferably, 10 to 30%) of active ingredient in combination with a pharmaceutically acceptable carrier.
- the preparations of the present invention may be given orally, parenterahy, topically, or rectahy. They are of course given in forms suitable for each administration route. For example, they are administered in tablets or capsule form, by injection, inhalation, eye lotion, ointment, suppository, etc. administration by injection, infusion or inhalation; topical by lotion or ointment; and rectal by suppositories. Oral administrations are preferred.
- parenteral administration and “administered parenterahy” as used herein means modes of administration other than enteral and topical administration, usually by injection, and includes, without limitation, intravenous, intramuscular, intraarterial, intrathecal, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous, subcuticular, intraarticular, subcapsular, subarachnoid, intraspinal and intrastemal injection and infusion.
- systemic administration means the administration of a compound, drug or other material other than directly into the central nervous system, such that it enters the patient’s system and, thus, is subject to metabolism and other like processes, for example, subcutaneous administration.
- These compounds may be administered to humans and other animals for therapy by any suitable route of administration, including orally, nasally, as by, for example, a spray, rectally, intravaginally, parenterally, intracisternally and topically, as by powders, ointments or drops, including buccally and sublingually.
- the compounds of the present invention which may be used in a suitable hydrated form, and/or the pharmaceutical compositions of the present invention, are formulated into pharmaceutically-acceptable dosage forms by conventional methods known to those of skill in the art.
- the selected dosage level will depend upon a variety of factors including the activity of the particular compound of the present invention employed, or the ester, salt or amide thereof, the route of administration, the time of administration, the rate of excretion or metabolism of the particular compound being employed, the rate and extent of absorption, the duration of the treatment, other drugs, compounds and/or materials used in combination with the particular compound employed, the age, sex, weight, condition, general health and prior medical history of the patient being treated, and like factors well known in the medical arts.
- a physician or veterinarian having ordinary skill in the art can readily determine and prescribe the effective amount of the pharmaceutical composition required.
- the physician or veterinarian could start doses of the compounds of the invention employed in the pharmaceutical composition at levels lower than that required in order to achieve the desired therapeutic effect and gradually increase the dosage until the desired effect is achieved.
- a suitable daily dose of a compound of the invention will be that amount of the compound which is the lowest dose effective to produce a therapeutic effect. Such an effective dose will generally depend upon the factors described above.
- the compounds are administered at about 0.01 mg/kg to about 200 mg/kg, more preferably at about 0.1 mg/kg to about 100 mg/kg, even more preferably at about 0.5 mg/kg to about 50 mg/kg.
- the effective amount may be less than when the agent is used alone.
- the effective daily dose of the active compound may be administered as two, three, four, five, six or more sub-doses administered separately at appropriate intervals throughout the day, optionally, in unit dosage forms. Preferred dosing is one administration per day.
- the invention further provides a unit dosage form (such as a tablet or capsule) comprising a naphthyl-substituted quinolin-4( 1H)-onc or related compound described herein in a therapeutically effective amount for the treatment of a medical disorder described herein.
- a unit dosage form such as a tablet or capsule
- a naphthyl-substituted quinolin-4( 1H)-onc or related compound described herein in a therapeutically effective amount for the treatment of a medical disorder described herein.
- Step 1 Benzyl 4-(8-tert-butoxycarbonyl-3,8-diazabicyclo[3.2.1]octan-3-yl)-2-chloro-6,8- dihydro-5H-pyrido[3,4-d]pyrimidine-7-carboxylate
- Step 2 Benzyl 4-(8-tert-butoxycarbonyl-3,8-diazabicyclo[3.2.1]octan-3-yl)-2-[[(2R,8S)-2- fluoro-l,2,3,5,6,7-hexahydropyrrolizin-8-yl]methoxy]-6,8-dihydro-5H-pyrido[3,4- d]pyrimidine-7-carboxylate
- Step 3 tert- Butyl 3-[2-[[(2R,8S)-2-fluoro-l,2,3,5,6,7-hexahydropyrrolizin-8-yl]methoxy]- 5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl]-3,8-diazabicyclo[3.2.1]octane-8-carboxylate
- Step 4 tert -Butyl 3-[2-[[(2/?,8S)-2-fluoro-l,2,3,5,6,7-hexahydropyrrolizin-8-yl]methoxy]-7- [3-(methoxymethoxy)-8-methyl-l-naphthyl]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]- 3,8-diazabicyclo[3.2.1]octane-8-carboxylate
- Step 5 4-[4-(3,8-Diazabicyclo[3.2.1]octan-3-yl)-2-[[(2R,8S)-2-fluoro-l,2,3,5,6,7- hexahydropyrrolizin-8-yl]methoxy]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-7-yl]-5-methyl- naphthalen-2-ol (1-31)
- the assay quantifies the inhibition of SOSl-mediated nucleotide exchange of K-Ras (G12D, G12V, G12C, or wild-type).
- K-Ras K-Ras
- Tb-streptavidin Tb-streptavidin
- the K-Ras complex was allowed to incubate with varied concentrations of test compounds before the addition of the mixture of SOS1 and fluorescently- labeled GTP (BODIPY-GTP) to initiate the reaction.
- BODIPY-GTP fluorescently- labeled GTP
- the TR-FRET signal was monitored after 30 min.
- the TR-FRET signal was generated by Tb and BODIPY-GTP, that displaced unlabeled GDP.
- Biotinylated K-Ras enzyme G12D, G12V, G12C, and wild-type
- SOS1 were purchased from GenScript.
- Other materials were: Tb-streptavidin (Cisbio-610SATLB), BODIPY FL GTP (Thermo-G12411), and white 384-well ProxiPlus Assay Plates (Perkin-Elmer- 6008289).
- the assay buffer was 20 mM HEPES pH 7.5, 50 mM NaCl, 10 mM MgCl2, 0.01% Tween-20, 1 mM DTT.
- Total assay volume was 15 ⁇ L, and final assay concentrations were biotinylated K-Ras enzyme (G12D, G12V, or wild-type; 1.0 nM), SOS1 (200 nM), Tb-streptavidin (1 nM), and BODIPY-GTP (100 nM).
- the assay was conducted at 23 °C. Controls included all the reagents, but replaced test compound solution with DMSO (0% inhibition control) or 100 mM GDP (100% inhibition control).
- Test compound was dissolved and diluted in DMSO (100 mM top concentration, 3-fold dilution, 11 doses), then transferred to the assay plate using Echo. The final DMSO concentration was 1.5%.
- the mixture of 1.5x K-Ras enzyme (G12D, G12V, G12C, or wild-type) and Streptavidin-Tb in assay buffer was prepared, and then pre-incubated at 23°C for 1 hour. The enzyme mixture was then dispensed into the assay plate (10 ⁇ L/weII). The plate was allowed to react with enzyme and compound for 30 minutes. A mixture of 3x SOS1 and BODIPY-GTP in assay buffer was added (5 ⁇ L/well).
- the plate was spun at 1000 rpm for 30 seconds and then sealed. After incubating for 30 min, the assay signal was detected with Envision plate reader. The TR-FRET ratios were used to calculate percent inhibition values for each concentration of compound, using the no inhibition and 100% inhibition controls. IC50 values were calculated by Xlfit from the percent inhibition values using the 4-parameter logistical equation. Part II - Results
- An exemplary compound was tested for its ability to inhibit phosphorylation of ERK downstream of K-Ras G12D using a homogeneous time-resolved fluorescence assay. Assay procedures and results are described below.
- the culture/assay medium was RPMI-1640 +10% FBS. Cells were seeded at 6,000 cells/well, 50 mE/well. Compound treatment time was 4 hours. Controls replaced test compound solution with 0.8% DMSO (max control) or 0.2 mM trametinib (min control).
- Procedure Cells were harvested from T150 growthflask using 0.05% trypsin/EDTA solution. Medium (10 mL) was added to stop trypsinizing. The cells were pipetted into a conical-bottomed, 50-mL centrifuge tube and centrifuged for 5 minutes at 1,000 rpm. The cell pellet was resuspended in medium, and cell count was determined (ViCell counter). Cell density was adjusted using fresh medium, then 384-well poly-D-lysine coated plates were seeded with 50 ⁇ L/well of the cell suspension. The cell plate was incubated overnight in a 37 °C, 5% CO2 incubator.
- Test compounds were dissolved and diluted in DMSO (20 mM top concentration, 3-fold dilution, 10 doses) using Tecan. Compounds were added to the cell plate. The final DMSO concentration was 0.8%. The cell plate was incubated for 4 hours in the incubator.
- Detection was conducted using a CisBio pERK kit. Kit-supplied lysis buffer was prepared and kept on ice. Concentrated (4x) lysis buffer was diluted with 3 volumes of deionized water, then lOOx of the blocking agent was added. Media was removed from the cell plate. Lysis buffer (35 mE/well) was added, and then the plate was placed on a plate agitator and shaken at 300 rpm, 4 °C for 40 minutes. Upon completion, the resulting lysate plate was centrifuged for 3 minutes at 1500 rpm.
- Assay plates were prepared containing the HTRF antibody buffer. For each assay plate, 50 ⁇ L of d2-conjugate antibody was mixed with 950 ⁇ L of detection buffer. For each assay plate, 50 ⁇ L of cryptate antibody was mixed with 950 ⁇ L of detection buffer. The two diluted antibodies were then mixed together, and 3.4 ⁇ L of the resulting antibody buffer was dispensed to wells of an empty 384-well white Proxi plate. The plate was sealed and centrifuged 30 minutes at 1,000 rpm.
- An exemplary compound was tested for its ability to inhibit the binding of GMPPNP- bound KRas (G12D or WT) to the Ras binding domain of RAF.
- KRas protein was biotinylated and RAF protein was FLAG-tagged. Compounds were incubated with KRas-GMPPNP for 30 minutes at room temperature, followed by addition of RAF protein, Tb-anti-FLAG and SA-XL665 HTRF reagents. Fluorescence detection was carried out after 1.5 hours of incubation. IC50 values were calculated using a four-parameter fit.
- GMPPNP-loaded KRAS-G12D Biotinylated GMPPNP-loaded KRAS-G12D, GMPPNP-loaded KRAS-WT and FLAG-tagged-Raf-RBD were purchased from GenScript. GMPPNP was obtained from Sigma. Perkin Elmer and Cisbio provided the Tb-anti-FLAG and streptavidin XL665 reagents and the white 384W ProxiPlus assay plates.
- the assay buffer was 20 mM HEPES, pH 7.5, 150 mM NaCl,
- HTRF ratios were used to calculate percent inhibition values for each concentration of compound, using the no inhibition and 100% inhibition controls.
- IC50 values were calculated by Xlfit from the percent inhibition values using the 4-parameter logistical equation.
- EXAMPLE 5 Assay for Inhibition of K-Ras G12D-mediated Phosphorylation of ERK
- Compounds may be tested for ability to inhibit phosphorylation of ERK downstream of K-Ras G12D according to the following experimental procedure.
- AGS cells (ATCC CRL-1739) expressing G12D are grown in DMEM medium supplemented with 10% fetal bovine serum, 10 mM HEPES, and Penicillin/Streptomycin. Cells are plated in tissue culture treated 96 well plates at a density of 40,000 cells/well and allowed to attach for 12-14 hours. Diluted test compound is then added in a final concentration of 0.5% DMSO. After 3 hours, the medium is removed, 150 pL of 4.0% formaldehyde is added and the plates incubated at room temperature for 20 minutes. Then, the plates are washed with PBS, and permeabilized with 150 pL of ice cold 100% methanol for 10 minutes. Non-specific antibody binding to the plates is blocked using 100 pL Licor blocking buffer (Li-Cor Biotechnology, Lincoln NE) for 1 hour at room temperature.
- Licor blocking buffer Li-Cor Biotechnology, Lincoln NE
- the amount of phospho-ERK is determined using an antibody specific for the phosphorylated form of ERK and compared to the amount of GAPDH. Primary antibodies used for the detection are added as follows: Phospho-ERK (Cell Signaling cs-9101) diluted 1:500 and GAPDH(Millipore MAB374) diluted 1:5000 in Licor block + 0.05%Tween 20. The plates are incubated for 2 hours at room temperature. Then, the plates are washed with PBS + 0.05%
- Secondary antibodies used to visualize primary antibodies are added as follows: Anti- rabbit-680 diluted 1 : 1000 and Anti-mouse-800 diluted 1 : 1000 both in Licor block +0.05% TweeN20, and are incubated for 1 hour at room temperature. Then, the plates are washed with PBS + 0.05% Tween 20. A 100 pL aliquot of PBS is added to each well and the plates are read on a Li-Cor Odyssey CLX plate reader.
- the phospho-ERK Thr202/Tyr204 signal is normalized to the GAPDH signal for each well and percent of DMSO control values are calculated. IC50 values are generated using a 4- parameter fit of the dose response curve
- EXAMPLE 6 Biological Assay for Inhibiting 3D Cancer Cell Cultures Using Combination Therapy
- Exemplary compounds having K-Ras G12D inhibitory activity may be tested for ability to inhibit 3D cancer cell cultures of pancreatic cancer and lung cancer. Assay procedures are described below.
- cells are seeded in 231 soft agar in 96-well, low-attachment tissue-culture plates. After 24 hours, cells are treated with a concentration range of one or more K-Ras G12D inhibitors. At the time of treatment, assay plates that did not receive treatment are collected and cell viability is measured using alamarBlue reagent to establish baseline cell viability. Treated plates are incubated for 7 days, and alamarBlue readout is then collected.
- EXAMPLE 7 Biological Assay for Inhibiting Mouse Xenograft Tumor Growth
- Exemplary compounds having K-Ras G12D inhibitory activity may be tested, alone or in combination with other agents, such as trametinib, for ability to inhibit tumor growth in patient- derived mouse xenograft models of pancreatic cancer and lung cancer. Assay procedures are described below.
- mice (6-8 weeks old) are inoculated subcutaneously in the right flank with a primary human tumor xenograft model tumor fragment (2-3 mm 3 in diameter) for tumor development.
- mice are inoculated with a human lung adenocarcinoma tumor model (MSCLC, ADC model LU6424) that harbors a BRAF mutation (LU6424);
- mice are inoculated with a human pancreatic tumor model (adenosquamous carcinoma model PA6258) with a K-Ras G12D mutation (PA6258).
- mean tumor volume reaches approximately 150-200 mm 3 , animals are randomly allocated to appropriate treatment groups.
- mice are treated with one of the following: (l)Vehicle control, (2) Exemplary K-Ras G12D inhibitor alone, (3) Second anti-cancer agent alone, or (4) Combination of K-Ras G12D inhibitor and second anti-cancer agent. Tumors are measured twice per week using calipers.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
L'invention concerne des quinolin-4(1H)-ones à substitution naphtyle et des composés apparentés, des compositions pharmaceutiques, leur utilisation pour inhiber l'activité de K-Ras G12D et leur utilisation dans le traitement d'affections médicales, telles que le cancer.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202163173274P | 2021-04-09 | 2021-04-09 | |
US63/173,274 | 2021-04-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022217042A1 true WO2022217042A1 (fr) | 2022-10-13 |
Family
ID=83545779
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2022/024006 WO2022217042A1 (fr) | 2021-04-09 | 2022-04-08 | Quinoline-4(1h)-ones à substitution naphtyle et composés apparentés et leur utilisation dans le traitement d'affections médicales |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2022217042A1 (fr) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116120315A (zh) * | 2023-04-19 | 2023-05-16 | 山东绿叶制药有限公司 | 一种kras g12c抑制剂及其应用 |
WO2023198191A1 (fr) * | 2022-04-15 | 2023-10-19 | 杭州多域生物技术有限公司 | Composé à six et six chaînons, procédé de préparation, composition pharmaceutique et application |
WO2024115890A1 (fr) * | 2022-11-28 | 2024-06-06 | Redx Pharma Plc | Composés |
Citations (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009047255A1 (fr) * | 2007-10-09 | 2009-04-16 | Ucb Pharma, S.A. | Composés hétérobicycliques utiles comme antagonistes du récepteur h4 de l'histamine |
WO2017201161A1 (fr) * | 2016-05-18 | 2017-11-23 | Mirati Therapeutics, Inc. | Inhibiteurs de kras g12c |
US20190144444A1 (en) * | 2017-11-15 | 2019-05-16 | Mirati Therapeutics, Inc. | Kras g12c inhibitors |
CN112142735A (zh) * | 2020-04-09 | 2020-12-29 | 上海凌达生物医药有限公司 | 一类稠和氰基吡啶类化合物、制备方法和用途 |
CN112430234A (zh) * | 2019-08-26 | 2021-03-02 | 信达生物制药(苏州)有限公司 | 一种新型kras g12c蛋白抑制剂及其制备方法和用途 |
WO2021041671A1 (fr) * | 2019-08-29 | 2021-03-04 | Mirati Therapeutics, Inc. | Inhibiteurs de kras g12d |
US20210094919A1 (en) * | 2019-09-25 | 2021-04-01 | Jacobio Pharmaceuticals Co., Ltd. | Kras mutant protein inhibitors |
CN112830928A (zh) * | 2019-11-22 | 2021-05-25 | 四川海思科制药有限公司 | 一种嘧啶并环衍生物及其在医药上的应用 |
WO2021102288A1 (fr) * | 2019-11-22 | 2021-05-27 | Senda Biosciences, Inc. | Dérivés de pyridopyrimidinone utilisés comme antagonistes de l'ahr |
WO2021107160A1 (fr) * | 2019-11-29 | 2021-06-03 | Taiho Pharmaceutical Co., Ltd. | Composé ayant une activité inhibitrice contre la mutation kras g12d |
WO2021108683A1 (fr) * | 2019-11-27 | 2021-06-03 | Revolution Medicines, Inc. | Inhibiteurs de ras covalents et leurs utilisations |
WO2021210970A1 (fr) * | 2020-04-17 | 2021-10-21 | Dong-A St Co., Ltd. | Dérivés de pyridopyrimidinone et leur utilisation en tant que modulateurs du récepteur d'hydrocarbure aryle |
CN113683616A (zh) * | 2020-05-18 | 2021-11-23 | 广州百霆医药科技有限公司 | Kras g12c突变蛋白抑制剂 |
WO2021244603A1 (fr) * | 2020-06-04 | 2021-12-09 | Shanghai Antengene Corporation Limited | Inhibiteurs de la protéine kras g12c et leurs utilisations |
WO2022042630A1 (fr) * | 2020-08-26 | 2022-03-03 | InventisBio Co., Ltd. | Composés hétéroaryle, leurs procédés de préparation et leurs utilisations |
WO2022066646A1 (fr) * | 2020-09-22 | 2022-03-31 | Mirati Therapeutics, Inc. | Inhibiteurs de kras g12d |
WO2022068921A1 (fr) * | 2020-09-30 | 2022-04-07 | 上海医药集团股份有限公司 | Composé quinazoline et son application |
-
2022
- 2022-04-08 WO PCT/US2022/024006 patent/WO2022217042A1/fr active Application Filing
Patent Citations (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009047255A1 (fr) * | 2007-10-09 | 2009-04-16 | Ucb Pharma, S.A. | Composés hétérobicycliques utiles comme antagonistes du récepteur h4 de l'histamine |
WO2017201161A1 (fr) * | 2016-05-18 | 2017-11-23 | Mirati Therapeutics, Inc. | Inhibiteurs de kras g12c |
US20190144444A1 (en) * | 2017-11-15 | 2019-05-16 | Mirati Therapeutics, Inc. | Kras g12c inhibitors |
CN112430234A (zh) * | 2019-08-26 | 2021-03-02 | 信达生物制药(苏州)有限公司 | 一种新型kras g12c蛋白抑制剂及其制备方法和用途 |
WO2021041671A1 (fr) * | 2019-08-29 | 2021-03-04 | Mirati Therapeutics, Inc. | Inhibiteurs de kras g12d |
US20210094919A1 (en) * | 2019-09-25 | 2021-04-01 | Jacobio Pharmaceuticals Co., Ltd. | Kras mutant protein inhibitors |
WO2021102288A1 (fr) * | 2019-11-22 | 2021-05-27 | Senda Biosciences, Inc. | Dérivés de pyridopyrimidinone utilisés comme antagonistes de l'ahr |
CN112830928A (zh) * | 2019-11-22 | 2021-05-25 | 四川海思科制药有限公司 | 一种嘧啶并环衍生物及其在医药上的应用 |
WO2021108683A1 (fr) * | 2019-11-27 | 2021-06-03 | Revolution Medicines, Inc. | Inhibiteurs de ras covalents et leurs utilisations |
WO2021107160A1 (fr) * | 2019-11-29 | 2021-06-03 | Taiho Pharmaceutical Co., Ltd. | Composé ayant une activité inhibitrice contre la mutation kras g12d |
CN112142735A (zh) * | 2020-04-09 | 2020-12-29 | 上海凌达生物医药有限公司 | 一类稠和氰基吡啶类化合物、制备方法和用途 |
WO2021210970A1 (fr) * | 2020-04-17 | 2021-10-21 | Dong-A St Co., Ltd. | Dérivés de pyridopyrimidinone et leur utilisation en tant que modulateurs du récepteur d'hydrocarbure aryle |
CN113683616A (zh) * | 2020-05-18 | 2021-11-23 | 广州百霆医药科技有限公司 | Kras g12c突变蛋白抑制剂 |
WO2021244603A1 (fr) * | 2020-06-04 | 2021-12-09 | Shanghai Antengene Corporation Limited | Inhibiteurs de la protéine kras g12c et leurs utilisations |
WO2022042630A1 (fr) * | 2020-08-26 | 2022-03-03 | InventisBio Co., Ltd. | Composés hétéroaryle, leurs procédés de préparation et leurs utilisations |
WO2022066646A1 (fr) * | 2020-09-22 | 2022-03-31 | Mirati Therapeutics, Inc. | Inhibiteurs de kras g12d |
WO2022068921A1 (fr) * | 2020-09-30 | 2022-04-07 | 上海医药集团股份有限公司 | Composé quinazoline et son application |
Non-Patent Citations (2)
Title |
---|
FELL, J. B ET AL.: "Identification of the Clinical Development Candidate MRTX849, a Covalent KRASG12C Inhibitor for the Treatment of Cancer", JOURNAL OF MEDICINAL CHEMISTRY, vol. 63, 2020, pages 6679 - 6693, XP055788094, DOI: 10.1021/acs.jmedchem.9b02052 * |
PAIN, C. ET AL.: "Synthesis of 5-substituted 2-(4- or 3-methoxyphenyl)-4(1H)-quinolones", TETRAHEDRON, vol. 59, 2003, pages 9627 - 9633, XP085016395, DOI: 10.1016/j.tet.2003.09.094 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023198191A1 (fr) * | 2022-04-15 | 2023-10-19 | 杭州多域生物技术有限公司 | Composé à six et six chaînons, procédé de préparation, composition pharmaceutique et application |
WO2024115890A1 (fr) * | 2022-11-28 | 2024-06-06 | Redx Pharma Plc | Composés |
CN116120315A (zh) * | 2023-04-19 | 2023-05-16 | 山东绿叶制药有限公司 | 一种kras g12c抑制剂及其应用 |
CN116120315B (zh) * | 2023-04-19 | 2023-06-09 | 山东绿叶制药有限公司 | 一种kras g12c抑制剂及其应用 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11690915B2 (en) | Ras inhibitors | |
AU2021344830A1 (en) | Use of SOS1 inhibitors to treat malignancies with SHP2 mutations | |
CN114867735A (zh) | Ras抑制剂 | |
CN114786777A (zh) | Ras抑制剂 | |
WO2022217042A1 (fr) | Quinoline-4(1h)-ones à substitution naphtyle et composés apparentés et leur utilisation dans le traitement d'affections médicales | |
AU2018208231B2 (en) | Imidazopyrazine compound, preparation method therefor and use thereof | |
CN109219604A (zh) | 四氢异喹啉雌激素受体调节剂及其用途 | |
WO2017071516A1 (fr) | Inhibiteur de kinase et procédé pour sa préparation et utilisation pharmaceutique correspondante | |
WO2022051569A1 (fr) | 3-pipéridinyl-pyrrolo[2,3-b]pyridines substituées et composés apparentés et leur utilisation dans le traitement d'états médicaux | |
CN115916194A (zh) | 用于延迟、预防和治疗针对ras抑制剂的获得性抗性的方法 | |
WO2022051568A1 (fr) | 4-pipéridinyl-pyrrolo[2,3-b]pyridines substituées et composés apparentés et leur utilisation dans le traitement d'états médicaux | |
US20200071326A1 (en) | Tam kinase inhibitors | |
WO2022051567A1 (fr) | Pyrido[2,3-b]pyrazinones substituées et composés apparentés et leur utilisation dans le traitement d'états médicaux | |
AU2021262482A1 (en) | Bicyclic kinase inhibitors and uses thereof | |
JP2021503479A (ja) | 置換ヘテロアリール化合物及び使用方法 | |
TW202340209A (zh) | 用於治療癌症之環狀2-胺基-3-氰基噻吩及衍生物 | |
CA3161339A1 (fr) | Composes cycliques et leurs procedes d'utilisation | |
WO2023105387A1 (fr) | Antagonistes du récepteur 4 de la mélanocortine et leurs utilisations | |
WO2023059609A1 (fr) | Composés hétérobifonctionnels et leur utilisation dans le traitement de maladies | |
WO2022245814A1 (fr) | Méthodes de traitement d'états médicaux et d'inhibition de la transcriptase inverse de la line1 à l'aide d'un acide 4-fluoro-2,5-dihydrofuranyle phosphonique substitué ou d'un composé apparenté | |
CN116600808A (zh) | 一类作为kras突变体g12c抑制剂的四氢萘啶类衍生物、其制备方法及其应用 | |
WO2021057867A1 (fr) | Classe d'inhibiteur de cdk à base d'arsine organique, son procédé de préparation et application associée | |
CN115707705A (zh) | 芳杂环类化合物、其制备方法及用途 | |
CN115867552A (zh) | 咪唑并嘧啶类衍生物、其制备方法及其在医药上的应用 | |
WO2021105481A1 (fr) | Nouveaux composés pour le traitement de maladies liées à l'expression de dux4 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22785517 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 22785517 Country of ref document: EP Kind code of ref document: A1 |